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1. General Introduction
1.1 General problem definition
Finding new drugs is a difficult, time-consuming and expensive task. On average 14 years 
will pass from target discovery to an approved drug [1]. Figure 1 shows the average timeline 
of the drug discovery process. The development of a drug starts with the identification and 
validation of a (new) disease-modifying target, which is normally a protein [2]. This target 
needs to be druggable, i.e. the protein must have the ability to bind a small molecule that 
has the appropriate properties and the required binding affinity [3]. Next step in the process 
is to identify compounds that modulate the target (hit screening). Traditionally, compounds 
(hits) are identified by measuring the binding of a compound to a target in a high throughput 
biochemical or functional assay [4]. After validation of this hit in a multi-point activity 
determination the compound (confirmed hit) needs to be optimized in terms of efficacy, 
safety and selectivity before it enters the clinical part of the timeline. This is the most 
critical point in the drug discovery timeline and is called ‘the killing fields’, since 90% of all 
compounds that reach this phase fail at this point. Although recent developments in structural 
biology [5], high throughput techniques [6] and profiling methods [7] have improved the 
drug discovery process, improvement of the timeline in terms of speed and quality is still one 
of the biggest challenges in drug discovery. Emerging strategies to increase the number of 
new drug approvals are translational medicine and therapeutics [8]. This new discipline aims 
to bridge the gap between research and development in current pharmaceutical industry by 
early implementation of basic scientific technologies in clinical studies and vice versa, i.e. 
researchers have to harvest and integrate preclinical and clinical data back into research to 
increase the chances for successful drug development. Both research and clinical development 
utilize more and more molecular profiling techniques, which encompass all measurements 
Figure 1. The different stages of the drug discovery timeline with the estimated time indicated in 
years.
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that characterize a compound by its clinical properties or by its effect on the state of a cell 
or a tissue. 
In the next sections of this general introduction, we will first describe the general working 
mechanism of a drug. Second, the various methods to profile drugs, their implementation in 
the drug discovery process and the benefits of these methods will be discussed. As a final 
point we will describe how the content of this thesis contributes to the improvement of the 
speed and quality of the drug discovery process. 
1.2 Working mechanism of a typical drug
Figure 2 schematically shows the working mechanism of a drug. After absorption in the 
body, the drug binds to a target protein. Due to the binding of the drug, the target protein 
undergoes a conformational change, which affects the interaction with other molecules in the 
cell. This cascade of interactions eventually determines the definitive effect of the drug in the 
Figure 2. Working mechanism of a drug. A drug (a) typically binds in the ligand binding pocket (b) 
of a target protein (c). The binding of the drug leads to a conformational change at the surface of the 
protein, which leads to a change in interactions with other proteins (d) and other factors in the cell 
(e). The final balance of all these interactions and their effect on gene transcription will define the 
pharmacological effect in humans (f). Diethylstilbestrol (DES (a),(b)), estrogen alpha receptor (ERα) 
((b), (c)) are from 3ERD [9]. Figure (e) http://en.wikipedia.org/wiki/Image:Epithelial-cells.jpg. Color 
version: see Appendix 2.
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cell and organism. From a drug discovery perspective it is important to rapidly identify new 
drugs that bind to a target and to reveal as early as possible their pharmacological effects. 
If, for example, in an early stage can be proven that the drug does not induce the desired 
pharmacological effect, the development of this drug can be stopped. Since it is not possible 
to measure the pharmacological effect of a drug in humans in an early stage of drug discovery, 
alternative methods need to be explored. Drug profiling is such an alternative method that 
describes the effect of a drug in less complex systems than the human body, such as cells or 
tissues. It is believed that drugs that induce a similar drug profile in cells or tissues may also 
have identical pharmacological effects in humans. 
1.3 Drug profiling
Figure 3 summarizes the different drug profiling techniques that are available nowadays. 
Depending on the complexity of the system a drug can be profiled on a molecular, cellular or 
in vivo level. The various techniques and the benefits of drug profiling in drug discovery will 
be discussed in the next two sections.
1.3.1 Drug profiling at the molecular, cellular and in vivo level
Developments in high throughput screening and combinatorial chemistry have dramatically 
increased the rate in which hits are delivered nowadays [10]. To decrease failure rates at 
later stages in the drug discovery timeline it is necessary to predict biological properties 
of possible drugs at an early stage in the timeline. Therefore, several molecular predictive 
modeling techniques have become an integral part of the lead discovery and optimization 
stage. These methods predict various properties of the hit on the basis of steric and electrostatic 
fields of the hit. Examples of such techniques are COMFA [11], for prediction of functional 
properties (including potency, selectivity and toxicity) and ADME [10], for prediction of 
absorption, distribution, metabolism and excretion. Both the description of compounds 
by several molecular descriptors as well as the predicted property can be used to profile a 
compound at the molecular level. Other examples are ligand binding profiling and peptide 
interaction profiling. The first method profiles the binding mode of a compound in a protein 
in terms of atomic contacts between the ligand and the protein in a crystal structure or in a 
model structure from molecular docking studies. The second method measures the effect of a 
compound on the interaction of a protein with short peptides and has for instance been used 
to classify nuclear receptor (NR) ligands [12, 13].
At the cellular profiling level, the most commonly used methods are gene and protein 
expression profiling which are a result of the recent developments in high-throughput 
technologies that facilitate large scale genomic (DNA micro arrays [14]), proteomic (protein 
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micro arrays [15]) and metabolic [16, 17] measurements. In general, these techniques are used 
to monitor global cellular changes in response to perturbation caused by a drug or a disease. 
Gene and protein expression profiling is applied in drug discovery to identify new disease-
related molecular targets (target discovery), to profile drugs for toxicity (toxicogenomics) 
and to identify disease biomarkers [18, 19]. Protein interaction profiling is used to study 
the interaction of a protein with other full-length proteins. A well-known example of this 
profiling technique is the yeast two-hybrid assay [20]. 
At the cellular level, drugs are profiled in various cellular assays. The parameters that can be 
measured in a cell are sheer unlimited and are selected depending on the drug in study and 
Figure 3. Drug profiling in the drug discovery process. A drug can be profiled at multiple levels 
ranging from low to high complexity. At each level, analysis of the profiles (or fingerprints) measured 
by individual profiling methods (I) reveals information about the drug in relation to the measured 
property. When a clinical drug is included in profile measurements, profiles of novel drugs can be 
compared with that of the reference drug from the clinic. This assists categorization of compounds 
on basis of (dis)similarity of their profiles with the profile of the known drug. Comparison of drug 
profiles measured with different profile methods (II) is performed to find correlations between distinct 
profiles, which are useful in understanding the working mechanism of a drug at different levels of 
system complexity. This approach is necessary to determine whether molecular and cellular profiling 
methods are predictive for in vivo pharmacological effects. 
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the expected phenotypic effect.  
In the most complex systems (animals and humans) in vivo profiling methods are applied. 
Ideally, the efficacy of the drug is reflected by the level of certain biomarkers. In addition, 
other pharmacological biomarkers such as temperature, blood composition, organ size etc. 
are monitored to reveal the effect of a drug in vivo.
1.3.2 Drug profiling in drug discovery: concluding remarks and perspectives
How can drug profiling improve the drug discovery process? 
First, data derived from drug profiling methods contribute to the understanding of the working 
mechanism of a drug in more detail. In general, the profiling methods on the right in Figure 3 
are useful to determine the final pharmacological effect of a compound in animals or humans, 
while the methods on the left in the scheme provide insights in the basic mechanisms of a 
drug that underlie the final pharmacological effect of the drug in vivo. 
Secondly, drug profiling facilitates the comparison of drugs that are being developed for one 
therapeutic indication. Comparison of molecular or cellular profiles of novel drugs with that 
of known reference compounds leads to clusters of compounds with similar molecular or 
cellular profiles. 
Finally, the challenge in drug discovery nowadays is to determine whether the currently 
developed molecular and cellular profiling methods are predictive for the in vivo profile. 
This requires that clinical data obtained in development have to be fed back into research 
to investigate whether the molecular and cellular profiles correlate with the in vivo 
pharmacological effect. 
New technical developments such as increasing accuracy of the individual measurements, the 
possibility to measure larger datasets and the simultaneous collection of measurements from 
one cell culture or animal, all contribute to the improvement of both quality and quantity of 
the data. This will lead to more and better profiles along the timeline of drug discovery and 
increases the possibility to find correlations between in vivo and cellular/molecular profiles. 
This will also improve the interpretation of the data in the context of a biological working 
model and the understanding of underlying molecular and cellular mechanisms. From a 
more global view, molecular profiling in drug discovery can change the main product of 
pharmaceutical industries from a medicine to a much wider portfolio including compound, 
biological insights and knowledge of disease (stages) [7].
1.4 This thesis 
To increase the number of high quality drugs that will reach the market, it is important to 
speed up the process of drug discovery. In this thesis we describe two different strategies that 
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facilitate the drug discovery process:
(1) the use of the growing amount of protein sequence and structure data to improve/accelerate 
drug discovery in the hit screening and hit to lead stage. We used entropy-variability analysis 
to determine the role of each amino acid in the nuclear receptor ligand binding domain and a 
family-based structural analysis to determine the key ligand binding residues in the nuclear 
receptor protein family. These two methods require the use of dedicated nuclear receptor 
information systems, which are described in Chapter 3 and 5. 
(2) the use of drug profiling to improve/accelerate the lead optimization stage and bridge the 
gap between research and development. Chapter 4 will describe two distinct drug profiling 
methods, peptide recruitment profiling and ligand binding profiling, which describe the 
ligand-induced conformational change at the surface of the NR and the binding mode of the 
ligand in the receptor, respectively. We searched for a correlation between the two profiles 
and revealed that the ligand binding profile is predictive for the peptide recruitment profile 
for a selected set of ligands.
These two strategies were applied to the superfamily of nuclear receptors (NRs). This class 
of proteins is introduced in Chapter 2 of this thesis. 
2. The nuclear receptor superfamily
2.1 Nuclear receptors
Nuclear receptors (NRs) are ligand-inducible transcription factors that regulate gene 
expression in important biological processes such as reproduction, cell growth and death, 
homeostasis, differentiation, organ physiology and embryonic development [21]. A total of 48 
human NRs have been identified [22]. Their ligands are lipophilic compounds, ranging from 
metabolic intermediates, steroid hormones to vitamins. However, the endogenous ligands are 
not yet known for 30% of the NRs [23]. The lipophilic compounds go directly through the 
cell and nuclear membrane to influence gene transcription in the nucleus via their cognate 
receptor. After ligand binding, the receptor undergoes a conformational change, which allows 
the binding of coactivators or corepressors [24]. The activated receptor consequently binds to 
regulatory regions in the promoter of a target gene, the so-called hormone response element 
(HRE) either as a mono-, homo-, or heterodimer. The involvement of NRs in the regulation 
of gene expression in key processes and the possibility to influence this regulation with 
ligands makes this class of receptors a bona fide target for the pharmaceutical industry in the 
treatment of significant diseases such as cancer, hyperlipidemia, cholestasis, coronary heart 
disease and diabetes. 
All NRs have a modular structure [25]: a variable N-terminal domain, a central conserved 
DNA-binding domain (DBD) that binds to the HRE of the target gene, a flexible linker region 
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and a ligand-binding domain (LBD) at the C-terminus. Some receptors possess an additional 
far C-terminal region for which the function is not yet fully known. The transactivation 
functions AF-1 and AF-2 are located in the N-terminal domain and LBD, respectively.
2.1.1 The DNA binding domain (DBD)
The DBD is the most conserved domain between all members of the NR family. It consists of 
66 residues and contains two C
4
 type zinc fingers that bind to the HRE in the promoter region 
of a target gene. These HREs normally consist of a repeat of the nucleotides AGGTCA. The 
repeat can either be an inverted, everted or direct repeat. Furthermore, the spacing between 
the two elements of the repeat determines which receptor can bind to the HRE.
2.1.2 The ligand binding domain (LBD)
The LBD consists of about 250 residues. While this domain is much less conserved than the 
DBD, it has a common fold that consists of 10-13 helices, organized in a helical sandwich, 
and one beta sheet that normally consists of two short strands [26]. The ligand-binding pocket 
(LBP) located in the lower part of the structure accommodates the ligand. The LBP is very 
hydrophobic and is mainly formed by the helices H3, H5, H6, H11, and the small sheet. The 
LBD contains, in addition to the LBP, the AF-2 function and a dimerization interface.
2.2 Conformational states of NRs
The activation function AF-2 in the LBD is a short helix, H12, which is highly flexible. It’s 
repositioning upon ligand binding is important for the interaction with transcription cofactors, 
either coactivators or corepressors. Upon agonist binding, H12 docks at the entrance of the 
LPB in the so-called H12 groove that is mainly formed by H3 and H11. This structural 
conformational change modifies the surface of the LBD that leads to a hydrophobic cleft and 
the formation of a charge clamp [27] consisting of a conserved positively charged residue 
at the C-terminal end of H3 and a conserved negatively charged residue in H12. The charge 
clamp is crucial for coactivator binding by interacting with the two poles of the helix dipole of 
the recognition helix of the coactivator [28, 29]. This helix has a conserved LXXLL sequence 
motif that mediates the binding of the coactivator in the hydrophobic groove of the LBD. In 
some cases H12 is further stabilized by a direct interaction with the bound ligand. 
When an antagonist binds to the LBD, the ligand prevents H12 to dock in the H12 groove and 
corepressors bind to the receptor. Corepressors bind in the groove similarly to coactivators, 
but their position is slightly tilted so that they partly overlap with the agonistic location of 
H12 [30]. Due to the absence of H12 in the agonist position, corepressors cannot use the 
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charge clamp, but they do have a conserved sequence motif LXX(I/H)IXXX(I/L) [31-33] 
that is involved in hydrophobic interactions in the groove.
3. Using the wealth of NR data: a family-based approach
NRs are well suited for family-based studies since the family is compact in size and the 
available genomic, proteomic, structural and ligand binding data related to this class of 
proteins are massive. In general, these different types of biological data are stored in generic 
databases such as protein sequences in SWISS-PROT [34], crystal structures in the Protein 
Data Bank [35] and genes in the EMBL nucleotide sequence database [36]. However, 
experimental scientists tend to focus on one class (or family) of proteins and therefore need 
class-specific databases. These databases preferably contain all available data of one class of 
proteins and offer the opportunity to deploy computational analysis of the thoroughly linked 
data, which may lead to new insights in the function or working mechanism of one protein 
family.
The Molecular Class Specific Information System (MCSIS) for NRs is such a class-specific 
database and is described in more detail in section 3.1. The major difference between 
MCSIS-based databases and other databases in the field of NRs (described in section 3.2) 
is that sequences in MCSIS-based databases are aligned on the basis of superposition of 
all available crystal structures. This alignment and subsequent generic numbering scheme 
of residues that are structurally conserved forms the core of the database and allows for 
a seamless comparison of data linked to both structures and sequences. The NR MCSIS 
is therefore well suited for family-based computational studies. Two examples of such 
family-based computational studies are described in Chapter 2 and 3 of this thesis. Chapter 2 
describes the entropy-variability analysis to reveal the function of residues in the NR ligand 
binding domain, while Chapter 3 describes the family-based structure analysis to determine 
the most important ligand binding residues in the NR ligand binding pocket.
3.1 Molecular Class Specific Information System (MCSIS)
A MCSIS is a database that is automatically generated by using computational scripts that 
cover the four major phases of class-specific database development: (1) extraction of the data 
from heterogeneous sources, (2) validation of these data, (3) storage of these data, and finally 
(4) the creation of a user-interface to allow data query and subsequent data analysis. The fully 
automated procedure facilitates regular updates and prevents errors due to human manual 
intervention. Each MCSIS contains sequences, a structure-based alignment, classification 
schemes and structures of the members of the specific class of proteins. The use of a structure-
based multiple sequence alignment and coherent numbering of structurally conserved 
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residues allows for the seamless combination of data in this database. Moreover, it facilitates 
the smooth integration of data created by independent MCSIS modules. Examples of these 
modules are MuteXt [37] that automatically extracts point mutations from the literature, 
the Nuclear Receptor Mutation Database (NRMD) [38] that collects point mutations from 
different web-resources and the Automatic Residue Extraction System (ARES) [39] that 
automatically extracts residue positions from NR structures that are in contact with a ligand, 
cofactor or dimerpartner. All these data are automatically integrated into the core of the 
MCSIS database and are described in more detail in Chapter 3 (ARES) and 5 (NRMD).
The NR database created by MCSIS technology is the so-called NucleaRDB [40] and is 
available at http://www.receptors.org/NR. This database was set up to gather, combine and 
disseminate information on NRs. This information system integrates sequence data, mutation 
data, ligand binding data and three-dimensional structures to form a one-stop-shopping-
centre for NR-related information. The website gives also access to a large number of point 
mutations that are extracted automatically by MuteXt [37]. A nuclear receptor structural server 
(NRSAS) completes this database [41].  This server performs a large number of structure 
analyses on NRs such as homology modeling, structure validation and surface accessibility.
The MCSIS technology has recently been updated with additional scripts to automatically 
generate structure-based  sequence alignments and a to provide a more user friendly query-
interface (Joosten et al. in preparation [42]).
3.2 Available databases on NRs
Besides the NR-MCSIS, there are several other information resources that collect NR data 
from various sources. 
NURSA (http://www.nursa.org)
The primary directive of the Nuclear Receptor Signaling Atlas (NURSA) [43] program 
is to gather and organize information related to key aspects of orphan nuclear receptor 
biology, with the aim of extending this blueprint to the wider discipline of nuclear receptor 
signalling. 
For this purpose a web-based resource was created [44], which stores data from different 
areas of the NR field. This information can be freely accessed, shared and evaluated by the 
entire community. For example this website gives access to chip analysis data and tissue 
distribution of different receptors. 
The Nuclear Receptor Resource (NRR) (http://nrr.georgetown.edu/nrr/nrr.html )
After the release of the Glucocorticoid Receptor Resource in 1996 the project expanded in 
1998 into a network of individual resources named The Nuclear Receptor Resource (NRR) 
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[45, 46]. This project include information on the glucocorticoid (GRR), thyroid hormone 
(THRR), mineralocorticoid (MRR), androgen (ARR), peroxisome-proliferator activated 
receptor resource (PPAR) and vitamin D (VDRR) receptors as well as the steroid receptor 
associated proteins resource (SRAPR). The Androgen Receptor Mutation Database [47] is 
also part of the network. Through the years the MRR and ARR are not available anymore and 
the estrogen receptor resource was added. Each resource has its own specific design and data 
content. In general the network offers the user information on NR structure and function and 
more general information on meetings, funding etc. The resource also provides a forum for 
discussion of both published and unpublished material.
NUREBASE (http://www.ens-lyon.fr/LBMC/laudet/nurebase.html )
NUREBASE [48, 49] is a NR database with protein and DNA sequences, reviewed alignments 
and phylogenies, taxonomy and annotation for all NRs.
Nurisite (http://structure.bu.edu/terrence/nurisite/)
The Nuclear Receptor Interaction Site (Nurisite) is a database that stores the interaction sites 
of 3D structures of NRs and provides detailed information on the interactions between NRs 
and their partners. These include (1) the interactions between LBD residues and various 
ligands (agonists, partial agonists and antagonists), as well as coregulators (i.e., coactivators, 
corepressors, or their fragments), and (2) the interactions of residues in the DBDs with the 
DNA. The data in this database resembles the data described in Chapter 3, but lacks the 
generic numbering system of structurally conserved residues, which is essential for the 
family-based structural analysis of residues involved in interaction sites.
4. Profiling of NR ligands 
In section 1.3 we described the advantages of using molecular and cellular profiling techniques 
to predict pharmacological effects of drugs in vivo. In this section we will introduce the two 
different drug profiling methods that were used to describe and classify ligands of one family 
member of the NR protein family; the retinoid X receptor (RXR). The first method, peptide 
recruitment profiling, is believed to be a fingerprint of the ligand-induced conformational 
change of the NR surface. This conformational change determines the final interaction with 
NR regulatory proteins. The second method, ligand-receptor interaction profiling, is believed 
to represent the binding mode of a ligand in the LBP. In Chapter 4 we evaluated the predictive 
value of ligand-receptor interaction profiles by determining whether there is a correlation 
between ligand-receptor interaction profiles and peptide recruitment profiles.
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4.1 Profiling of NR ligands based on conformational change: peptide recruitment profiling
Peptide recruitment profiling is a biochemical profiling method at the molecular level, which 
measures the interaction between a peptide and a protein in a time-resolved fluorescence 
resonance energy transfer (TR-FRET) assay (Figure 4). Receptor and peptide are labeled 
with Europium (Eu) and allophycocyanin (APC), respectively. When the peptide binds to 
the receptor, Eu and APC are in close proximity. Excitation of the Eu at 337 nm leads to 
an emission of Eu at 620 nm. The 620 nm emission is absorbed by APC when peptide and 
receptor are in close proximity. The final APC fluorescence at 665 nm is a measure for the 
binding between receptor and peptide. 
A peptide recruitment profile describes the interaction between a large number of peptides 
and a protein (Figure 5), and is commonly used as a method to profile ligands [12]. Early 
Figure 4. The principle of the time-resolved fluorescence resonance energy transfer (TR-FRET) assay. 
The nuclear receptor ligand binding domain (NR LBD) is fused with glutathione S-transferase (GST) 
that binds an α-GST-Europium antibody. After ligand binding, the induced conformational change of 
the NR LBD allows the binding of cofactor peptides. Peptides are labeled with biotin that binds in one 
of the four biotin binding sites of streptavidin. Streptavidin is coupled to allophycocyanin (APC). When 
a peptide binds to the NR LBD, APC and europium (Eu) are in close proximity, which enables energy 
transfer. This energy transfer is initiated by the excitation of Eu at 337 nm and leads to an emission of 
Eu at 620 nm. Due to the short distance between Eu and APC upon ligand-induced peptide binding, the 
energy is absorbed by APC. Finally, the emission at 665 nm of the chromophores in APC is a measure 
for the concentration of peptide that binds to the NR.
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studies with the estrogen receptor (ER) showed that ER ligands can be classified on the 
basis of their peptide recruitment profile [50-52]. Similar studies were performed with the 
peroxisome proliferator-activated receptor (PPAR [53, 54]). Latest developments make use 
of peptide interaction assays that simultaneously measure the interaction between a large 
number of cofactor peptides and an NR [55, 56]. These comprehensive peptide interaction 
patterns are used to cluster different classes of ligands. By adding reference compounds from 
the clinic to the set of ligands in such a study, one can identify peptide interaction patterns 
that represent desired or undesired pharmacological effect in humans. This relatively high 
throughput molecular profiling method provides a filter before progression of the compounds 
into expensive and time consuming animal models [12]. Recently, a study of Iannone et al. 
successfully showed that the peptide recruitment profiles of 400 ERα compounds classifies 
compounds according to desired and undesired activities in cellular assays [57].
Figure 5. Profiling of NR ligands at the molecular level: peptide recruitment profiling and ligand-
receptor interaction profiling. Peptide recruitment profiling describes the ligand-induced variation in 
affinity of peptides for the NR LBD. Ligand receptor interaction profiles are derived from structural 
analysis of crystal structures or models and describe the number of contacts between a ligand and the 
residues in a protein in a 2D fingerprint. Color version: see Appendix 2.
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4.2 Profiling of NR ligands based on observed crystal contacts: ligand-receptor interaction 
profiling
The ligand-receptor interaction profiling is a profiling method at the molecular level, and 
is based on the observed contacts in the crystal structures of NR LBDs. As data input we 
used the calculated contacts that were obtained from NR LBD crystal structures by ARES. A 
ligand-receptor interaction profile describes the interactions of the ligand with each residue 
position in the protein [58], thereby converting complex 3D data into 2D fingerprints (Figure 
5). This conversion allows for easy comparison of different binding modes since it is possible 
to compare the binding modes by comparison of 2D fingerprints instead of visual inspection 
of each protein-ligand complex separately. 
5. Outline of this thesis
The outline of this thesis is schematically depicted in Figure 6. First, we revealed the residues 
that were involved in the signal transduction pathways within a NR LBD by use of an 
Figure 6. A ligand (L) binds to the NR LBD (I), triggers a cascade of interactions between residues 
(II) that results in a conformational change at the receptors surface (III). This thesis studies three parts 
of this process by (1) prediction of the function of the NR LBD residues, for example residues that 
are involved in signal transduction between ligand binding pocket and the surface (Chapter 2). The 
predicted function was verified by mutation data that were collected in a nuclear receptor mutation 
database (NRMD), which is described in more detail in Chapter 5, (2) analysis of the interactions 
between ligands and NR LBDs as observed in crystal structures (Chapter 3) and (3) measurements of 
the conformational changes at the surface by peptide recruitment in relation to ligand binding (Chapter 
4). 
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alignment analysis method. Secondly, an extensive study of all available LBD structures was 
performed to reveal the binding modes of the ligands. Third, we tried to correlate the binding 
mode of NR ligands with the conformational changes at the surface of the protein. 
Chapter 2 discusses the use of sequence entropy-variability plots as a method to reveal 
important residues in the structure and function of the LBD of NRs. Mutation data extracted 
from the literature and intermolecular contacts observed in NR structures were analyzed in 
view of this classification to evaluate the functional classification of the residues. Furthermore, 
we discuss the possibilities presented by the massive amounts of data that are becoming 
available in the ‘omics era’.
In Chapter 3 we focus on the direct interactions between the NR LBDs and their three 
interaction partners: ligands, cofactors, and dimer partners. All NR LBDs have a similar fold, 
which allows for comparison of the structures of their three main functional sites: the ligand 
binding pocket, the cofactor-binding groove and the dimerization interface. We describe a 
fully automated method by the use of the Automatic Residue Extraction System to identify 
these functionally important residues in nearly one hundred NR LBD crystal structures. 
Additionally we analyze the data and discuss the possibilities of the application of this 
method in drug design.
In Chapter 4 we investigated the conformational change of the LBD induced by different 
ligands in an in vitro time-resolved fluorescence resonance energy transfer assay with 52 
different cofactor peptides measuring the ligand-induced cofactor recruitment to the retinoid 
X receptor alpha in the presence of eleven compounds. Simultaneously, we revealed the 
binding mode of these ligands by molecular docking. An automated method converted the 
complex 3D data that describes the ligand-receptor interactions into 2D fingerprints, the so-
called ligand-receptor interaction profiles. The combination of both methods was used to 
reveal a correlation between the binding mode of a ligand and the conformational change 
it induces at the surface of the RXRα LBD. Finally, we discuss how well the data from a 
peptide recruitment assay reflects the effect of a compound in a cellular context.
Chapter 5 describes a database system called NRMD (Nuclear Receptor Mutation Database). 
This system automatically collects mutation information from SWISS-PROT/TrEMBL, 
several web-based mutation data resources, and data extracted from the literature. A common 
numbering scheme for all NR LBDs eases the use of the information for many kinds of 
studies.
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Chapter 2
A family-based approach reveals the function of 
residues in the nuclear receptor ligand-binding 
domain
Simon Folkertsma, Paula van Noort, Joost Van Durme, Henk-Jan Joosten, Emmanuel 
Bettler, Wilco Fleuren, Laerte Oliveira, Florence Horn, Jacob de Vlieg, and Gerrit 
Vriend
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Literature studies, 3D structure data, and a series of sequence analysis techniques were 
combined to reveal important residues in the structure and function of the ligand-binding 
domain of nuclear hormone receptors. A structure-based multiple sequence alignment allowed 
for the seamless combination of data from many different studies on different receptors into 
one single functional model.
It was recently shown that a combined analysis of sequence entropy and variability can 
divide residues in five classes; (1) the main function or active site, (2) support for the main 
function, (3) signal transduction, (4) modulator or ligand binding and (5) the rest. Mutation 
data extracted from the literature and intermolecular contacts observed in nuclear receptor 
structures were analysed in view of this classification and showed that the main function or 
active site residues of the nuclear receptor ligand-binding domain are involved in cofactor 
recruitment. Furthermore, the sequence entropy-variability analysis identified the presence 
of signal transduction residues that are located between the ligand, cofactor and dimer 
sites, suggesting communication between these regulatory binding sites. Experimental and 
computational results agreed well for most residues for which mutation data and intermolecular 
contact data were available. This allows us to predict the role of the residues for which no 
functional data is available yet.
This study illustrates the power of family-based approaches towards the analysis of protein 
function, and it points out the problems and possibilities presented by the massive amounts 
of data that are becoming available in the ‘omics era’. The results shed light on the nuclear 
receptor family that is involved in processes ranging from cancer to infertility, and that is one 
of the more important targets in the pharmaceutical industry.
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Introduction
Nuclear receptors
Nuclear receptors (NRs) are ligand-inducible transcription factors that regulate processes, 
such as homeostasis, differentiation, embryonic development and organ physiology [1]. A 
total of 48 human NRs have been identified [2]. Their ligands are lipophilic compounds such 
as steroids, thyroid hormone, vitamin D3, and retinoids. However, the endogenous ligands 
are not yet known for 30% of the NRs [3]. NRs are implicated in many important diseases like 
cancer [4], diabetes [5], and osteoporosis [6], and, therefore, are targets for pharmaceutical 
industries with similar importance as the G protein-coupled receptors (GPCRs), ion channels, 
or kinases [7].
Figure 1 shows the common architecture of NRs [8]. They consist of a variable N-terminal 
domain, a conserved DNA-binding domain (DBD) that binds to the hormone response 
element (HRE) of the target gene, a flexible linker region, and a C-terminal ligand-binding 
domain (LBD). Some receptors possess an additional far C-terminal region for which the 
function is not yet known. The N-terminal region of most NRs has a hormone-independent 
trans-activation function (AF-1). The hormone-dependent trans-activation function (AF-2) is 
located in the LBD [9].
The DBD is highly conserved. It consists of 66 residues, and contains two C
4 
type zinc fingers 
[10]. The LBD consists of about 250 amino acid residues. LBDs are much less conserved than 
DBDs. Nevertheless, LBDs have a common fold that consists of twelve helices (numbered 
H1-H12; see Figure 2) organised in a helical sandwich, and one beta sheet that normally 
consists of two short strands [11]. The structure of this sheet is rather variable. For example, 
the pregnane X receptor (PXR) has a beta sheet of five strands [12] and the peroxisome 
proliferator-activated receptors (PPARs) have four strands [13]. The region between H1 and 
Figure 1. Schematic representation of a NR. NRs consist of six domains (A-F). The N-terminus (A/
B) is variable, the DNA binding domain (DBD; C) is the most conserved region and contains two 
zinc fingers. The hinge region (D) is the connection between the DBD and the ligand-binding domain 
(LBD). The LBD (E) is mainly responsible for ligand binding and dimer formation and contains the 
activation function 2 (AF-2) domain. Some receptors possess an additional F region, for which the 
function is yet unknown.
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the retinoic acid-related orphan receptors (RORs), the vitamin D receptor (VDR) and liver 
receptor homolog 1 (LRH-1)). In some X-ray structures, the H2 region is not observed due 
to disorder or mobility. 
The ligand-binding pocket is very hydrophobic and is mainly formed by helices H3, H5, H6, 
and H11 and the small sheet. The residues of the ligand-dependent activation function 2 (AF-
2) are located in H12 [9]. The position of this helix is highly flexible, and its repositioning 
upon ligand binding is essential for recruitment of transcription cofactors, the so-called 
coactivators or corepressors. The three-dimensional structures of NRs have been determined 
in four different receptor conformations. At present these four conformations have not yet 
been solved for one receptor and therefore multiple receptors are used to illustrate these four 
conformations: apo-form (Figure 2a), agonist-bound (Figure 2b), and two different types of 
antagonist bound (Figure 2c, d). 
Most NRs can bind coactivators and corepressors that both bind at nearly the same spot, the so-
called cofactor-binding site. Coactivators and corepressors cannot be bound simultaneously. 
Upon agonist binding, H12 docks at the entrance to the ligand-binding pocket in the so-called 
H12 groove that is mainly formed by H3 and H11 (Figure 2b). This creates a charge clamp 
[17] consisting of the conserved glutamate in H12 and the conserved lysine at the C-terminal 
end of helix 3. This charge clamp is crucial for coactivator binding by interacting with the two 
poles of the helix dipole of the recognition helix of the coactivator [18, 19]. Upon antagonist 
binding, the ligand prevents H12 from docking in the H12 groove, a corepressor occupies 
part of this groove and H12 is forced to take an alternative position (Figure 2c). On the other 
hand, antagonists can also force H12 to dock in the cofactor-binding groove, resulting in 
repression of transactivation (Figure 2d). In this position H12 blocks coactivator binding 
[20]. Some NRs do not fit this mechanistic model. The Estrogen-Related Receptor 3 (ERR3) 
and LRH-1 constitutively activate transcription without any ligand bound [21, 22]. Similarly, 
the orphan receptor Nurr1 neither has a ligand-binding pocket, nor a cofactor-binding site 
and is constitutively active [22, 23]. Ligand-independent stabilisation is important for the 
transcription activity of these receptors [22, 23].
Sequence analysis
The analysis of conservation, correlation and variability patterns in multiple sequence 
alignments is a powerful tool for the study of protein families. The constraints that structure 
and function put on the sequence variation caused by evolutionary processes leave their traces 
in the multiple sequence alignment in many different ways [24-27]. The most prominent 
evolutionary trace, residue conservation, has been evaluated in multiple sequence alignments 
by means of variability (number of different amino acids found), Shannon entropy, variance-
based and score-matrix indices [28-30]. Conservation patterns have been used to improve 
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Figure 2. (a) Apo form of a NR LBD (figure based on PDB entry 1LBD [14], human retinoid X 
receptor (hRXRα)). (b) Structure with a bound agonist (3ERD [15], hERα, human estrogen receptor 
alpha). Act = the nuclear receptor coactivator 2 (NCoA-2) box II. (c) Structure with a bound antagonist 
and corepressor (1KKQ [16], hPPARα). Rep = the nuclear receptor co-repressor 2 (N-CoR2). (d) 
Structure with a bound antagonist (3ERT [15], hERα). Figures were generated with YASARA (http://
www.yasara.org). Helices 1-12 are shown as cylinders, the sheet as (red) arrows. Color version: see 
Appendix 2.
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Conserved residues sometimes are clustered at “universally conserved positions” [32], that can 
form a motif characteristic of the fold. These positions also can be found in the corresponding 
segments of analogs and their location often coincides with that of super-sites [33]. The 
identification of conservation patterns in proteins has been used to search for function. Some 
methods are based on energy calculations, and look for surfaces that potentially interact [34-
39]. Other methods predict functional motifs from an analysis of protein interaction surfaces 
using principal component analysis [40], analysis of physicochemical descriptors of protein-
protein interactions [41], motifs in Blocks databases [42], or alignment of hinge regions 
[43]. Evolutionary trace analyses involve searching for conservation patterns in different 
branches of phylogenetic trees and mapping them onto 3D structures to look for clusters of 
functionally important residues [27, 44-46].
These sequence analysis methods normally use a single measure of variability, and a Shannon-
type entropy term is commonly selected. Many of these methods are well suited to find 
functionally important residues but cannot generate a comprehensive overview of residue 
functions relative to each other and relative to the structure. 
We previously developed a sequence analysis technique based on the combination of two 
sequence variability measures. The first is a Shannon-type entropy. The second, variability, 
is the number of different amino acid types observed at one position in a multiple sequence 
alignment. A relation between the function of a residue and its location in a plot of entropy 
versus variability has been shown [24, 25]. Fine-tuning of the entropy by the variability and 
fine-tuning of the variability by the entropy allows us to draw many more conclusions about 
the role of individual residue positions than is possible using techniques based on variability 
or entropy alone.
The method was tested on four protein families for which very many sequences are available 
and for which the function of nearly all residues have been well-established experimentally: 
globin chains [47-50], GPCRs [25], ras-like proteins [51-55], and serine-proteases [56, 57]. 
Positions related to the main function, related to co-factor or regulator binding, positions in 
the core of the protein, and positions not associated with any known function cluster in the 
entropy-variability plots. This method requires correct alignments, which can be difficult to 
obtain when sequences in the family share low sequence identity. To circumvent this problem 
a multiple sequence alignment method based on structure superposition was used for the 
LBDs.
To corroborate the predicted role of residues in the LBD, the nuclear receptor mutation 
database [58] (NRMD) was used as a source for experimental verification. Experimental 
data on mutants are available for more than 75% of all residue positions in the NR LBD 
family. These experimental results were compared with the residue function as predicted 
from the sequence entropy and variability analysis. The excellent agreement between theory 
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and experiment for the residues for which mutation and structural data are available gives 
confidence in the prediction of the functional classification of the residues in the NR LBD for 
which no experimental data are available yet.
Results and discussion
The structurally conserved residues 
A fully automatic structure-based alignment of 184 individual LBD domains from 97 PDB 
files revealed 152 structurally conserved residues of which the C
α
 is within 1.9 Å of the 
average C
α
. The fully automatic multiple structure superposition procedure uses rather strict 
acceptance criteria upon defining this structurally conserved core. After visual inspection of 
the superposed LBD domains, 23 residues were added (mainly located at both ends of H1, 
the second sheet, H6 and the N-terminal part of H7). Helix 12 holds the conserved LXXLL 
sequence motif, which allows us to unambiguously add a helix of eight amino acids to the 
Figure 3. (a) Structurally conserved regions of the NR LBD mapped on 3ERD [15]. Figure was 
generated with YASARA (http://www.yasara.org). (b) A C
α
 trace of the structurally averaged LBD 
residues is shown in red. The three-dimensional blue ellipsoids represent the spread of the positions of 
the superposed alpha carbons. Details of the ellipsoid calculations are given on the website http://www.
receptors.org/NR/articles/JMB04/structsup.html. Color version: see Appendix 2.
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of 183 aligned residues (conserved regions, CR, Figure 3a) includes all helices and strands 
except the highly variable, and often even absent helix 2. Details about the automatic structure 
superposition method are available at http://www.receptors.org/NR/articles/JMB04/structsup.
html. This WWW page holds a detailed explication of the superposition method [59], the list 
of files and domains used, the RMS deviation for each residue in the superposition, pictures 
of each superposed domain, etc. Figure 3 shows the core of 183 residues (Figure 3a) and the 
RMS deviation per residue (Figure 3b). 
The retinoid X receptors (RXRs) have an insertion of a glutamic acid in the middle of H7 
[60]. For convenience, this glutamic acid is part of the alignment, but has not been included 
in the analyses. Table 1 shows for all regular secondary structure elements their lengths and 
lists the most conserved residues. Per structural element, the most conserved residue was 
labelled with the helix number followed by ‘50’.
Table 1. Numbering and length of secondary structure elements in the CR. The last two digits are the 
residue number in the secondary structure element. The helix number, or L or B precedes these two 
digits for loop or β-strand, respectively.
Secondary 
structure 
element
Numbering Length 3D number and 
identity of most 
conserved residue
Percent 
identity
Helix 1 137-156 20 150 E 48
Helix 3 328-353 26 350 A 95
Loop H3-H4 L341-L346 6 -
Helix 4 447-458 12 450 D 100
Helix 5 548-560 13 550 E 75
Beta sheet 1 B150-B155 6 -
Beta sheet 2 B250-B254 5 -
Helix 6 (if 
present)
647-653 7 650 (A, G, L, M) 18/11/23/21
Helix 7 736-751 16 750 L 46
Loop H7-H8 L781-L785 5 -
Helix 8 848-859 12 850 E 84
Helix 9 936-958 23 950 L 88
Helix 10/11 1038-1061 24 1050 L 68
Helix 12 1245-1252 8 1250 E 80
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Multiple sequence alignment of the NR LBDs
The structure-based alignment of 97 NR LBDs was used to generate an alignment profile. 
Starting from this profile 443 NR sequences could be reliably aligned. This alignment is 
available from the NucleaRDB at http://www.receptors.org/NR/. The sequences of the 
nematode Caenorhabditis elegans were not included in the multiple sequence alignment, 
because their LBDs are too different from all others [61]. Also, despite the structure-based 
Figure 4. Location of the 56 ligand binding positions in the NR LBD. (a) LIG1 (purple, six residues). 
(b) LIG2 (red, ten residues). (c) LIG3 (orange, 14 residues). (d) LIG4 (yellow, 26 residues). (e) Main 
hydrogen bond forming positions (light blue). Ligand (BMS184394) is shown in purple. The depicted 
structure is the LBD of the human retinoic acid receptor gamma (hRARγ), 1FCX [62]. Color version: 
see Appendix 2.
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and H12 in all receptors. The multiple sequence alignment shows well-aligned sequence 
fingerprints in many helices, e.g. the (W/F)A(K/R) motif in the C-terminal end of H3, the 
conserved DQ in H4 and the conserved glutamate in H12, as described by Wurtz et al. [11]. 
The ligand-binding residues
To identify the ligand-binding residues in the structure-based multiple sequence alignment 
the 3D positions of ligand-binding residues were determined in 86 LBD structures. NR LBD 
ligand-binding pockets vary widely in shape and volume. Consequently, we observe residue 
positions that are involved in ligand binding in some NRs but not in others. The positions 
of residues that are frequently (Ligand Interacting Group 1, LIG1), moderately (LIG2), 
occasionally (LIG3), or rarely (LIG4) involved in ligand contacts are shown in Figure 4 and 
listed (quantitatively) at http://www.receptors.org/NR/articles/JMB04/ligs.html. The dataset 
consists of 72 unique ligand-receptor combinations; LIG1 residues generally make at least 
one contact in 63-72 of these unique complexes, LIG2 in 38-62, LIG3 in 12-37 and LIG4 in 
1-11. Of the six LIG1 residues, two are in H3, two in the middle of H5, one in the sheet and 
one in H11 (Figure 4a). The ten LIG2 residues are located in the C-terminus of H3, in H5 and 
in H11 (Figure 4b). The LIG3 and LIG4 residue positions generally are further away from the 
centre of the ligand-binding pocket (Figure 4c and d).
PPAR, for example, can bind fatty acids and their long hydrophobic tails make contacts in 
regions of the receptor LBD where steroids never bind. Several LIG4 residue positions are 
involved in ligand binding in the PXR receptor. PXR serves as a broad chemical ‘sensor’ [12] 
and can bind very large compounds (such as rifampicin). Figure 4e shows the four residue 
positions (B155, 342, 559, 1057) that often form a hydrogen bond with the ligand. Most 
ligands are anchored in the binding pocket by at least one such hydrogen bond.
Entropy-variability plot 
Previous studies on four very well characterised protein families [24, 25] (globins, ras-
like proteins, GPCRs, and serine-proteases) showed that residues can be clustered in five 
groups as function of their entropy and variability. These groups correspond to boxes in the 
entropy-variability plot as shown in Figure 5, and the following relation between the boxes 
and residue function was observed: box
11
 residues are involved in the main function of the 
protein; box
12
 contains the shell of residues around the main functional site; box
22
 residues 
are often spatially located between box
12
 and box
23
 residues, these positions are mainly 
involved in signal transduction between the modulator site and main functional site; box
23
 
mainly contains residues that interact with a modulator; box
33
 residues mainly are found at 
the surface of the protein away from the main functional site.
Figure 5 shows the entropy variability plot based on the alignment of 443 NR-LBDs. In the 
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following sections, the residues in the five boxes will be described box by box. However, it 
has to be kept in mind that the location of a residue in the entropy variability plot depends on 
the choice of sequences and on the alignment. Consequently, residues that are located near the 
border between boxes sometimes can end up in the neighbour box if just a few sequences are 
added to the alignment. We have previously observed that residues near the borders between 
two boxes display functional characteristics commensurate with both boxes [24, 25]; the 
constant factor is that residues that are at a similar location in the entropy-variability plot are 
also functionally similar. The recipe for defining the borders was optimised previously based 
upon experimental data on globins, ras-like proteins, GPCRs, and serine-proteases [24, 25].
Functional characterisation of box residues
Figure 6 shows the mapping of ligand-binding, cofactor-binding and dimer-binding residues 
on the different boxes. 
The important cofactor-binding residues are mainly observed in box
11
 and box
12
, indicating 
that the main function of NRs is the recruitment of cofactors (Figure 6a). The most frequent 
ligand-binding residues (LIG1 and LIG2) fall mainly in box
23
 (Figure 6b). As expected a 
large number of the less frequent ligand-binding residues (LIG3 and LIG4) tend to be located 
mainly in box
33
. Residues involved in homo- and heterodimerisation are located for 50% in 
box
33
 (Figure 6c). These residues are located at the surface of the LBD. Some of the frequently 
observed dimerisation residues, however, are observed in box
22
 and box
23
, suggesting that a 
dimerisation partner may also act as a modulator and that signal transduction between the 
Figure 5. Entropy-variability plot for residue positions in the CR. The five boxes (11, 12, 22, 23, and 33) 
are indicated. The curved line indicates the maximum entropy possible as function of the variability.
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three binding sites (cofactor, ligand, dimer) plays a role in dimerisation. A recent article 
describing the heterodimer of the ecdysone receptor (EcR) and ultraspiracle (USP) shows 
that ligand binding to EcR requires interaction with USP, allowing the flexible part of the 
EcR to mould around the ligand [63]. It is also known that a ligand of one member of an 
RXR heterodimer can affect the activity of the partner LBD, which is known as the ‘phantom 
ligand effect’ [64, 65]. 
Box
11
. The seven box
11
 residues are located at the C-terminal end of H3, the loop between H3 
and H4, and at the N-terminal end of H4 (Figure 7a). This region is known as the cofactor-
binding site, and the location of box
11
 residues in this region confirms that cofactor binding is 
Figure 6. Distribution of residue positions involved in the three functions of the NR LBD. (a) Cofactor-
contacting residues. COF1 are residue positions found to bind the cofactor in more than 60% of the 
known cases, COF2 are the less frequently observed cofactor-binding residue positions (but observed 
in >30% of the known structures). (b) Ligand-contacting residues (LIG1, LIG2, LIG2, LIG4). (c) 
Residues involved in dimerisation. DIM1 and DIM2 as COF1 and COF2 but contacts are dimerisation 
contacts. (d) Number of CR positions that are not involved in intermolecular interactions in any of the 
97 PDB files studied. (e) As (d) but expressed as a percentage.
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the main function of NRs. Three out of seven box
11
 residues make a contact with the cofactor 
fragment in at least one PDB [67] file. Because we do not observe box
11
 residues outside the 
cofactor-binding pocket, we concluded that this pocket is the entire cofactor-binding region, 
and that the structurally unknown rest of the cofactor does not make additional important 
contacts with the LBD.
Figure 7. Structural location of the residues in the five boxes. (a) Box
11
 (purple). (b) Box
12
 (orange). 
(c) Box
22
 (yellow). (d) Box
23
 (green). (e) Box
33
 (light blue). In (f) box
33
 residues (light blue) are shown 
again but this time accessible residues are indicated with small dots. For easy reference, the coactivator 
helix of the glucocorticoid receptor-interacting protein 1 (GRIP-1), as observed in a PDB file of hERα 
(3ERD [15]), and the agonist dihydrotestosteron as observed in the PDB file of the human androgen 
receptor (1I37 [66]) are shown in yellow and purple, respectively. Color version: see Appendix 2.
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box
11
 residues and either the ligand-binding pocket or the dimer interface (Figure 7b). Our 
cofactor contact analysis showed that three of these box
12
 residues (347, 351 and 456) are 
frequently (84%, 100% and 74%, respectively) observed in an interaction with a cofactor. 
The predicted function of box
12
 residues is assistance to the main function. The location of 
the box
12
 residues suggests that ligand and dimer partner are assisting in cofactor recruitment 
through these box
12
 residues.
Box
22
. Box
22
 contains 23 residues, which form the second shell of positions around the 
box
11
 and box
12
 residues. They are mainly located in the ‘core’ of the protein in-between the 
cofactor site and either the ligand-binding pocket or the dimer interface. The location of these 
residues in the LBD is in agreement with a potential signal transduction role between the 
three functional sites (cofactor-binding site; ligand-binding site; dimer interface site). A few 
box
22
 residues are located at the dimer interface surface (Figure 7c). Previous entropy versus 
variability analyses showed that box
22
 residues were most often buried, but when observed at 
the surface, they were almost invariably involved in functionally important inter molecular 
interactions. In haemoglobins, for example, surface-exposed box
22
 residues are implicated in 
subunit-subunit interactions [24] that are important for the cooperativity of oxygen binding. 
In LBDs, we observe three box
22
 residues at the surface of helix 10. This helix often plays 
an important role in dimer formation [60, 68]. The fact that we observe box
22
 residues at 
the dimer interface surface is in agreement with the known LBD-LBD interactions that are 
functionally very important. This suggests that cooperativity can exist in the ligand binding 
of two LBDs that form a dimer.
Box
23
. The 53 box
23
 residues comprise almost the entire ligand-binding pocket and consist 
mainly of residues in H3, H5 and H11 (Figure 7d). The majority of the box
23
 residues are 
members of the LIGs (Figure 6b). This is in good agreement with the predicted function of 
modulator binding residues.
Box
33
. Box
33
 contains 70 residues. Figure 7e shows that they are located at the surface of 
the LBD. Many of them are involved in dimerisation (see Figure 6c). Half of the LIG3 and 
LIG4 residues, only one LIG2 residue, but none of the LIG1 residues are observed in box
33
 
(Figure 6b). This confirms the predicted role of box
33
 residues as being surface-exposed and 
not essential for the function of the protein.
To corroborate the function of the various box residues, mutation data for the CR residues 
were extracted (when available) from the nuclear receptor mutant database [58] (NRMD). 
The results of mutations of box
11
 residues have been summarised at http://www.receptors.
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org/NR/articles/JMB04/box11mutations.html. Five out of seven box
11
 mutations are related 
to a disease, indicating distortion of the main function. Only the box
11
 residue mutations 
at positions 350 and 454 have not yet been observed to be related to a disease. However, 
mutation of residue 350 in the human androgen receptor results in less than 10% of the 
amount of ligand bound compared to the wild-type receptor, while there was no change in 
affinity for the longer isoform of coactivator ARA
70
 [69]. Mutation of residue 454 led to 
impairment of transcription activation by the human VDR. The mutant could bind 1,25-
dihydroxyvitamin but was defective in forming a heterodimer with RXR [70].
To characterise and verify the potential functional role of the residues in the five boxes we 
analysed their mutations. 45% of the mutations in the NRMD are extracted automatically from 
the literature by MuteXt [71], the rest are collected automatically from several web-based 
resources (list available at http://www.receptors.org/NR/articles/JMB04/mutationsources.
html) or manually extracted from the literature. MuteXt can identify 64.5% of the NR point 
mutations with a specificity of 85.8% (specificity is the ratio between the true positives and 
the sum of true positives and false positives). A total of 375 mutations were distributed over 
five functional classes: (a) disease or transcription; (b) cofactor binding; (c) dimerisation; (d) 
ligand binding; (e) no effect. Disease and transcription were taken as one category because 
they are related and for both it is unclear whether they are caused by the underlying effects 
on cofactor, ligand or dimer partner binding. 
Figure 8 shows that almost 50% of the mutations are disease or transcription related. The 
remaining 50% of the mutations are approximately evenly distributed across the four other 
categories. 5% of all mutations were described to have an effect in multiple categories, and 
in 50% of all cases different studies showed different effects for the same mutated position. 
Figure 8. Number of mutations per category for the CR.
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This seems to suggest that some studies are conflicting, but we think that more often the 
data actually are complementary. Residues (especially those in box
22
) often are involved in 
multiple aspects of the functioning. If a study aims at measuring ligand binding of a certain 
residue, then it is likely that effects at transcription might not be observed in that same study. 
In all these cases, we simply counted each experimental observation once, so that we have 
considerably more mutations than residue positions in this study. The distribution of the 
mutations of residues over the five categories for the five entropy-variability boxes is depicted 
in Figure 9 and will be described per category.
a. Disease and transcription. Due to the nature of the assays it is often hard to precisely 
pinpoint the molecular consequences of mutations. For example, if a mutation has been 
described to cause a disease, it is not clear whether this results from diminished ligand 
binding, modified cofactor specificity, loss of dimerisation, etc. The same problems hold if 
Figure 9. Distribution of the mutations throughout each entropy-variability box for various mutation 
categories. (a) Disease and transcription. (b) Cofactor. (c) Dimerisation. (d) Ligand binding. (e) No 
effect.
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the observed effect is altered transcription. For this reason disease and transcription were 
combined in one category. Figure 9a shows that disease and transcription related mutations 
are evenly distributed throughout all boxes, suggesting that this category, as extracted from 
the NRMD mutant description information, is too general to correlate with the detailed 
functional role of the residues. 
b. Cofactor binding. Mutations with an effect on cofactor binding are mainly located in 
box
12
 (Figure 9b). Corollary, 35% of the mutations in box
12
 show a cofactor-related effect. 
This supports very well the previous finding that box
12
 residues are involved in the cofactor 
binding function of NRs. Actually, one would expect that mutation of box
11
 residues would 
lead to effects on cofactor binding, but this is not observed. A potential explanation is the 
fact that box
11
 residues are involved in the main function of the protein. They are therefore 
so important that their mutation is likely to lead to a completely inactive protein. This can 
explain the very small number of data on box
11
 residues and the absence of clear effects on 
cofactor binding.
c. Dimerisation. Box
22
 normally contains residues involved in signal transduction between 
the main functional site and modulator sites. Most box
22
 mutations in NRs cause a change 
in dimerisation properties (Figure 9c). This suggests that dimerisation could be a modulator 
for the main function: cofactor binding. Thus, dimerisation may be a prerequisite for specific 
cofactor binding. Gampe et al. [72] already described that helix 12 of PPARγ is stabilised by 
interaction with residues in its heterodimeric partner RXRα. Since this helix is important in 
cofactor recruitment, this interaction could create a different cofactor-binding environment 
at the surface of PPARγ than without this interaction. On the other hand, analysis of the 3D 
structures reveals a large series of box
23
 and box
33
 residues that are involved in dimerisation 
too. So, despite a low conservation of the dimer interface, the residues involved in signalling 
between the main functional site and the dimer/modulator site are also observed in box
22
, as 
expected from previous entropy-variability analysis studies [24].
d. Ligand binding. Mutations that result in an effect on ligand binding, are almost all found 
in box
23
 (Figure 9d). Corollary, nearly 30% of all mutations described for box
23
 disturb 
ligand binding. The other effects observed upon mutation of box
23
 residues are probably the 
result of either noise in the entropy-variability analysis method, or incomplete experimental 
characterisation of the mutants. For example, if a series of mutations are analysed for their 
function in cofactor binding, then the described effect can only be observed on cofactor 
binding, even if this effect is the indirect result of modified ligand interactions.
e. No effect. The mutations that show no effect on transcription, dimerisation or ligand 
binding are mainly located in box
23
 and box
33
 (Figure 9e). However, for each published silent 
mutation, we found at least one other study in which a mutation at the equivalent position in 
the same or another molecule did show some effect on some functional aspect.
No mutation. We could not find mutation information for 39 residues in the CR. Most of 
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these positions fall in box
33
, which confirms the less important nature of residues in this box 
(Figure 10). 
It is, of course, not clear whether these residues have never been mutated yet, or that they 
have been mutated but showed no effects and therefore were not published.
Problems with mutation analysis
The heterogeneity of mutation data makes their analyses difficult. Some scientists study the 
effect on ligand binding, others on transcription of a specific gene, and for some mutations, 
it is only known that they are related to a specific disease. Obviously, effects that are not 
analysed cannot be reported, leading to under-reporting of effects that are difficult to observe 
experimentally. It is highly likely that for many mutations only the most severe effect is 
reported. If, for example, a mutation influences ligand binding in a way that results in a loss 
of cofactor binding, then this cofactor influence is reported and not the underlying ligand 
binding effect. The data shown in Figure 9 should therefore not be seen as a quantitative 
measure, but merely as qualitative indications.
Concluding Remarks
We have demonstrated that a family-based approach in which theoretical and experimental 
data are combined can reveal much information about a protein family. This approach works 
well because residues located at equivalent positions in structures of homologous proteins 
have similar functions, even when the residue types are different. This family-based approach 
requires a high quality multiple sequence alignment that only includes residues located at 
positions that are equivalent in the structures. Insertions and loops that can adopt different 
local conformations in different structures should not be part of the study and thus not be part 
of the alignment. In addition, the huge amount of sequences available in today’s publicly 
Figure 10. Distribution throughout the entropy-variability boxes, of the residue positions for which no 
mutant information is available (as percentage of the total number of positions for which no mutation 
information is available).
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available databases, allows us to introduce new multiple sequence alignment analysis 
techniques such as entropy-variability analysis. This new approach was applied to the nuclear 
receptor protein family to functionally classify residues in the NR LBD. The experimental 
and structural data available for these residues agreed well with this functional classification, 
which gives us faith in the predictive value of the classification scheme for those residues for 
which experimental data are not (yet) available. 
This classification scheme showed that the main function of the nuclear receptors is cofactor 
recruitment. In addition, a more interesting result is the prediction of the existence of signal 
transduction residues between ligand-binding pocket, the cofactor-binding pocket and the 
dimer interface. This idea is supported by the specific location of these residues in the LBD 
and by a study of the mutation data. Recent publications by Shulman et al. [73] and Nettles 
et al. [74] and the so-called ‘phantom ligand effects’ [64, 65] confirm the existence of signal 
transduction processes. In this study, potential signal transduction residues were identified that 
will be the subject of future research. In addition, NRs contain more sequence signals than 
just those that we discussed here. Examples are glycosylation, sumoylation, phosphorylation 
sites etc. However, those signals often are not conserved throughout the entire NR family, 
and consequently are not very important from a family-wide perspective.
Finally, the huge amount of data used in this study also made it very clear that many more 
(automated) literature data-extraction, and sequence and structure analysis methods are 
required to classify residues better, and with more detail. Many more data and results from 
this family based study are available at the WWW address: http://www.receptors.org/NR/.
Materials and Methods
Structure superposition-based sequence alignment
Sequences were obtained from SWISS-PROT and TrEMBL [75], and the NucleaRDB [76]. 
A total of 97 NR LBD structures were extracted from the PDB [67] and grouped in 26 
subfamilies according to the classification of the Structural Classification of Proteins (SCOP) 
structure comparison resource [77]. Structure superposition [59] and sequence alignment 
were performed using WHAT IF [78]. The structure-based sequence alignment is a five-step 
process that is described in great detail at the WWW at http://www.receptors.org/NR/articles/
JMB04/structsup.html, and will only be briefly summarised here. 1) 184 LBD domains 
are collected, validated and stored in the WHAT IF internal database. 2) All domains are 
structurally superposed on one (randomly chosen) domain. 3) All positions that superpose 
within essentially 1.9 Å of the average C
α
 in more than 90% of the domains were structurally 
averaged. 4) All domains are superposed again, but now on this set of averaged residues. 5) 
Residues that superpose on the same averaged residue in this second superposition round are 
placed ‘underneath each other’ in the final, structure-based sequence alignment. 
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conserved parts were included to arrive at the final conserved regions (CR), despite the fact 
that their r.m.s.d. was >1.9 Å. The functionally very important helix 12 was included despite 
the fact that it cannot be structurally superposed. However, the alignment is quite reliable 
due to the LXXLL-like motif in H12. For each of the 26 subfamilies, a sequence profile was 
derived from the corresponding superposed structures. Residue positions not present in the 
CR were removed from these subfamily-specific structure-based sequence profiles. These 
subfamily-specific profiles were used to align all sequences with more than 40% sequence 
identity. This cutoff was based on the experience that sequences in one subfamily seldom 
differed more than 60%. The representative structures were superposed and the resulting 
structure-based alignments were used to combine the family-specific multiple sequence 
alignments into one big alignment. An overall profile was generated from this overall 
alignment and all sequences that had not yet been included were aligned against this profile. 
The final multiple sequence alignment did not include all available sequences, but only the 
sequences that could be aligned well.
Numbering scheme for structurally conserved residues
A common residue-numbering scheme was introduced to allow for a coherent discussion of 
the results. Each residue is labelled with a two-digit number preceded by either the number 
of the helix, or a B or L for beta strands and loops, respectively. The two digit numbers are 
chosen such that the most conserved residue in each helix gets number 50.
Analysis of the multiple sequence alignment
Entropy-variability analysis was performed as described [24]. For each residue position in 
the alignment, two parameters were defined: the variability and a Shannon-type entropy. The 
variability, V
p
, is defined as the number of different amino acids observed at position p in 
the multiple sequence alignment, in at least 0.5% of all sequences. The Shannon entropy is 
given by:
           20
Sp =  - Σ  f
pi
 * ln(f
pi
)   
           i=1
in which i loops over the 20 amino acid types, p loops over all positions in the structural 
alignment, and f
pi
 is the weighted frequency of residue type i at position p in the multiple 
sequence alignment [24]. The residue positions were clustered in five groups according to 
their entropy and variability. The recipe for the definition of the borders was optimised to 
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generate a maximal correlation between box number and residue function in four protein 
families for which the function of nearly all residues has been well-established experimentally: 
globin chains, GPCRs, ras-like proteins, and serine-proteases [24, 25]. This recipe divides the 
entropy axis into three parts. The lower boundary is at 0.4. The upper boundary is halfway 
between the lower boundary and the highest observed entropy. The first boundary of the 
variability axis is at the highest variability in box
11
, the second boundary was at the highest 
variability in box
22
. According to this recipe, box
11
 residues are involved in the main function, 
box
12
 residues are support for the main function, box
22
 are signal transducing residues between 
modulator and main function, box
23
 are modulator binding residues and box
33
 residues have 
no important function.
Extraction of contact residues from structures
Residues that are in contact with a ligand, cofactor or dimeric partner, were extracted from 
the X-ray structures using WHAT IF [78]. A contact was defined as two atoms for which the 
distance between the Van der Waals’ surfaces is less than 1.0 Å (ligand) or 0.25 Å (cofactor 
and dimer). A total of 86 LBDs out of 97 PDB files contain a ligand and were used to analyse 
the residues in the LBD that form a contact with the ligand. Ions, cosolvents and compounds 
that did not bind in the ligand-binding pocket were excluded from the analysis by means of 
an exclusion dictionary, minimum size and visual inspection. Four sets of residues, so-called 
Ligand Interacting Groups (LIGs), were defined based on the frequency of contacts with 
the ligand. LIG1, LIG2, LIG3 and LIG4 residues showed to have >1000, >500, >100, and 
1-100 contacts, respectively, integrated over all structures. Cofactor contacting residues were 
similarly identified using 16 structures, i.e., 15 coactivators and one corepressor structure. 
Residues involved in homo- or heterodimer contacts were extracted using the same method 
for 22 dimer structures. Functional dimers were identified by visual inspection, and the 
literature.
Nuclear receptor mutation database (NRMD)
Information about mutations in NRs was extracted from the mutation data in the NucleaRDB, 
databases and lists on the Internet (http://www.receptors.org/NR/articles/JMB04/
mutationsources.html), and scientific papers.
Most of these mutation data were extracted from full text articles (using fully automatic 
methods [71]) and collected in the NRMD. The database contains 1095 mutation entries 
divided over 41 NRs, of which 375 fall in the CR. Each NRMD entry contains one mutation 
and, if available, its effect. 
Mutation effects
The effects of mutations at residue positions in the CR were classified according to the 
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cofactor binding, c) dimerisation, d) ligand binding, and e) no effect. Disease and transcription 
were grouped in one category, because for both it is unclear whether they are caused by the 
underlying effects on cofactor, ligand or dimer partner binding. If a mutation led to an effect 
on more than one function, all were used in the analysis. If a position was mutated together 
with other positions (double or triple mutants) the resulting effect was used for all mutated 
positions. 
Acknowledgements
We thank Unilever and Organon for financial support and Henk Stunnenberg for critically 
reading this manuscript.
C
hapter 2
49
References
1. Mangelsdorf, D.J., et al., The nuclear receptor superfamily: the second decade. 
Cell, 1995. 83(6): p. 835-9.
2. NRNC, A unified nomenclature system for the nuclear receptor superfamily. Cell, 
1999. 97(2): p. 161-3.
3. Kliewer, S.A., J.M. Lehmann, and T.M. Willson, Orphan nuclear receptors: shifting 
endocrinology into reverse. Science, 1999. 284(5415): p. 757-60.
4. Huang, H. and D.J. Tindall, The role of the androgen receptor in prostate cancer. 
Crit Rev Eukaryot Gene Expr, 2002. 12(3): p. 193-207.
5. Jones, A.B., Peroxisome proliferator-activated receptor (PPAR) modulators: 
diabetes and beyond. Med Res Rev, 2001. 21(6): p. 540-52.
6. Bonnelye, E., et al., Estrogen receptor-related receptor alpha impinges on the 
estrogen axis in bone: potential function in osteoporosis. Endocrinology, 2002. 
143(9): p. 3658-70.
7. Hopkins, A.L. and C.R. Groom, The druggable genome. Nat Rev Drug Discov, 
2002. 1(9): p. 727-30.
8. Katzenellenbogen, J.A. and B.S. Katzenellenbogen, Nuclear hormone receptors: 
ligand-activated regulators of transcription and diverse cell responses. Chem Biol, 
1996. 3(7): p. 529-36.
9. Danielian, P.S., et al., Identification of a conserved region required for hormone 
dependent transcriptional activation by steroid hormone receptors. Embo J, 1992. 
11(3): p. 1025-33.
10. Evans, R.M., The steroid and thyroid hormone receptor superfamily. Science, 1988. 
240(4854): p. 889-95.
11. Wurtz, J.M., et al., A canonical structure for the ligand-binding domain of nuclear 
receptors. Nat Struct Biol, 1996. 3(2): p. 206.
12. Watkins, R.E., et al., The human nuclear xenobiotic receptor PXR: structural 
determinants of directed promiscuity. Science, 2001. 292(5525): p. 2329-33.
13. Kliewer, S.A., et al., Peroxisome proliferator-activated receptors: from genes to 
physiology. Recent Prog Horm Res, 2001. 56: p. 239-63.
14. Bourguet, W., et al., Crystal structure of the ligand-binding domain of the human 
nuclear receptor RXR-alpha. Nature, 1995. 375(6530): p. 377-82.
15. Shiau, A.K., et al., The structural basis of estrogen receptor/coactivator recognition 
and the antagonism of this interaction by tamoxifen. Cell, 1998. 95(7): p. 927-37.
16. Xu, H.E., et al., Structural basis for antagonist-mediated recruitment of nuclear co-
repressors by PPARalpha. Nature, 2002. 415(6873): p. 813-7.
17. Bourguet, W., P. Germain, and H. Gronemeyer, Nuclear receptor ligand-binding 
domains: three-dimensional structures, molecular interactions and pharmacological 
implications. Trends Pharmacol Sci, 2000. 21(10): p. 381-8.
18. Darimont, B.D., et al., Structure and specificity of nuclear receptor-coactivator 
interactions. Genes Dev, 1998. 12(21): p. 3343-56.
19. Nolte, R.T., et al., Ligand binding and co-activator assembly of the peroxisome 
proliferator-activated receptor-gamma. Nature, 1998. 395(6698): p. 137-43.
20. Brzozowski, A.M., et al., Molecular basis of agonism and antagonism in the 
oestrogen receptor. Nature, 1997. 389(6652): p. 753-8.
21. Greschik, H., et al., Structural and functional evidence for ligand-independent 
50
E
nt
ro
py
-v
ar
ia
bi
lit
y transcriptional activation by the estrogen-related receptor 3. Mol Cell, 2002. 9(2): 
p. 303-13.
22. Sablin, E.P., et al., Structural basis for ligand-independent activation of the orphan 
nuclear receptor LRH-1. Mol Cell, 2003. 11(6): p. 1575-85.
23. Wang, Z., et al., Structure and function of Nurr1 identifies a class of ligand-
independent nuclear receptors. Nature, 2003. 423(6939): p. 555-60.
24. Oliveira, L., et al., Identification of functionally conserved residues with the use of 
entropy-variability plots. Proteins, 2003. 52(4): p. 544-52.
25. Oliveira, L., et al., Sequence analysis reveals how G protein-coupled receptors 
transduce the signal to the G protein. Proteins, 2003. 52(4): p. 553-60.
26. Bork, P. and T.J. Gibson, Applying motif and profile searches. Methods Enzymol, 
1996. 266: p. 162-84.
27. Lichtarge, O., H.R. Bourne, and F.E. Cohen, An evolutionary trace method defines 
binding surfaces common to protein families. J Mol Biol, 1996. 257(2): p. 342-58.
28. Mirny, L. and E. Shakhnovich, Evolutionary conservation of the folding nucleus. J 
Mol Biol, 2001. 308(2): p. 123-9.
29. Pei, J. and N.V. Grishin, AL2CO: calculation of positional conservation in a protein 
sequence alignment. Bioinformatics, 2001. 17(8): p. 700-12.
30. Shenkin, P.S., B. Erman, and L.D. Mastrandrea, Information-theoretical entropy as 
a measure of sequence variability. Proteins, 1991. 11(4): p. 297-313.
31. Zuckerkandl, E. and L. Pauling, Evolutionary divergence and convergence in 
proteins. Evolving genes and proteins. New York: Academic Press, 1965: p. 97-
166.
32. Mirny, L.A. and E.I. Shakhnovich, Universally conserved positions in protein folds: 
reading evolutionary signals about stability, folding kinetics and function. J Mol 
Biol, 1999. 291(1): p. 177-96.
33. Russell, R.B., P.D. Sasieni, and M.J. Sternberg, Supersites within superfolds. Binding 
site similarity in the absence of homology. J Mol Biol, 1998. 282(4): p. 903-18.
34. Kuntz, I.D., et al., A geometric approach to macromolecule-ligand interactions. J 
Mol Biol, 1982. 161(2): p. 269-88.
35. DesJarlais, R.L., et al., Using shape complementarity as an initial screen in designing 
ligands for a receptor binding site of known three-dimensional structure. J Med 
Chem, 1988. 31(4): p. 722-9.
36. Honig, B. and A. Nicholls, Classical electrostatics in biology and chemistry. Science, 
1995. 268(5214): p. 1144-9.
37. Miranker, A. and M. Karplus, Functionality maps of binding sites: a multiple copy 
simultaneous search method. Proteins, 1991. 11(1): p. 29-34.
38. Lamb, M.L. and W.L. Jorgensen, Computational approaches to molecular 
recognition. Curr Opin Chem Biol, 1997. 1(4): p. 449-57.
39. Wang, W., et al., Biomolecular simulations: recent developments in force fields, 
simulations of enzyme catalysis, protein-ligand, protein-protein, and protein-nucleic 
acid noncovalent interactions. Annu Rev Biophys Biomol Struct, 2001. 30: p. 211-
43.
40. Casari, G., C. Sander, and A. Valencia, A method to predict functional residues in 
proteins. Nat Struct Biol, 1995. 2(2): p. 171-8.
41. Jones, S. and J.M. Thornton, Prediction of protein-protein interaction sites using 
patch analysis. J Mol Biol, 1997. 272(1): p. 133-43.
C
hapter 2
51
42. Pietrokovski, S., J.G. Henikoff, and S. Henikoff, The Blocks database--a system for 
protein classification. Nucleic Acids Res, 1996. 24(1): p. 197-200.
43. Shatsky, M., R. Nussinov, and H.J. Wolfson, Flexible protein alignment and hinge 
detection. Proteins, 2002. 48(2): p. 242-56.
44. Sali, A., et al., From comparisons of protein sequences and structures to protein 
modelling and design. Trends Biochem Sci, 1990. 15(6): p. 235-40.
45. Innis, C.A., J. Shi, and T.L. Blundell, Evolutionary trace analysis of TGF-beta and 
related growth factors: implications for site-directed mutagenesis. Protein Eng, 
2000. 13(12): p. 839-47.
46. Landgraf, R., I. Xenarios, and D. Eisenberg, Three-dimensional cluster analysis 
identifies interfaces and functional residue clusters in proteins. J Mol Biol, 2001. 
307(5): p. 1487-502.
47. Nobbs, C.L., H.C. Watson, and J.C. Kendrew, Structure of deoxymyoglobin: a 
crystallographic study. Nature, 1966. 209(21): p. 339-41.
48. Perutz, M.F., The Croonian Lecture, 1968. The haemoglobin molecule. Proc R Soc 
Lond B Biol Sci, 1969. 173(31): p. 113-40.
49. Perutz, M.F., Stereochemistry of cooperative effects in haemoglobin. Nature, 1970. 
228(273): p. 726-39.
50. Royer, W.E., Jr., W.A. Hendrickson, and E. Chiancone, Structural transitions upon 
ligand binding in a cooperative dimeric hemoglobin. Science, 1990. 249(4968): p. 
518-21.
51. Pai, E.F., et al., Structure of the guanine-nucleotide-binding domain of the Ha-ras 
oncogene product p21 in the triphosphate conformation. Nature, 1989. 341(6239): 
p. 209-14.
52. Pai, E.F., et al., Refined crystal structure of the triphosphate conformation of H-ras 
p21 at 1.35 A resolution: implications for the mechanism of GTP hydrolysis. Embo 
J, 1990. 9(8): p. 2351-9.
53. Takai, Y., T. Sasaki, and T. Matozaki, Small GTP-binding proteins. Physiol Rev, 
2001. 81(1): p. 153-208.
54. Huang, L., et al., Structural basis for the interaction of Ras with RalGDS. Nat Struct 
Biol, 1998. 5(6): p. 422-6.
55. Pacold, M.E., et al., Crystal structure and functional analysis of Ras binding to its 
effector phosphoinositide 3-kinase gamma. Cell, 2000. 103(6): p. 931-43.
56. Ruhlmann, A., et al., Structure of the complex formed by bovine trypsin and bovine 
pancreatic trypsin inhibitor. Crystal structure determination and stereochemistry of 
the contact region. J Mol Biol, 1973. 77(3): p. 417-36.
57. Huber, R., et al., Structure of the complex formed by bovine trypsin and bovine 
pancreatic trypsin inhibitor. II. Crystallographic refinement at 1.9 A resolution. J 
Mol Biol, 1974. 89(1): p. 73-101.
58. Van Durme, J.J., et al., NRMD: Nuclear Receptor Mutation Database. Nucleic 
Acids Res, 2003. 31(1): p. 331-3.
59. Vriend, G. and C. Sander, Detection of common three-dimensional substructures in 
proteins. Proteins, 1991. 11(1): p. 52-8.
60. Gampe, R.T., Jr., et al., Structural basis for autorepression of retinoid X receptor by 
tetramer formation and the AF-2 helix. Genes Dev, 2000. 14(17): p. 2229-41.
61. Enmark, E. and J.A. Gustafsson, Comparing nuclear receptors in worms, flies and 
humans. Trends Pharmacol Sci, 2001. 22(12): p. 611-5.
52
E
nt
ro
py
-v
ar
ia
bi
lit
y 62. Klaholz, B.P., A. Mitschler, and D. Moras, Structural basis for isotype selectivity of 
the human retinoic acid nuclear receptor. J Mol Biol, 2000. 302(1): p. 155-70.
63. Billas, I.M., et al., Structural adaptability in the ligand-binding pocket of the 
ecdysone hormone receptor. Nature, 2003. 426(6962): p. 91-6.
64. Schulman, I.G., et al., The phantom ligand effect: allosteric control of transcription 
by the retinoid X receptor. Genes Dev, 1997. 11(3): p. 299-308.
65. Willy, P.J. and D.J. Mangelsdorf, Unique requirements for retinoid-dependent 
transcriptional activation by the orphan receptor LXR. Genes Dev, 1997. 11(3): p. 
289-98.
66. Sack, J.S., et al., Crystallographic structures of the ligand-binding domains of 
the androgen receptor and its T877A mutant complexed with the natural agonist 
dihydrotestosterone. Proc Natl Acad Sci U S A, 2001. 98(9): p. 4904-9.
67. Berman, H.M., et al., The Protein Data Bank. Nucleic Acids Res, 2000. 28(1): p. 
235-42.
68. Bourguet, W., et al., Crystal structure of a heterodimeric complex of RAR and RXR 
ligand-binding domains. Mol Cell, 2000. 5(2): p. 289-98.
69. Alen, P., et al., Interaction of the putative androgen receptor-specific coactivator 
ARA70/ELE1alpha with multiple steroid receptors and identification of an internally 
deleted ELE1beta isoform. Mol Endocrinol, 1999. 13(1): p. 117-28.
70. Whitfield, G.K., et al., A highly conserved region in the hormone-binding domain 
of the human vitamin D receptor contains residues vital for heterodimerization with 
retinoid X receptor and for transcriptional activation. Mol Endocrinol, 1995. 9(9): 
p. 1166-79.
71. Horn, F., A.L. Lau, and F.E. Cohen, Automated extraction of mutation data from 
the literature: application of MuteXt to G protein-coupled receptors and nuclear 
hormone receptors. Bioinformatics, 2004. 20(4): p. 557-68.
72. Gampe, R.T., Jr., et al., Asymmetry in the PPARgamma/RXRalpha crystal structure 
reveals the molecular basis of heterodimerization among nuclear receptors. Mol 
Cell, 2000. 5(3): p. 545-55.
73. Shulman, A.I., et al., Structural determinants of allosteric ligand activation in RXR 
heterodimers. Cell, 2004. 116(3): p. 417-29.
74. Nettles, K.W., et al., Allosteric control of ligand selectivity between estrogen 
receptors alpha and beta: implications for other nuclear receptors. Mol Cell, 2004. 
13(3): p. 317-27.
75. Boeckmann, B., et al., The SWISS-PROT protein knowledgebase and its supplement 
TrEMBL in 2003. Nucleic Acids Res, 2003. 31(1): p. 365-70.
76. Horn, F., G. Vriend, and F.E. Cohen, Collecting and harvesting biological data: the 
GPCRDB and NucleaRDB information systems. Nucleic Acids Res, 2001. 29(1): p. 
346-9.
77. Murzin, A.G., et al., SCOP: a structural classification of proteins database for the 
investigation of sequences and structures. J Mol Biol, 1995. 247(4): p. 536-40.
78. Vriend, G., WHAT IF: a molecular modeling and drug design program. J Mol 
Graph, 1990. 8(1): p. 52-6, 29.
C
hapter 3
53
Chapter 3
The Nuclear Receptor Ligand-Binding Domain: 
a family-based structure analysis
Simon Folkertsma, Paula I. van Noort, Ralph F.J. Brandt, Emmanuel Bettler, Gerrit 
Vriend and Jacob de Vlieg
Curr Med Chem. 2005 12(9):1001-16
54
S
tru
ct
ur
al
 a
na
ly
si
s Abstract
Nuclear receptors (NRs) are ligand-dependent transcription factors that play a central role in 
various physiological processes. The pharmaceutical industry has great interest in this gene-
family for the discovery of novel or improved drugs for treatment of, for example, cancer, 
infertility, or diabetes. The usage of three-dimensional coordinates of protein structures to 
analyse and predict interactions with ligands is an important aspect of this process. All NR 
ligand-binding domains have a similar fold, which allows for comparison of the structures 
of their three main functional sites: the ligand-binding pocket, the cofactor-binding groove, 
and the dimerization interface. We performed an analysis of nearly one hundred NR ligand-
binding domain structures, and identified the functionally important residues. The combined 
knowledge about the shape of the binding sites and the residues involved in the binding 
is important for drug design in two ways. First, knowledge about the location of residues 
that interact with a ligand in all crystal structures or in certain subfamilies assists in the 
design and docking of drugs. Second, similarities and differences in the residue types of the 
most frequent ligand- and cofactor-binding residues provide insight about potential cross-
reactivity of ligands or cofactors.
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Introduction
Nuclear receptors (NRs) are ligand-dependent transcription factors that regulate gene 
expression in important biological processes such as homeostasis, differentiation, embryonic 
development, and organ physiology [1]. NRs are regulated by small hydrophobic ligands 
such as steroids, vitamin D3, and retinoids. After ligand binding, the receptor undergoes a 
conformational change, that allows cofactors to bind [2]. The activated receptor modifies 
gene expression by binding as a monomer, homodimer, or heterodimer, to regulatory regions 
on the DNA that are called hormone response elements (HRE). NRs have been grouped in 
seven major families (NR0-NR6; see Table 1) based on pharmacological and phylogenetic 
data [3]. 48 Human NRs have been identified [4]. 
NRs all consist of a variable N-terminal domain, a conserved DNA-binding domain (DBD) 
that binds to the HRE of the target gene, a flexible linker region, and a C-terminal ligand-
binding domain (LBD). Some receptors possess an additional far C-terminal region for which 
the function is not yet known. 
The DBD consists of 66 residues and contains two C
4 
type zinc fingers. The LBD sequence is 
less conserved than the DBD. The LBD consists of approximately 250 amino acids and has 
a common fold that has been described as a triple helical sandwich consisting of 12 helices 
and one beta sheet that normally consists of two short strands [6, 7]. The sheet region and the 
region between helix 1 (H1) and helix 3 (H3) are the most variable in sequence and structure 
[8].
The LBD is important for the NR activation process because it contains the ligand-binding 
pocket (LBP), the coactivator-binding groove, and a large portion of the NR’s dimerization 
surface. Binding of an endogenous ligand in the LBP leads to folding of the activation helix 
(H12) into the agonist position [2, 7, 9] where it helps to form a hydrophobic groove in which 
cofactors can bind [10]. Crystallographic studies revealed that the LBD-binding helices of 
NR0 Knirps like (KNI,KNRL,EGON,ODR7) (no LBD) DAX 
like (DAX,SHP) (no DBD)
NR1 Thyroid hormone like (TR,RAR,ROR,PPAR,VDR)
NR2 HNF4-like (HNF4,RXR,TLL,COUP,USP) 
NR3 Estrogen like (ER,ERR,GR,MR,PR,AR) 
NR4 Nerve Growth factor IB-like (NGFIB,NURR) 
NR5 Fushi tarazu-F1 like (SF1,FTF,FTZ-F1) 
NR6 Germ cell nuclear factor like (GCNF1) 
Table 1. Overview of representative NRs over the seven subfamilies (NR0-NR6) [3, 5].
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that they bind in a slightly different way. Both the LBD and the DBD contribute to NR 
dimerization. The LBD has a stronger interaction with its dimer partner than the DBD [13]. 
Ligand-binding pocket
The LBP is very hydrophobic and is mainly formed by the helices H3, H5, H6, H11, and 
the small sheet. At present, the endogenous ligand has been identified for 70% of all human 
NRs, while the remaining 30% are still orphan receptors [14], or perhaps do not have an 
endogenous ligand [15]. The crystal structure of several orphan receptors such as HNF4α 
[16, 17], RORα [18], and RORβ [19] contain so-called pseudo ligands. These hydrophobic 
molecules were enclosed in the ligand-binding pocket during purification or crystallization 
but cannot induce transactivation.
The cofactor-binding groove
The C-terminus of H3, the loop between H3 and H4, the N-terminus of H4, and H12 when 
folded in the agonist position, form the coactivator-binding groove. Coactivator binding is 
stabilized by hydrophobic interactions and by a pair of charged residues that interact with 
the dipole of the binding helix of the coactivator. The positive residue that interacts with the 
C-terminus of this helix is located in H3 and the negative residue that interacts with the N-
terminus of this helix is located in H12. This combination of charged interactions is called 
the charge clamp [20]. Coactivators have multiple highly conserved LXXLL sequence motifs 
that are called nuclear receptor boxes [21]. These boxes mediate binding of the coactivators 
to the LBD. They form amphipatic alpha helices with the conserved leucines on one face of 
the helix to interact with hydrophobic residues in the cofactor-binding groove of the LBD. 
Other residues in the coactivator helix are more variable and thus can cause NR-binding 
selectivity. 
Corepressors, such as N-CoR (Nuclear CoRepressor) and SMRT (Silencing Mediator for 
Retinoid and Thyroid hormone receptors), bind in the groove similarly to coactivators, but 
their position is slightly tilted so that they partly overlap with the agonistic location of H12 
[22]. Consequently corepressors cannot bind when H12 is in the agonist position and thus 
cannot use the charge clamp, but they do have a conserved sequence motif LXX(I/H)IXXX(I/
L) [11, 22-24] that is involved in hydrophobic interactions in the groove. 
Dimerization
NRs can act as monomer, homodimer, or heterodimer. Some NRs form only homodimers (e.g. 
the steroid hormone receptors) while members of the NR1 family form both homodimers and 
heterodimers with the ‘common’ partner retinoid X receptor (RXR). A tetramer has only 
been observed in two crystal structures of the human RXRα in the apo form [25]. Homo- and 
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heterodimers share approximately the same dimer interface that is mainly formed by H10 [6, 
26-29]. Other structural elements that are induced in dimerization are parts of H9 and H7, 
and the loop between H8 and H9 (L8-9). Heterodimers, obviously, are much less symmetric 
than homodimers, because of the sequence differences, but also structurally there is less 
symmetry in heterodimers because the common heterodimer partner RXR has a one residue 
insertion in the middle of H7 [25]. As a result, the distance between H7 of RXR and L8-9 
of its heterodimeric partner is shorter than the distance between RXR’s L8-9 and H7 of its 
heterodimeric partner [26]. A recent mutation study indicates that preferences for homo- or 
heterodimerization are not only determined by residues at the dimer interface but also by 
residues that are buried in the LBD structure [13]. 
We recently performed an extensive structure-based multiple sequence alignment analysis 
and predicted an allosteric communication network between ligand, cofactor and dimerization 
binding sites [8]. Such communication in NRs was first described in 1997 [30, 31] and 
recently confirmed by two other groups [32, 33]. Knowledge on allosteric communication 
between the three functional sites in the LBD is crucial in the process of drug design, albeit 
difficult to translate into ligand modification steps. In this work, we focus on the direct 
interactions between the LBDs and their three interaction partners: ligands, coactivators, and 
dimer partners. We use the average number of contacts per residue as a qualitative measure 
for these interactions.
Analysis of the fit of a ligand in a binding pocket requires two steps. The first step is the 
determination of the residues that make a significant contact with that ligand. This part of 
the process is done automatically with the Automatic Residue Extraction System (ARES) 
software that is described in this article. The second part is the analysis of the residue types 
that are, or can be present at these positions. This information is obtained from a mapping 
of multiple sequence alignments onto the superposed structures. The latter is done using 
the NucleaRDB, which is an example of a Molecular Class Specific Information System 
(MCSIS) [5]. 
By means of this family-based approach we identified the residues that are essential for ligand 
binding in all LBDs. This knowledge is very useful in the process of drug design in two ways. 
First, it guides the docking of novel drugs in the ligand-binding pocket. Second, comparisons 
of the residues types that are at these positions provide insight in potential cross-reactivity of 
NR ligands between NR (sub)families. Other interesting aspects of ligand binding that were 
revealed are antagonist specific and partial agonist specific residue positions and a series of 
subfamily specific ligand-binding residues. 
ARES was also applied to analyse the binding of cofactors in the cofactor-binding groove and 
to analyse the dimerization interfaces. Comparison of the residue types of the most important 
cofactor-binding residues in the LBD revealed residues that are responsible for selectivity of 
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This work shows that an automated analysis of structure, sequence and function data guides 
the prediction of ligand and cofactor binding and helps the process of drug design. 
Materials and Methods
The program ARES (Automatic Residue Extraction System) was written in Python 2.2.2 
and integrated in the MCSIS [5] program suite. The data collected by ARES were stored in 
the MCSIS database (PostgreSQL software 7.4.1 [34]). Using NR related keywords a set of 
119 NR structures were extracted from the PDB using SRS 7.1.1 (February 2004) [35]. A 
keyword search in the PDB file automatically divided these 119 structures into 97 LBD and 
22 DBD structures. A complete NR, including DBD and LBD, has not been crystallized yet.
PDB files contain many small molecules that are called HET groups. Some HET groups 
are genuine ligands, but most are ions and other crystallization additives. ARES separates 
NR ligands from the other HET groups by rejecting molecules with less than 10 atoms, and 
molecules that are on a (short) black list (e.g. the steroid part of a detergent, several sugars, 
and other crystallization additives). 
Ligands were clustered into six classes: agonist, partial agonist, antagonist, pure antagonist, 
non-activating and pseudo ligands. Antagonists that possess a bulky side-group that does not 
fit in the pocket and sticks out into the space that H12 occupies in its agonist position [36] 
are called ‘pure antagonists’. ‘Normal’ antagonists do not have such a bulky side-group and 
antagonize via other mechanisms, for example via disruption of the loop between H11 and 
H12 [36]. Pseudo ligands [16-19, 37-39] and non-activating ligands [25, 40] are fixed in the 
LBP during crystallization and show little or no transcriptional activity. The classification of 
ligands was done via extensive literature studies. In a few cases, a ligand showed different 
effects in different receptors. In these cases all effects were used in the subsequent analyses. 
Cofactors were determined by searching in the PDB files for peptides with a unique chain 
identifier and a maximum length of 32 residues. Cofactor peptides were stored in the database 
using consistent names and nuclear receptor box numbers. Residues in the cofactor binding-
helix are numbered relative to the conserved LXXLL motif, in which the first L gets number 
1 and the first residue N-terminal to this L gets number -1.
Recently we performed a 3D structure-based multiple sequence alignment of all LBDs and 
determined structural conserved residues (SCR) [8]. The SCR consists of 183 residues, 152 
of which superpose their C
α
 position within 1.9Å of the average C
α
 position in 90% of all 
LBDs. The other 31 residues of the SCR were added based on visual inspection of structures 
and sequence motifs [8]. The 183 residues of the SCR were numbered using a common 
numbering scheme that gives each residue a number according to the location in the multiple 
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structure alignment, the so-called 3D structure-based sequence number (3D number). SCR 
definition and numbering scheme are used for all residues throughout this study and also 
throughout the NucleaRDB [5]. The 3D number starts with one or two digits that indicate the 
helix number. Similarly ‘B’ and ‘L’ reflect residues in the beta sheet and loops, respectively. 
Residues that are not in the SCR and therefore do not have a 3D number all got the number 
zero. H11 is a continuous extension of H10 in a series of receptors. We therefore number the 
residues in these two helices continuously with ‘10’ as the first two digits. 
Dimers were identified using the number of contacts between monomers. The following 
empirically derived criteria were used to discriminate between crystallographic dimers and 
‘true’ dimers. A dimer was classified as ‘true’ when 1) the contact interface between two 
monomers involved only contacts in H10, or 2) at least 20 contacts are observed in H10 or 
3) more than 22 contacts are observed in the β-sheet. If any contacts in H1 were detected, 
the structure was not a ‘true’ dimer. These criteria were determined empirically after visual 
inspection of a series of NR structures and extensive literature study.
WHAT IF [41] was used to determine the contacts between a ligand and the LBD, between 
the cofactor and the LBD, and between the monomers in a dimer. A contact between two 
atoms was stored in the database when the distance between the Van der Waals’ surfaces 
of these atoms was less than the default cut-off used by WHAT IF. Hydrogen bonds were 
detected using the hydrogen bond network optimisation options in WHAT IF [42]. Because 
the definition of the atom types in the ligands is not consistent, hydrogen bonds with ligands 
could not yet be calculated fully automatically.
Contacts were annotated with additional information including the Swiss-Prot residue 
number, 3D number, distance, and atom types. The number of contacts per residue position 
in the SCR was determined in two steps. First, contacts in multiple copies of the same LBD-
ligand complex were normalized. If, for example, a LBD-ligand complex is observed six 
times in one PDB file and three times in another, all contacts in all nine chains are summed 
up and divided by nine. It is therefore possible to end up with non-integer contact numbers. 
Second, contacts were normalized across all unique LBD-ligand complexes. If a contact is 
observed in just a few complexes the final average contact count can be less than one. If a 
residue makes multiple contacts in all complexes the final contact count can even be more 
than ten. We consider the number of contacts as a measure for the importance of a residue 
for ligand binding. 
The standard deviation on the number of contacts made by a residue is a measure of how 
consistently this residue is involved in ligand binding across the NR superfamily. If, for 
example, a residue position makes many contacts in a few LBDs, but not at all in others, 
then the standard deviation on the number of contacts will be high. A low standard deviation, 
on the other hand, indicates that the residue position is involved in ligand binding in a 
similar fashion in most family members. Contacts between cofactors and LBDs and between 
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Residue positions that make contacts with ligands were clustered in four so-called ligand-
binding groups (LIG1-LIG4). The boundaries between these groups are 7.0, 4.5, and 1.0 
respectively. I.e., residue positions with more than 7.0 contacts belong in the group LIG1, 
residue positions with more than 4.5, but less than 7.0 contacts belong in LIG2, etc. Contacts 
with cofactors are clustered in four so-called cofactor-binding groups (COF1-COF4) with 
boundaries at 7.0, 1.5, and 0.25. Homodimer contacts are clustered in four homodimer-
binding groups (HOM1-HOM4) with boundaries at 2.4, 1.2, and 0.7. Heterodimer contacts 
are clustered in four heterodimer-binding groups (HET1-HET4) using the same boundaries 
as for the definition of the HOMs.  The cut-off values that separated the four groups were 
determined by visual inspection of the data. Residue positions with a similar average number 
of contacts were clustered in one group. The clustering was considered to be significant 
when, within the standard deviation, the average number of contacts between residues from 
these two groups did not overlap.
Results
1. Ligands
87 of the 97 LBD structures in the PDB contain a ligand. These 87 LBDs came from 28 
different NRs that mainly cover the three main families NR1, NR2, and NR3 [3]. 63 of the 
87 ligands are unique, i.e. some ligands were solved two times or more in the same or in 
different receptors. Table 2a shows the ligands that are observed more than once in the same 
receptor type. Seven ligands are observed in two different receptor types, and one ligand 
is solved in three different types (Table 2b). Estradiol (EST), for example is observed in 
19 monomers in  seven different crystal structures of the estrogen receptor α (ERα). When 
the same ligand is observed in multiple NRs, these NRs normally are members of the same 
subfamily (e.g. ERα and ERβ). Exceptions are metribolone, 9-cis retinoic acid and all-trans 
retinoic acid, which have been solved in receptors of different subfamilies (Table 2b). In 
some cases the ligand has a dual activity, for example tetrahydrochrysene (ETC) is an agonist 
in ERα, while it has an antagonistic effect in ERβ [36], and trans retinoic acid (REA) is an 
agonist in RARγ [7], a partial agonist in RORβ [43], and a non-activating ligand in RXRα 
[25]. Figure 1 shows the distribution of functions observed for the 87 ligands that were found 
in LBD crystal structures. The majority of the ligands are agonists (66%). Pure antagonists 
and pseudo ligands both are good for 12%. 
Three-letter codes for ligands in PDB files cause a serious problem for the complete 
automation of ARES. Several times these codes are identical in different PDB files, while 
the compounds actually are analogs. Two examples are VDX and REA. VDX is used for 
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20-epi-1α,25-dihydroxyvitamin D
3
 in 1IE9 and 1α,25-dihydroxyvitamin D
3
 in 1DB1. REA 
is used for 9-cis-retinoic acid and all-trans retinoic acid in 5 and 3 different NR structures, 
respectively. These errors require manual intervention in the data storage process.
a)
b)
Table 2. Overview of the ligands that are observed more than once in: (a) the same NR, and (b) different 
NRs. The ligands are named according to the 3-letter code of the ligand in the PDB file. The AC is from 
the Swiss-Prot database [44].
AC Recep-
tor
Ligand 
(PDB 
name)
Ligand Number 
of struc-
tures
Number 
of mono-
mers
P03372 hERα EST 17β-estradiol 7 19
P10828 hTRβ-1 4HY TRIAC 4 4
P19793 hRXRα cREA 9-cis retinoic acid 4 6
P15207 rAR DHT dihydrotestosteron 2 2
O75469 hPXR SRL SR12813 2 3
P37231 hPPARγ BRL rosiglitazone 2 4
P19793 hRXRα BM6 BMS649 2 5
P04150 hGR DEX dexamethasone 2 6
P55055 hLXRβ 444 T0901317 2 8
Ligand 
(PDB name)
Ligand Receptor AC
R18 Metribolone hAR, hPR P10275, P06401
AZ2 AZ242 hPPARα, hPPARγ Q07869, P37231
RAL Raloxifene hERα, rERβ P03372, Q62986
ETC Tetrahydrochrysene hERα, hERβ P03372, Q92731
544 GW409544 hPPARα, hPPARγ Q07869, P37231
IH5 IH5 hTRα, hTRβ-1 P10827, P10828
cREA 9-cis retinoic acid hRXRα, hRARγ-2 P19793, P22932
tREA all-trans retinoic acid hRXRα, rRORβ, 
hRARγ-2
P19793, 
P45446, P22932
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Figure 1. Distribution of the function of the 87 NR ligands observed in the PDB files used in this study. 
Color version: see Appendix 2.
Figure 2. (a) Ligands, ions and heteroatoms of the 87 LBD ligand-bound structures superposed onto 
the C
α
 coordinates of 1FCY [45].
(b) The electron density is calculated for all ligands and all densities are added up. The yellow dashed 
contour lines surround space where at least 5 ligands have been superposed. The orange, solid contour 
lines surround space where at least 25 ligands have been superposed. The electron density was calculated 
using WHAT IF [41]. Color version: see Appendix 2.
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All LBD structures were superimposed as described before [8]. The structures were 
superimposed using the C
α
 coordinates of the 152 residues of the SCR that superposed well in 
at least 90% of the LBDs. The transformation that was obtained from the C
α
 superposition was 
in each case applied to all atoms in the LBD, and to all waters, ligands, and ions associated 
with it. 
Figure 2a shows all bound ligands superposed on the average LBD C
α
 trace. It can be seen 
that these ligands contact a wide variety of residues and position their side-groups in a series 
of different pockets. The electron density was calculated for all ligands shown in Figure 2a, 
and all densities were added up. This density was contoured at two levels that correspond 
to the equivalent of 5 (yellow) and 25 (orange) atomic density equivalents (Figure 2b). The 
orange contour level reflects the average position of the central parts of all ligands. 
Clearly, NRs use two different mechanisms for obtaining specificity in binding their 
(endogenous) ligands. The first method is based on subfamily specific pockets, i.e. in one 
subfamily a side-group of a ligand fills a side-pocket of the LBP whereas in other subfamilies 
that side-pocket is closed, or displaced. The second method is based on differences of 
the physico-chemical characteristics of key-residues that make contacts with the ligands. 
Obviously, subfamily specific side-pockets are mainly of interest for the study of ligands that 
are specific for that subfamily. Residue positions that are involved in ligand contacts in most 
LBDs are of broader interest for drug design as their role in one NR can provide information 
that may be applicable to other NRs. These residues are anchor points in the LBP in all 
NRs, and provide the first filter for the selection of novel small molecules of pharmaceutical 
value.
Ligand-binding residues
The 63 unique ligands in 87 PDB structures were co-crystallized with 72 different NRs. 
Figure 3a shows the average number of contacts per residue calculated for 72 unique receptor 
– ligand complexes. The LBP is lined by 56 residue positions in the SCR that together make on 
average 146 contacts. In all cases the majority of the LBD - ligand contacts involve residues 
in the SCR. In ERα only four contacts are observed between estradiol and residues outside 
the SCR, while in an extreme case like PXR 28 contacts are observed between hyperforin 
and residues outside the SCR. The latter had to be expected because hyperforin is one of the 
largest NR ligands found in the PDB [46]. 
The positions of residues that are involved in ligand contacts, and their average number of 
contacts, are shown in Figure 3a. The LIG1 residues form a statistically significant distinct 
group. 
Figure 4 shows the location of the LIG residues in the SCR. Two of the LIG1 residues are 
located in H3, two in H5, one in H11, and one in the beta-sheet. The LIG2 residues are 
located in the same helices. Most LIG3 and LIG4 residues are further away from the centre 
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Figure 3. (a) Average number of ligand - LBD contacts in 72 unique receptor – ligand complexes. The 
division into LIG1-4 is indicated by the horizontal lines at 7, 4.5 and 1. (b) Average number of contacts 
between ligand and LBD for NR1 (black bars), NR2 (grey bars) and NR3 (white bars). (c) Distribution 
of the number of contacts between ligand and LBD for agonists (white), partial agonists (light-grey), 
antagonists (dark-grey), and pure antagonists (black). The rightmost bars in (a) and (b) (indicated by an 
*) show the number of contacts for all residues outside the SCR added up and divided by ten.
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Figure 4. The ligand-binding residue positions in the LBD are indicated by colored spheres at their C
α
 
positions. (a) LIG1 (purple, 6 residues). (b) LIG2 (red, 6 residues). (c) LIG3 (orange, 17 residues). (d) 
LIG4 (yellow, 27 residues). The C
α
 backbone structure is from 1FCX [45]. Color version: see Appendix 
2.
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The LIG1 residues are located in the middle of the LBP and interact mainly with the central 
part of the ligand. Obviously, the ligand specificity within the superfamily is influenced by 
the physico-chemical properties of the LIG1 residues. Figure 5a shows the residue types 
and the dendogram of the LIG1 residues of the 48 human NRs. LIG1 residues are mainly 
hydrophobic, which is in agreement with the hydrophobic nature of the endogenous ligands. 
Polar LIG1 residues are observed in a few subfamilies that are known to bind ligands with a 
more polar character.
The physico-chemical properties of the LIG1 residues are a first filter for selective ligand 
binding. In the RAR subfamily (NR2B), the RARα isotype differs at only one LIG1 position 
(339) from RARβ or RARγ. Mutation of Ser 339 to Ala (undoing the only LIG1 difference 
with RARβ) has been shown to give RARα the same ligand binding profile as RARβ [47]. 
The RORγ isotype differs at only one LIG1 position from the other RORs. The isotypes in 
the PPAR subfamily, on the other hand, differ at two positions from each other, while up to 
four of the six positions differ between the ERR isotypes. 
The use of LIG1 residues can reveal functional relations between LBPs that are not seen 
in classical phylogeny studies. It was shown, for example, that the pocket of the (orphan) 
receptor Nurr1 is nearly closed [15] by several bulky side chains of LIG1 residues. The Nurr 
receptor NR4A2 NR42 (see Figure 5a) has three phenylalanines in LIG1, which upon visual 
inspection indeed are seen to fill most of the LBP. The LIG1 residues of Rev-erbA (NR1D1 
NRD1 in Figure 5a) and Rev-erbB (NR1D2 NRD2 in Figure 5a) contain four phenylalanines, 
suggesting that these NRs also have no LBP, or a very small one as was already predicted by 
Renaud et al. [49].
Family specific LBP residues
The LIG1 residues line the wall of the central, most important part of the LBP. These residues 
determine the physico-chemical properties of the most frequent interactions between the 
central core of the ligand and the LBD. Interactions with LIG 2-4 residues reflect substrate 
specificity for less frequent ligand - LBD interactions like those that occur in one or a few 
NR subfamilies. 
Figure 3b shows the average number of contacts per residue for the NR1, NR2, and NR3 
family. Comparison of the number of contacts per position shows that 23 positions are 
uniquely involved in ligand binding in just one family. Most of these positions have a 
negligable average number of contacts, except position 154 and 334, both LIG3 residues, 
that make two or more contacts per LBD. Position 154 contacts the ligand in various NR1 
receptors like VDR, RAR, ROR and LXR in agreement with the observation that ligands in 
the NR1 receptors occupy an additional pocket near the structurally flexible H1 and H2. This 
pocket is not used by ligands in the classical steroid hormone receptors (NR3). The LBP of 
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Figure 5. Dendograms based on (a) LIG1 residues 335, 339, 552, 556, B154, 1057, (b) COF1/2 
residues 347, 351, 448, 452, 456, 1247, 1250, (c) HOM1 residues 947, 1038, 1051 and HET1 residues 
944, 947, 1041, 1045, 1048, 1051 (7 residues in total due to HOM1 - HET1 overlap). Residues are 
colored according to their type. Most hydrophobic residues are green, cysteines are brown, glycines 
are purple, prolines are yellow, and the hydrophylic residues are red, gray, or blue. Residues are shaded 
using the same colors at similarity threshold levels of 40% for LIG1 residues and 30% for COF1/2 and 
HOM1/HET1 residues (BLOSUM62 similarity matrix). The beta-sheet and H12 residues are missing 
for NR0B1 DAX1 and NR0B2 SHP and for NR1D1 NRD1 and NR1D2 NRD2, respectively. Residues 
are sorted from left to right according to their 3D number. Dendograms were created with CLUSTALW 
[48] version 1.82 with default values. Color versions: see Appendix 2. Figure continues on page 66 and 
67.
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Figure 5 continued from page 65 and continues on page 67.
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Figure 5 continued from page 66.
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s PPAR has a side-pocket that protrudes towards the N-terminal end of H3 [50]. Residue 334 
lines the wall of this pocket and indeed only contacts the ligand in the PPAR LBD. 
In NR1-3, 19, 19, and 9 contacts are observed, respectively, between ligands and residues 
outside the SCR. This indicates that the ligands of the NR3 family make fewer contacts 
outside the SCR than the others. This difference is caused by an arginine and a glutamine that 
bind the steroid, but block a pocket located between H3 and H5/6 towards H1 [51].
H12 and ligand binding
Ligand-induced folding of H12 into the agonist position is a crucial step in the NR activation 
process. Stabilization of H12 in this position is realized in many different ways. Contacts 
between H12 and the rest of the LBD can be ligand independent as is observed, for example, 
in the RXR receptors of the NR2 family, in which these contacts are indirectly induced by 
a water-mediated H-bond network between H12 and tryptophan 548 in H5 [9]. Recently, it 
was observed that the folding of H12 in the agonistic position of the LXR and FXR receptors 
was stabilized by ligands in an indirect manner [52, 53]. A hydrogen bond between the ligand 
and histidine 1057 at the end of H11 causes the imidazole ring of this histidine to stack 
against tryptophan 1252 in H12, resulting in favorable pi-pi interactions that lock H12 in the 
agonistic position. In this study we concentrate on direct contacts between ligands and H12.
Surprisingly, the number of contacts between the ligand and H12 is relatively low. Only two 
residues in H12, 1248 and 1252, are occasionally seen to contact the ligand (see Figure 3a). 
These contacts are mainly seen in NR1 LBDs (Figure 3b). Residue 1248 makes hydrophobic 
contacts with the ligand (three contacts on average). In PPARs residue 1252 is a tyrosine that 
is involved in a hydrogen bond with the ligand. Surprisingly, members of the NR2 family do 
not show any interaction between ligand and H12.
Agonist/antagonist specific positions
Figure 3c shows the contribution of each ligand-binding SCR residue to agonist, partial 
agonist, antagonist, and pure antagonist binding. Although there is a majority of agonist 
bound structures in the database, we could detect antagonist specific positions at 340 and 343. 
When an agonist is bound to the LBD, residue 340 is normally involved in the stabilization 
of H12 in the agonist position. When residue 340 makes a contact with a pure antagonist, 
this stabilization is disrupted, making the folding of H12 in its agonist position less favorable 
and thus binding of corepressors more favorable. Residue 340 makes a contact with all pure 
antagonists in ERα, ERβ, GR, PPAR and RARα. The pure ER antagonist ICI164384 is an 
exception because it does not make a contact with residue 340.  ICI164384 sticks out of the 
LBP far enough to block both H12 folding in the agonist position and all forms of cofactor 
binding. 
Partial agonists bind more frequently at the N-terminus of H3 (positions 328 and 330) than 
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agonists. It might be that these interactions prevent the movement of H3 towards the core 
of the LBD, which has been described by Egea et al. for RXR as one of the conformational 
changes induced by the ligand (9-cis retinoic acid) [9]. Such a minor reduction of the stability 
of the folding of H12 in the agonist state can lead to partial agonism. 
2. Cofactors
22 of the 97 LBD structures contain the LBD-binding helix of a cofactor, of which 21 are 
from a coactivator and one from a corepressor [22]. One file contains a synthetic cyclic 
peptide [54] in the cofactor-binding groove. These 22 complexes cover ten different receptors: 
six, one, and three from the NR1, NR2, and NR3 family, respectively. Only four different 
Figure 6. (a) Average number of contacts between cofactor and LBD for 14 unique receptor – cofactor 
combinations. The divisions into COF1-4 are indicated by the horizontal lines at 7, 1.5 and 0.25, 
respectively. (b) Average number of contacts between coactivator and LBD for NR1 (black bars), NR2 
(grey bars) and NR3 (white bars). The rightmost bars (indicated by an *) show the number of contacts 
for all residues outside the SCR added up and divided by ten.
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coactivator peptides have been co-crystallized: the first and second box of the steroid receptor 
coactivator-1 (SRC-1) and the first and second box of the nuclear receptor coactivator 2 
(NcoA-2, TIF2). The only co-crystallized corepressor peptide is box 2 of SMRT (N-CoR2). 
The total number of unique receptor-cofactor combinations is 14.
Coactivator-binding residues
Figure 6a shows the residue positions that interact with the coactivator or corepressor 
Figure 7. The cofactor-binding residue position in the LBD are indicated by colored spheres at their 
C
α
 positions. (a) COF1 (purple, 1 residue). (b) COF2 (red, 6 residues). (c) COF3 (orange, 5 residues). 
(d) COF4 (yellow, 7 residues). (e) The corepressor-binding residues using the same criteria and colors 
for the COF1-4 as in Figure 6a and Figure 7a-d, respectively. 3ERD [55] was used for the coactivator 
pictures (a-d) and 1KKQ [22] was used for the corepressor picture (e). Color version: see Appendix 2.
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fragment. The distribution of these residue positions over the COF groups is indicated. COF1 
and COF2 form statistically significant groups. The location of these residue positions in the 
structure is shown in Figure 7. COF1 consists of only the conserved glutamate at position 
1250. Two COF2 residues are located in H3 (including the conserved lysine at position 351), 
three residues are located in H4 and one is located in H12. 
The aforementioned charge clamp, that involves interactions of the lysine at position 351 
and the glutamate at position 1250 with the negative and the positive end of the helix dipole 
of the coactivator helix respectively, is an important aspect of the binding of the coactivator 
helix. Lysine 351 and glutamate 1250 form hydrogen bonds with the peptide backbone of the 
coactivator by means of the side-chain amine and carboxylate, respectively. This explains 
the general character of the LXXLL peptide binding. Our data shows that contacts between 
residue 351 and the helix are restricted to charge - dipole interactions with the C-terminal 
end of the cofactor helix, whereas residue 1250 makes, besides its charge - dipole interaction 
with the N-terminal end of the cofactor helix, also a large number of interactions with side 
chains in this helix. These side chain - side chain contacts occur with positions -3 and -1 of 
the coactivator helix and are important for cofactor binding selectivity [56, 57].
Figure 6a shows that, besides 351 and 1250, residues at positions 347, 448, 452, 456, and 1247 
are important for cofactor binding. Figure 5b shows the dendogram of these most important 
coactivator-binding residues (COF1 and COF2) for all 48 human NRs. Due to the absence 
of H12, Rev-erbA (NR1D1 NRD1 in Figure 5b) and Rev-erbB (NR1D2 NRD2 in Figure 5b) 
miss two coactivator-interacting residues [49]. It was not possible to align the H12 region 
with the conserved negative charge at position 1250 in the TR2 and TR4 receptors (NR2C1 
TR2 and NR2C2 TR4 in Figure 5b) [8]. The alignment of H12 of GCNF (NR6A1 NR61) 
is included in Figure 5b), but needs to be confirmed by other methods. The main problems 
are that the linker region between the H11 and H12 is very short, and position 1250, which 
normally is the negative residue of the charge clamp, is a histidine in GCNF.
The charge clamp is highly conserved throughout the human NRs. The combination K
351
/
E
1250
 is most common (present in 70% of the receptors). Other combinations are R
351
/D
1250
, 
K
351
/D
1250
, R
351
/E
1250
 in 6, 4 and 4 % of all receptors, respectively. The NR4 cluster (6 % of 
all receptors) contains an opposite charge clamp, E
351
/K
1250
 and a few of the residues in the 
cofactor-binding groove that normally are hydrophobic, are polar in these receptors. This 
could explain why classical coactivator binding to the LBD of NR4 has not been observed 
[15]. The remaining 10 % are receptors that lack H12, or that have an unreliable alignment 
of H12 (e.g. GCNF).
Comparison of COF1 and COF2 residue types among the seven NR families shows that 
all cofactor interfaces consist mainly of hydrophobic residues. However, every NR has a 
conserved hydrophilic residue at position 456 and various subfamilies have additional 
hydrophilic residues at different locations of the cofactor interaction surface. The dendogram 
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residue types. The PPARs are quite distinct from the other members of the NR1 family due to 
a Thr on position 347. The tree also indicates that the orphan receptors SF1 (NR5A1_STF1) 
and CPF (NR5A2_NR52) of the NR5 family may recruit the same cofactors as GR, PR, 
AR and MR. The COF1 and COF2 residues of all isotypes are 100% identical, suggesting 
that isotypes may recruit similar coactivators. However, specificity may occur through other 
means like e.g. sumoylation and phosphorylation [58]. 
The selectivity of coactivator binding by ligand-bound NRs is determined by the residue 
types lining the cofactor-binding groove and by the residue types of the cofactor helix. The 
contact data show that residue 347 is mainly involved in contacts with the three leucines 
(numbering 1, 4, 5) of the LXXLL motif, positions 448 and 452 can interact with many 
different positions in the coactivator, while position 456 and 1247 show a clear preference for 
contacts with the coactivator positions -3 and -1, respectively.  This suggests that the residues 
at position -3 and -1 in the LXXLL peptide may play a role in binding selectivity. 
The number of contacts of the coactivator with residues outside the SCR is remarkably low, 
on average 0.66 contacts per monomer. Obviously, this is mainly due to the fact that the LBD 
is structurally most conserved in the coactivator binding [8] so that all residues in and around 
this groove are part of the SCR.
Family specific cofactor-binding residues 
Figure 6b shows the coactivator-binding positions per family for NR1, NR2, and NR3. No 
structures with bound coactivators are available for any of the other four families. Four 
positions (347, 456, 1247, 1250) show significant differences in the number of coactivator 
contacts between the three families. The NR3 family makes more contacts with residue 
position 347, while members of the NR2 family make more contacts with residue positions 
456 and 1247. NR1 receptors make most contacts with residue position 1250. These family 
specific differences are caused by differences in residue types in both the receptor and the 
cofactor. The NR2 family, for example, has a bulky Arg at position 456 while the NR3 family 
has a smaller Glu or Asn at this position (see Figure 5b). The NR3 family is dominated in the 
PDB by ERs that have an Ile at position 347, while the NR1 and NR2 family have a smaller 
Val at this position.
Residue positions involved in corepressor binding
Corepressor binding and folding of H12 into the agonist position are mutually exclusive. 
Consequently, corepressor binding does not involve contacts with the negative residue of 
the charge clamp at position 1250. The contacts with the lysine at position 351 that are 
seen in all coactivator-bound structures, however, are also observed in the one available 
LBD-corepressor complex (see Figure 6a and Figure 7e) and is described by Xu et al. [22]. 
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Contacts with residues in H1, and with residues 549 and 1054 are important for corepressor 
binding but are not observed in the coactivator – LBD complexes. The residues at position 
549 and 1054 make contacts with the C-terminus of the corepressor peptide. This part of 
the corepressor peptide is structurally not well resolved, which undermines its importance 
in corepressor binding selectivity. Other residues that contact the corepressor but not the 
coactivator are located at positions 340, 348, and 449. These residues were mutated in TRβ 
[22, 59] and shown to indeed be involved in corepressor binding. The variability of these 
residues is high throughout the NR superfamily, which indicates that they may play a role in 
selective corepressor binding. 
3. Dimers
A total of 34 dimers are available in the 97 LBD structures in the PDB database. 30 Of those 
are homodimers and 4 are heterodimers. Homodimers have been crystallized for ten different 
receptors, and they are equally divided over the NR1, NR2 and NR3 families. Heterodimers 
are available for the NR1 and NR2 families, i.e. one RARα-RXRα and three PPARγ-RXRα 
heterodimers. 
The normalized contact statistics for residues involved in homo- and heterodimerization are 
shown in Figure 8 and summarized in Table 3. Table 3 shows that the total number of contacts 
between two monomers is higher for homodimers than for heterodimers. This difference is 
mainly caused by contacts made by residues outside the SCR. Although the average number 
of contacts is only a very qualitative estimate of binding intensities, the differences are large 
enough to note a disagreement with the observation that heterodimers are more stable than 
homodimers [26]. 
The homodimer contact data contain several homodimers that deviate from the classical 
homodimer structure. The progesterone receptor (PR) dimer interface is formed by the C-
Table 3. Contact statistics for residues involved in homo- and heterodimerization. a Excluding the PR, 
GR and PXR homodimer.
Type of dimer Number of 
residues within 
the SCR
Number of 
contacts within 
the SCR
Number of re-
sidues outside 
the SCR
Number of 
contacts out-
side the SCR
Homodimer (all) 36 33 ≤13 17
Homodimera 32 45 ≤7 7
Heterodimer 26 38 ≤2 3
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Figure 8. (a) Average number of contacts between monomers in 10 unique homodimers (black bars) 
and 2 unique heterodimers (white bars). The divisions into HOM1-4 and HET1-4 are indicated by the 
horizontal lines at 2.4, 1.2 and 0.7, respectively. (b) Average number of contacts between monomers 
in 10 unique homodimers for NR1 (black bars), NR2 (grey bars) and NR3 (white bars). The rightmost 
bars (indicated by an *) show the number of contacts for all residues outside the SCR added up and 
divided by ten.
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terminus of H10/H11 and includes residues beyond the C-terminus of H12. This C-terminal 
extension of 12 residues is also found in the other 3-keto-steroid receptors GR, AR and 
MR [60-63] and forms a beta sheet with residues in the loop between H8 and H9. This beta 
sheet is not observed in other NRs and prevents the formation of a classical dimer. However, 
GR is an exception to the rule and forms a dimer with the conserved beta sheet and the C 
terminus of H1 [64]. Another outlier is PXR that forms a dimer with the five-stranded beta 
sheet between H2 and H3, the N-terminus of H3 and the loop between H1 and H3. The 
size of the PXR dimerization interface (54 contacts) suggest a functional relevance [65]. 
Figure 9. The homo- and heterodimerization residue positions in the LBD are indicated by colored 
spheres at their C
α
 positions. (a) HOM1 (purple, 3 residues). (b) HOM2 (red, 7 residues). (c) HOM3 
(orange, 5 residues). The C
α
 backbone structure is from 3ERD [55]. (d) HET1 (purple, 6 residues). (e) 
HET2 (red, 7 residues). (f) HET3 (orange, 4 residues). The C
α
 backbone structure is from 1FM9 [27]. 
Color version: see Appendix 2.
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The contact residues in the PR and PXR homodimers are mainly located outside the SCR. 
Removal of the three presumably exceptional or artificial dimers from the homodimer dataset 
resulted in more average contacts in the SCR and fewer outside the SCR (Table 3). However, 
as the removal of these three dimers did not lead to significant changes in the evaluation of 
the dimer interfaces, we left these three dimers in the dataset for all subsequent analyses. 
The positions of residues that are involved in homo- and heterodimerization are shown in 
Figure 9. The standard deviation on the number of contacts for homo- and heterodimers is 
too large to observe residue positions that are significantly over-represented in either homo- 
or heterodimer interfaces (Figure 8a). Figure 8b shows the residue positions that are part 
of the homodimer interfaces for the NR1-3 families. The standard deviation on the number 
of contacts is again too large to draw reliable conclusions. Most of the residues that seem 
important for specificity are observed in non-classical homodimers. Figure 5c shows a 
dendogram for the 48 human NRs based on the seven residues that HOM1 and HET1 have 
in common; these seven residues are indicated for each receptor. The tree shows that there is 
little sequence conservation at the dimer interface. Isotypes are distributed across branches 
of the tree for all NRs, except RXR. The role of all RXR isotypes as common dimerization 
partner is reflected by this conservation of residue types at the dimerization interface. A few 
NRs are monomers, but as data on the monomeric or dimeric state of activated NRs is scarce, 
we made no attempt to remove the monomers from this dendogram.
The tree also shows that homo- and heterodimers are not associated with one branch of the 
dendogram and indicates that the physico-chemical characteristics of the HOM1 and HET1 
residues are not determining homo- and/or heterodimerization. Recent efforts by Brevilet et al. 
[13] revealed several residues that are important for dimerization specificity. These residues 
were located in a salt-bridge network between H1 and H10 inside the protein. Since these 
residues are not at the dimer interface they were not identified by our contact analysis. Vivat-
Hannah et al. [66] identified selective homo- and heterodimerization residues by mutation of 
19 different residues (and combination of these) at the dimerization interface. They mutated 
three residues from the HOM1/HET1 group. Their main conclusion is that Tyr 947 is the only 
residue that shows major differences upon mutation in homo- and heterodimers. A scan of the 
mutation section of the NucleaRDB [5] revealed that all seven HOM1/HET1 residues have 
been implicated directly or indirectly in dimerization in at least one NR. 
Discussion
Gene transcription by NRs involves a series of events. First a LBD binds an endogenous 
agonist. This causes H12 to fold into the agonist position, which completes the coactivator-
binding groove. A coactivator binds to this groove, a homo- or heterodimer is formed, and the 
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whole complex causes a physiological response by binding to a hormone response element. 
The steps in this path do not need to take place in this particular order and not all NRs require 
all steps of this path to be taken. Some NRs can function as a monomer, some NRs do not 
require a ligand, etc. But it is clear, however, that there exists a causal path from ligand 
binding to action at the response elements, and therefore, there exists a causal path from 
binding a small molecule to a physiological response. It is the challenge of contemporary 
drug design to influence this complicated process by small molecules.
The LBD is the focal point of pharmacological interests because drugs must bind to the LBD, 
and in doing so, must allow for the proper interactions between the LBD and the coactivator, 
and between the LBD and dimer partners. The LBD also is responsible for the communication 
between the three binding sites, and this communication has been the topic of several other 
studies [8, 32, 33] that indicated the importance of many LBD residues for proper functioning 
of NRs. Therefore, the interactions of the LBD with ligand, cofactor, and dimer partner, must 
be studied in a holistic manner to facilitate the drug design process. Here, we studied these 
interactions qualitatively, by simply counting the average number of contacts of each residue 
with the three binding partners. 
We adopted a family-based approach in which we combined sequence, structure and function 
data from various publicly available databases. To explore the data we built a NR structure 
analysis tool, which is almost fully automated and can be repeated with very little effort 
each time a new LBD structure becomes available. The manual intervention that is still 
required involves correction of administrative errors in PDB files and adding the names of 
new crystallization additives to the ligand-exclusion list.  It is still impossible to automate 
the classification of the function of all ligands found in the PDB. A detailed insight in the 
function of ligands can only be obtained by means of labor-intensive reading of all papers 
accompanying the release of the structures. Manual intervention is also needed to overcome 
problems caused by inconsistencies in the nomenclature of cofactors in the PDB. Other 
problems occurred with the three-letter codes for ligands in PDB files and the Swiss-Prot 
accession code. On two occasions the three-letter code was identical in different PDB files, 
while the compounds actually are analogs. The Swiss-Prot accession code, which is one of 
the required data types in our database, was not found for three structures (1G2N, 1R1K, 
1R20 [37, 39]) and consequently, these three structures were not used in all analyses. 
The family-based approach allows us to integrate all available data and convert it into 
information, but it creates the necessity to carefully analyse the generality of each observation. 
We have created gradations in the number of contacts per residue to express the generality of 
the contact information. LIG1 residues, for example are strongly involved in ligand binding in 
nearly all NRs, LIG2 residues are still important for ligand binding, but not in all NRs. LIG3 
residues tend to be involved in ligand binding in a few NR subfamilies, and the generality 
of the extractable ligand binding information is lowest for LIG4 residues. We took a similar 
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nature of this work, the differences in the number of contacts were sometimes significant 
enough to draw interesting conclusions that influence the drug design process. This will be 
discussed below for the three functional binding partners of the LBD.
Our study revealed information on the residue positions in the LBD that are most frequently 
involved in the binding of a ligand. The identity of these LIG1 residues facilitates the process 
of drug design in various ways. First, these residues guide the docking of novel ligands, 
because all NR ligands interact with these residues and it is very likely that novel ligands 
will do so as well. Following the same lines of reasoning, the identity of subfamily specific 
residues facilitates the docking of ligands in a receptor of a particular subfamily. Second, the 
residue types of the LIG1 residues determine the shape and the physico-chemical properties 
of the centre of the LBP. Ideally, these physico-chemical properties are compatible with the 
physico-chemical properties of the central part of the ligand. This is demonstrated in Figure 
10, which shows a selection of co-crystallized NR ligands plus their LIG1 binding residues 
and demonstrates that the hydrophilic/hydrophobic nature of the LIG1 residues match that of 
Figure 10. Schematic drawing of the interactions between the ligand and LIG1 residues within a 
distance of 4Å of the ligand: (a) LXRβ (T0901317 in 1PQC), (b) PPARγ (rosaglitazone in 1FM6), (c) 
PXR (SR12813 in 1NRL), (d) ERα (tetrahydrochrysene in 1L2I) and (e) RORβ (all-trans retinoic acid 
in 1NH4). Hydrophilic LIG1 residues are indicated by a rectangular box around the LIG1 residue type 
and 3D number. 
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the ligands. This is essential information when one would like to design a compound library 
for a specific NR. Especially the selection of the main scaffold of the ligand depends on the 
physico-chemical properties of the LIG1 residues in the target NR. The third application of the 
acquired information on the LIG1 residues is based on the dendogram of the LIG1 residues 
of the 48 human NRs. Obviously, a dendogram that is based on residues that are always 
involved in ligand binding better predicts cross-reactivity of ligands than a phylogenetic 
tree that is based on the full sequences. Predictions based on the LIG1 dendogram are more 
relevant and offers the possibility to design ligands, while taking potential cross-reactivity 
with other receptors into account. The same arguments can be used in the process of screening 
for ligands for orphan receptors. The hit-rate of screening for compounds that activate orphan 
NRs can be improved if one selects a library of compounds that activate the nearest non-
orphan NR in the dendogram.
Finally, our contact analysis revealed the identity of residues in the LBD that show a selective 
interaction with antagonists or partial agonists. This is crucial information in the design of 
ligands that need to have this particular function. 
The contact analysis study identified the most frequent coactivator-binding residues. 
Information on the identity of these COF1 and COF2 residues helps to obtain insight in 
the mechanism of cofactor recruitment throughout the NR superfamily. Obviously, our data 
confirm that the charge clamp residues interact with the dipole of the helix of the coactivator 
peptide and that a series of hydrophobic residues accommodate the LXXLL sequence motif. 
In addition, we identified a number of hydrophilic residues in the coactivator-binding groove 
that may determine the selectivity of coactivator binding. One of these hydrophilic residues 
lies at a conserved position in the cofactor-binding groove and interacts mainly with the 
residues at positions -3 and -1 of the coactivator peptide. The other hydrophilic residues 
are spread across 4 different positions in the coactivator-binding groove, and each of these 
positions is conserved within one NR subfamily. It is very likely that these hydrophilic 
residues and the coactivator residues at positions -3 and -1 play a role in selectivity of LBD 
- coactivator binding. 
The dendogram of the COF1 and COF2 residues helps us to understand and predict selective 
coactivator binding by different members of the NR superfamily. Two NRs that are in the 
same branch in the dendogram have similar coactivator-binding grooves and thus are likely 
to bind the same coactivator. To our surprise the dendogram showed that the cofactor-binding 
residues of different isotypes of one NR subfamily are completely conserved, which suggests 
that members of the same subfamily will recruit similar coactivators. 
The variability of the residue types that are most frequently involved in the interaction 
between monomers (HOM1 and HET1 residues) is considerably higher than that of the most 
frequent ligand-binding and cofactor-binding residues. Approximately all 48 human NRs 
have different residue types at every HOM1 and HET1 position, except RXR. The dendogram 
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heterodimerization and has to be treated with caution. At present, it is not clear whether this 
lack of predictive value of the dendogram of HOM1 and HET1 residues is the result of a lack 
of functional data, or that more fundamental problems exist like a strong involvement of the 
cofactors or DBDs in dimer formation.
We believe to have shown that a simple qualitative treatment of the functionally important 
contacts of LBD residues with ligands, cofactors, and dimer partners reveals much information 
that is important for the design of small molecules that can act on nuclear hormone receptors 
by binding to its ligand-binding domain. The use of all available data in a so-called family-
based approach allows us to appropriately generalize or specify the role of ligands, cofactors 
and residues at an atomic interaction level.
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Abstract
It is hypothesized that different ligand-induced conformational changes can explain the 
different interactions of nuclear receptors with regulatory proteins, resulting in specific 
biological activities. Understanding the mechanism of how ligands regulate cofactor interaction 
is of crucial importance in drug design. To investigate these ligand-induced conformational 
changes at the surface of proteins we performed a time-resolved fluorescence resonance 
energy transfer assay with 52 different cofactor peptides measuring the ligand-induced 
cofactor recruitment to the retinoid X receptor alpha in the presence of eleven compounds. 
Simultaneously we analyzed the binding modes of these compounds by molecular docking. 
An automated method converted the complex 3D data of ligand-protein interactions into 2D 
fingerprints, the so-called ligand-receptor interaction profiles.
For a subset of compounds the conformational changes at the surface as measured by peptide 
recruitment correlate well with the calculated binding modes, suggesting that clustering of 
ligand-receptor interaction profiles is a very useful tool to discriminate compounds that may 
induce different conformations and thus different effects in a cellular environment. In addition, 
we successfully combined ligand-receptor interaction profiles and peptide recruitment data to 
reveal structural elements that are involved in the ligand-induced conformations. Finally, the 
clustering of the peptide recruitment profiles provided novel insight of the potential cellular 
effect of the compound.
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Introduction
The communication between different functional sites of a protein is essential in the regulation 
of the various activities commonly displayed by each protein. The biological response in the 
cell is not defined by the activity of each of the different functional sites in the protein separately, 
but from the effective coupling of those diverse signals. The nuclear receptor (NR) ligand 
binding domain (LBD) is well suited to the study of this communication, since this domain 
has three distinct functional sites: (1) the ligand binding pocket (LBP) that accommodates 
the ligand; (2) the cofactor binding groove that facilitates binding of (de)activating regulatory 
proteins; and (3) the dimerization interface that allows for the interaction with other NRs. 
The LBD is a module of the full-length NR, which is a ligand-activated transcription factor 
with a common architecture [1-3]. NRs consist of a N-terminal domain that contains the 
ligand-independent activation function 1 (AF-1), a central DNA binding domain (DBD) 
and a C-terminal ligand binding domain (LBD) that harbors the important ligand-dependent 
activation function 2 (AF-2). In general, NRs are activated by binding of an agonist in the 
LBP of the LBD, which leads to stabilization of the AF-2 helix (also called helix 12) in the 
agonist position [4-6]. The movement of H12 facilitates the formation of the cofactor binding 
groove [7]. Coactivators bind into this groove with a short helix that contains a LXXLL 
sequence motif (NR box) [7-9]. On the contrary, an antagonist displaces H12 resulting in 
the dissociation of coactivators, and the association of corepressors. Corepressors bind 
into the cofactor binding groove similarly to coactivators, but with a LXX(I/H)IXXX(I/L) 
sequence motif [10-12]. The only available crystal structure with a corepressor shows that 
the corepressor peptide position is slightly tilted so that it partially overlaps with the agonistic 
location of H12 [10]. Subsequently, the receptor-cofactor complex binds either as a homo-, 
hetero or monomer to NR specific response elements in the promoter region of target genes, 
which results in up or down regulation of those genes.
The above described mechanism suggests that agonists and antagonists induce two distinct 
conformational states of the LBD, i.e. stabilizing H12 in the agonist or antagonist position, 
respectively. These distinct conformations lead to the interaction with coactivators or 
corepressors and results in two distinct patterns of gene expression. However, it was observed 
that different agonists induce different gene expression profiles [13, 14]. This may suggest 
that H12 does not have two distinct positions but can take any position between the distinct 
agonist position and antagonist position. It is the combination of both compound and cofactor 
that determines the position of H12 and therefore the effect on gene expression. This suggests 
the existence of a more subtle communication pathway between the LBP and the cofactor 
binding groove of the NR. It has been shown for the estrogen receptor (ER) alpha and the 
peroxisome proliferator-activated receptor (PPAR) gamma [13, 15] that the binding of different 
ligands results in distinct patterns of cofactor binding. The cofactors in those studies are 
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mimicked by helical peptides of 20-25 amino-acids, containing the LXXLL coactivator motif 
or the LXX(I/H)IXXX(I/L) corepressor motif. These different patterns of peptide binding, 
so-called peptide recruitment profiles, are most likely caused by different conformations at 
the NR surface, in particular the cofactor binding groove. These studies show that peptide 
recruitment profiles are very useful to probe the conformation at the NR surface and to study 
the position of H12 in the presence of ligand and cofactor peptides. Moreover, compounds 
can be clustered according to their similarity in peptide recruitment profiles. It is believed 
that compounds in one peptide recruitment cluster induce similar conformations at the NR 
surface, which may result in transcription of the same set of target genes. From a structure 
based drug design perspective it is therefore important to know which interactions between 
ligand and receptor cause a specific NR surface conformation, i.e. peptide recruitment profile. 
In other words, molecular understanding of the communication between LBP and cofactor 
binding groove may be one step further towards the design of NR drugs with a certain gene 
transcription profile. 
In this paper we describe a methodology that helps to obtain this molecular understanding 
of ligand-induced conformations of the NR surface. We first measured peptide recruitment 
profiles for a set of different ligands. Secondly we studied whether these different ligands 
actually have distinct binding modes using the available X-ray structures and docking. 
The different binding modes of compounds were represented by so-called ligand-receptor 
interaction profiles, thereby converting complex 3D data into 2D fingerprints. Similarly, 
as for the peptide recruitment profiles, the ligand-receptor interaction profiles were used to 
cluster compounds that bind in a similar manner. Finally we compared the clusters of the 
peptide recruitment profiles with the clusters of the ligand-receptor interaction profiles to 
reveal residue positions that are involved in signaling between the LBP and the surface of 
the LBD.
As a representative of the NRs we used the retinoid X receptor (RXR) alpha. RXRs [16] are 
unique within the NR superfamily because they form heterodimers with many other NRs and 
also function autonomously, as a homodimer [17]. The receptors are involved in important 
processes such as the regulation of carbohydrate and lipid metabolism, cell differentiation, 
proliferation and morphogenesis. RXRs are regulated by retinoids, which are derivatives 
of vitamin A. The natural ligand of these receptors is 9-cis retinoic acid (9-cis-RA) [18]. 
Another class of RXR ligands are fatty acids, e.g. oleic acid, docosa hexaenoic acid (DHA) 
and phytanic acid [19-21]. Finally, there are many synthetic ligands known for RXR [22], 
some of which are currently available as drugs for the treatment of (skin) cancers and 
dermatological diseases, such as psoriasis and acne.
In this study the induced peptide recruitment profiles of ten well described RXR ligands (and 
one retinoic acid receptor (RAR) ligand, TTNPB) were determined using a time-resolved 
fluorescence resonance energy transfer (TR-FRET) assay with 52 peptides. Simultaneously, 
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the binding modes of these ligands in the pocket of RXRα were determined by modeling 
and molecular dynamics (MD) simulations. Clustering of the peptide recruitment profiles 
revealed that the compounds induced three distinct conformations at the surface of the LBD. 
Clustering of the binding modes showed two distinct modes of ligand binding for the RXR 
compounds. We successfully combined ligand binding profiles and peptide recruitment 
profiles to reveal structural determinants of signaling from the LBP to the surface of the 
LBD. 
Results
To investigate whether different RXR ligands induce different conformations at the RXRα 
LBD surface, we performed a peptide recruitment assay with 52 peptides (10-7
 
M) and eleven 
different ligands (10-5 M). The resulting peptide recruitment profiles are depicted in Figure 
1. Figure 1a shows the raw fluorescence intensity data, while Figure 1b shows the log(MI) 
values. Figure 1a shows that approximately half of the peptides already bind to the RXRα 
surface in the absence of ligand (dotted line). The majority of these peptides are derived from 
coactivators. This suggests that H12 is stabilized in the agonist position in the absence of 
ligand, which is also observed in several NR LBD apo crystal structures (e.g. [23-27]). Most 
likely, these peptides bind so well in the cofactor binding groove that they stabilize H12 in the 
agonist position. Figure 1a also shows the peptide recruitment profile in the presence of 9-cis 
RA, the natural ligand of RXRα (solid line). For many peptides, the fluorescence intensity, 
which is a measure of the peptide binding to the LBD, is higher in the presence of 9-cis RA. 
This indicates that the affinity of these peptides is increased due to the binding of 9-cis RA 
in the LBP. 
Since the basal ligand-independent signal varies between different peptides, it is difficult to 
easily compare the effect of the ligand. For this purpose, the log(MI) was calculated and the 
resulting peptide recruitment profile of 9-cis RA is depicted in Figure 1b (black line). This 
representation directly shows whether a compound is “associative” or “dissociative”. Values 
above zero indicate recruitment of peptides, and thus an associative effect of the ligand on 
peptide binding. On the contrary, values below zero indicate dissociation of peptides and 
therefore a dissociative effect of the compound on peptide binding. A log(MI) value of around 
zero means that the peptide does not bind or that the binding of a peptide is hardly changed 
by the ligand. 
Peptides that do not bind in the absence and presence of 9-cis RA
The peptide recruitment profile of 9-cis RA in Figure 1b (dark line) shows that 25 peptides 
have a log(MI) value around zero (|log(MI)|<0.1). Twelve of these 25 peptides also do not 
bind in the absence of 9-cis RA (Figure 1a) indicating that these peptides are not compatible 
with the RXRα cofactor binding groove. These 12 peptides comprise six peptides with a 
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Figure 1. (a) Binding of 52 biotinylated peptides (0.1 μM) to GST-labeled hRXRα LBD (10 nM) in the 
absence (dotted line) and presence of 10 μM 9-cis RA (solid line). (b) Peptide recruitment profiles of 11 
RXR ligands: the association and dissociation of 52 peptides to hRXRα LBD is represented as log(MI) 
values. The modulation index (MI) was obtained by dividing the fluorescence intensity in the presence 
of ligand by the intensity in the absence of ligand. Each line represents the peptide recruitment profile 
for one of the eleven compounds. The peptide recruitment profile of 9-cis RA is highlighted as a black 
solid line. Peptides have been divided in coactivators or corepressors on the basis of their sequence 
motif.  
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Figure 2. Sequence alignment of (a) coactivator peptides that do not bind to RXRα LBD in the absence 
of ligand nor in the presence of 10 μM 9-cis RA,  (b) coactivator peptides that equally bind to RXRα 
LBD in the absence of ligand and in the presence of 10 μM 9-cis RA (|log(MI)| < 0.1) and in addition 
show a significantly high fluorescence intensity (> 3500), (c) coactivator and (d) corepressor peptides 
that show an increase in affinity for the RXRα LBD upon addition of 10 μM 9-cis RA (log(MI) > 0.3). 
Sequences are aligned manually by their coactivator motifs or corepressor motifs. The amino acids that 
are part of these motifs are indicated in bold. The peptides in (b) and (c)/(d) are ordered by increasing 
fluorescence intensities in the absence and presence of 9-cis RA, respectively. F.D. pept. =  phage 
display peptide. 
a)
SWISS-PROT ID Peptide name Position Sequence
NCOA3_HUMAN SRC3_4 1043-1067 N-Biotinyl-  NLEGQSDERALLDQLHTLLSNTDAT    -C
NCOA6_HUMAN ASC2_2 1481-1504 N-Biotinyl-      SPAMREAPTSLSQLLDNSGAPNVT –C
NCOA4_HUMAN ARA70 321-339 N-Biotinyl-         SRETSEKFKLLFQSYNVND   -C
F. D. PEPT. Ppt4-1 - N-Biotinyl-            QPKHFTELYFKS       -C
NR1H3_HUMAN LXRa_H12 427-447 N-Biotinyl-        ALRLQDKKLPPLLSEIWDVHE  -C
SLIM3_HUMAN FHL2 208-225 N-Biotinyl-           YCLNCFCDLYAKKCAGC   -C
b)
SWISS-PROT ID Peptide name Position Sequence
PRGC1_HUMAN PGC_1 130-155 N-Biotinyl-  DGTPPPQEAEEPSLLKKLLLAPANTQ   -C
SHP_HUMAN SHP_1 9-33 N-Biotinyl-    CPCQGAASRPAILYALLSSSLKAVP  -C
NCOA3_HUMAN SRC3_3 724-748 N-Biotinyl-  QEQLSPKKKENNALLRYLLDRDDPS    -C
NRIP1_HUMAN RIP140_8 805-831 N-Biotinyl-  PVSPQDFSFSKNGLLSRLLRQNQDSYL  -C
NCOA2_HUMAN SRC2_3 732-756 N-Biotinyl-   QEPVSPKKKENALLRYLLDKDDTKD   -C
NCOA1_HUMAN SRC1a_4 1421-1441 N-Biotinyl-  TSGPQTPQAQQKSLLQQLLTE        -C
NRIP1_HUMAN RIP140_9 922-946 N-Biotinyl-  EHRSWARESKSFNVLKQLLLSENCV    -C
DAX1_HUMAN DAX_3_cys 134-159 N-Biotinyl-    FCGEDHPRQGSILYSLLTSSKQTHVA –C
NRIP1_HUMAN RIP140_5 366-390 N-Biotinyl-  LERNNIKQAANNSLLLHLLKSQTIP    -C
DAX1_HUMAN DAX_3 136-159 N-Biotinyl-      GEDHPRQGSILYSLLTSSKQTHVA –C
NCOA1_HUMAN SRC1_2 676-700 N-Biotinyl-  CPSSHSSLTERHKILHRLLQEGSPS    -C
NCOA3_HUMAN SRC3_2 671-695 N-Biotinyl-  SNMHGSLLQEKHRILHKLLQNGNSP    -C
NRIP1_HUMAN RIP140_3 172-196 N-Biotinyl-   EKDLRCYGVASSHLKTLLKKSKVKD   -C
Figure continues on page 92.
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corepressor motif (NCoR_1, NCoR_2, BL29, HR_1, HR_2, BT_1) and six peptides with a 
coactivator motif (SRC3_4, ASC2_2, ARA70, Ppt4-1, LXRα_H12 and FHL2). A sequence 
alignment of the six non-binding corepressor peptides did not reveal any sequence similarity 
that explains why these peptides do not bind (data not shown). The alignment of the six 
non-binding coactivator peptides (Figure 2a) showed that three coactivator peptides do not 
have a LXXLL motif but a FXXL(F/Y) motif. Several studies showed that the FXXL(F/Y) 
motif is preferred by the androgen receptor to interact with coactivators, while other NRs 
show no affinity for peptides with this motif [28-30]. Moreover, all six peptides posses a 
polar residue at the -1 position relative to the coactivator motif (LXXLL). This observation 
agrees well with previous studies, which showed that a hydrophobic residue is preferred 
at this position to facilitate proper coactivator binding to various NR LBDs [31, 32]. This 
hydrophobic residue at the -1 position is locked in an aromatic region that is induced by the 
peptide [33]. A polar residue at the -1 position is therefore unfavorable.
Figure 2 continued from page 91.
c)
SWISS-PROT ID Peptide name Position Sequence
HAIR_HUMAN HRCoA_1 552-576 N-Biotinyl-  TGLAKHLLSGLGDRLCRLLRREREA    -C
Q8N3L6_HUMAN LCoR 39-63 N-Biotinyl-  VTTSPTAATTQNPVLSKLLMADQDS    -C
F. D. PEPT. D47 - N-Biotinyl-         HVYQHPLLLSLLSSEHESG   -C
NRIP1_HUMAN RIP140_6 487-511 N-Biotinyl-  SKNSKLNSHQKVTLLQLLLGHKNEE    -C
SHP_HUMAN SHP_2 106-130 N-Biotinyl-    TFEVAEAPVPSILKKILLEEPSSSG  -C
F. D. PEPT. C33 - N-Biotinyl-         HVEMHPLLMGLLMESQWGA   -C
F. D. PEPT. D30 - N-Biotinyl-         HPTHSSRLWELLMEATPTM   -C
NRIP1_HUMAN RIP140_1 119-143 N-Biotinyl-  MVDSVRKGKQDSTLLASLLQSFSSR    -C
NRIP1_HUMAN RIP140_7 699-723 N-Biotinyl-  SGSEIENLLERRTVLQLLLGNPTKG    -C
CBP_HUMAN CBP_1 58-80 N-Biotinyl-    NLVPDAASKHKQLSELLRGGSGS    -C
NCOA2_HUMAN SCR2_1S 636-650 N-Biotinyl-           KGQTKLLQLLTTKSD     -C
ANDR_HUMAN ARAF1 17-32 N-Biotinyl-          KTYRGAFQNLFQSVRE     -C
HAIR_HUMAN HRCoA_2 744-768 N-Biotinyl-  AEDRAGRGPLPCPSLCELLASTAVK    -C
d)
SWISS-PROT ID Peptide name Position Sequence
PRGR_HUMAN PR_H12 907-933 N-Biotinyl-  EMMSEVIAAQLPKILAGMVKPLLFHKK  -C
NCOR1_HUMAN NCoR_3L 2251-2275 N-Biotinyl-GHSFADPASNLGLEDIIRKALMGSF      -C
NCOR2_HUMAN SMRT_ID2 2331-2352 N-Biotinyl- AVQEHASTNMGLEAIIRKALMG        -C
F. D. PEPT. BN2 - N-Biotinyl-     EYHEKRWLEGHIHHRIKSLLENS   -C
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Peptides that bind in the absence of ligand but are not inducible by 9-cis RA
Figure 1a and 1b show that the remaining 13 peptides equally bind to RXRα with and without 
9-cis RA. These data suggest that these peptides bind so strongly to the RXRα LBD that this 
interaction cannot be further enhanced by 9-cis RA. This is confirmed by the dose response 
curves of one of these peptides (RIP140_3), shown in Figure 3a. The apparent Kd values of 
the dose response curves in the absence and presence of 9-cis RA are nearly equal (192 nM in 
the absence and 174 nM in the presence of compound), which indicates that there is no effect 
on the peptide binding by 9-cis RA. 
Figure 2b shows the sequence alignment of these 13 strong binding peptides. Except 
RIP140_3, all peptides contain both the LXXLL motif and the favorable hydrophobic residue 
at the -1 position [31-33]. Obviously, this is one of the essential structural properties that 
coactivator peptides need, to bind so strongly to the LBD that binding of 9-cis RA is no 
longer required. 
RIP140_3 is the only peptide without the hydrophobic residue at the -1 position. This 
suggests that other residues in the coactivator peptide compensate for the absence of the 
hydrophobic residue. One possible explanation could be the lysine at position 2 that may have 
a favorable electrostatic interaction with aspartate 295 in the coactivator binding groove. This 
is corroborated by the observation that the four top-ranked peptides (in the absence of ligand) 
all contain a positive charge or H-bond donor at position 2 in the coactivator motif.
Figure 3. Ligand-independent (dashed line) and ligand-dependent (10 μM, solid line) dose-response 
curves of GST-hRXRα with (a) RIP140_3 and 10 μM 9-cis RA (b) SMRT_ID2 and 10 μM 9-cis RA (c) 
RIP140_3 and 10 μM DHA. 
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Peptides whose binding are inducible by 9-cis RA
Finally, there is a set of 17 peptides that weakly or not bind in the absence of ligand and 
significantly better bind (log(MI) > 0.30, i.e. 2 fold increase in fluorescence intensity) in 
the presence of 9-cis RA. Some of these peptides have been described in previous studies to 
interact with RXRα. For example, our observation that RIP140_7 is significantly enhanced 
in binding to the receptor upon addition of 9-cis RA agrees well with a study of Farooqui 
et al. [34]. Also the observation that the interaction of SHP_2 with the LBD is enhanced 
with 9-cis RA is in agreement with previous studies [35]. Surprisingly, upon addition of 
the agonist 9-cis RA, there is also a significant increase in the affinity of four corepressor 
peptides (NCoR_3L, SMRT_ID2, PR_H12 and BN2). To verify the effect of 9-cis RA on the 
affinity of SMRT_ID2, the dose response curves were measured and Figure 3b shows that 
the binding of SMRT_ID2 improves upon addition of 9-cis RA, i.e. the apparent Kd changes 
from 294 to 160 nM . It has been shown before that the second interaction domain of SMRT 
binds to RXRα in the absence of ligand [36]. However, for the first time, we demonstrate 
that the affinity of SMRT_ID2 increases upon addition of the natural agonist, 9-cis RA. 
Similar peptide recruitment data have been described for agonists in PPAR [37]. From a 
structural perspective, knowing that H12 adopts the agonist position in all 9-cis RA structures 
[6, 33, 38-40], this leads to the question what the role of this helix is in the recruitment 
of the corepressor peptides. The only crystal structure of an NR LBD with a corepressor 
peptide (SMRT_ID2 [10]) showed that the peptide binds in the coactivator binding groove 
and that H12 is not in the agonist position. The N-terminal part of SMRT_ID2 relocated 
H12 towards the N-terminus of H3 and partially overlaps with the agonistic location of H12. 
The recruitment of both coactivator and corepressor peptides by 9-cis RA suggest that 9-
cis RA induces a conformational change in H12 that is stabilized in the agonist position by 
coactivator peptides and in the antagonist position by corepressor peptides.
The sequence alignment of the 13 coactivator peptides and the four corepressor peptides 
that do not bind in the absence of 9-cis RA, but do significantly better bind to RXRα in the 
presence of 9-cis RA are shown in Figure 2c and 2d, respectively. The sequence alignment of 
the coactivator peptides shows that the residue types at position -1 and 2 are less conserved 
as compared to the residue types at these positions for peptides that already bind to RXRα 
in the absence of 9-cis RA (Figure 2b). This suggests that coactivator peptides without a 
hydrophobic residue at position -1 and without a positively charged or H-bond donating 
residue at position 2 can only bind to the LBD when H12 is sufficiently stabilized by the 
ligand. With a sufficiently stable H12, the structural composition of the peptides becomes less 
critical for binding to the receptor, i.e. more sequential variation of the peptides is allowed. 
Clustering of peptide recruitment profiles of various RXRα ligands
Figure 1b shows the peptide recruitment profiles of in total eleven different ligands and 
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9-cis RA is depicted as a reference (solid black line). The ten other ligands include five 
fatty acids, three synthetic agonists (targretin, LG100268, LG100324), a homodimer 
antagonist (LG100754), and a RAR agonist TTNPB (Table 1). Figure 1b clearly shows that 
some compounds induce peptide association in a similar manner as 9-cis RA, while other 
compounds induce peptide dissociation (negative log MI values). Dissociation of peptides is 
confirmed by dose response curves. For example, Figure 3c shows that the estimated Kd of 
RIP140_3 increases from 179 nM to 1288 nM upon addition of DHA. This indicates that the 
firm binding of RIP140_3 in the absence of ligand can be deteriorated by a ligand as DHA. 
This suggests that DHA destabilizes H12, and thereby destroys the optimal conditions for 
coactivator binding. 
To identify which compounds induce identical or unique peptide recruitment profiles, we 
performed a hierarchical clustering on the eleven ligand-induced peptide recruitment profiles 
(Figure 4). The dendrogram of the hierarchical clustering of these peptide recruitment profiles 
was used to determine a boundary to cluster compounds that induce similar peptide recruitment 
Figure 4. Hierarchical clustering of the peptide recruitment profiles of 11 different RXR compounds 
using a hierarchical unweighted clustering routine with a similarity measure that was based on 
correlation. The peptide recruitment profile of each ligand was represented as a row with 52 cells in the 
distance matrix. Each cell is colored according to the log(MI) value of the peptide with  green being the 
highest log(MI) and red the lowest log(MI) value. The vertical red line indicates the boundary that was 
chosen to define the separate clusters. Color version: see Appendix 2.
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profiles. Figure 5 shows the resulting four different clusters with the corresponding peptide 
recruitment profiles of the individual compounds in these clusters. On the basis of the shape 
of the peptide recruitment profiles we refer to these clusters as (1) a dissociative profile, (2) 
and (3) silent profiles and (4) an associative profile.
The natural ligand of RXRα, 9-cis RA, clusters together with targretin, LG100268, LG100324 
Figure 5. The peptide recruitment profiles of 11 RXR compounds grouped by the hierarchical 
clustering method (Figure 4). Cluster 1 contains oleic acid, phytanic acid and DHA. Cluster 2 contains 
pentadecanoic acid and LG100754. Cluster 3 contains TTNPB. Cluster 4 contains 9-cis RA, methoprene 
acid, LG100268, LG100324 and targretin. Each line represents the log(MI) values for all peptides for 
one compound. 
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and methoprene acid. These five compounds form the largest cluster (Figure 5, cluster 4, 9-
cis RA black line). All compounds in this cluster improve the binding of coactivator and 
corepressor peptides. The enhancement of the binding of coactivator peptides is in agreement 
with previous studies which demonstrate that these compounds act as agonists in RXRα 
mediated transcription pathways [18, 41-43]. The recruitment of the four corepressor peptides 
by 9-cis RA (see above) is also observed for the other agonists in this cluster.
The second largest cluster contains three compounds that comprise three of the five fatty 
acids in the ligand set (phytanic acid, oleic acid and DHA). These fatty acids deteriorate the 
binding of coactivator peptides and enhance the binding of the corepressor peptides SMRT_
ID2 and NCoR_3L, indicating that these fatty acids are classical antagonists. However, the 
corepressor peptide BN2 is dissociated upon binding of these classical antagonists suggesting 
that BN2 binds as a coactivator via its IXXLL motif.
The three remaining compounds are in cluster 2 and 3 (Figure 5). Cluster 2 contains the 
homodimer antagonist LG100754 and the fatty acid pentadecanoic acid, cluster 3 contains 
the RARα agonist TTNPB. Compared to the peptide recruitment profiles of the compounds 
in cluster 1 and 4, these compounds show negligible association or dissociation of most 
Figure 6. Competition studies of LG100754 and TTNPB with 9-cis RA. Dose-response curves of 9-cis 
RA were measured in a TR-FRET assay with GST-hRXRα LBD and CBP_1 (0.1μM) in the presence 
of increasing concentrations of (a) LG100754 and (b) TTNPB. 
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peptides. This raises the question whether these compounds actually bind to the receptor. 
Therefore, we performed a peptide recruitment competition assay with CBP_1 as peptide 
and 9-cis RA as ligand (Figure 6a). In the absence of LG100754 the EC
50
 of 9-cis RA is 
3 nM. In the presence of 10-7 M LG100754 the EC
50
 is increased to 43 nM indicating that 
LG100754 competes with 9-cis RA for the same binding site. At even higher concentrations 
LG100754 (10-5 M), 9-cis RA is completely substituted by LG100754. These data indicate that 
LG100754 binds in the LBP, but hardly affects the peptide binding profile i.e. the compound 
does not induce a conformational change in the LBD that results in a significant dissociation 
or association of peptides.
The same competition assay was performed with TTNPB (Figure 6b). In the presence of 
increasing concentrations of TTNPB, the EC
50 
of 9-cis RA is not changed, indicating that 
TTNPB does not compete with 9-cis RA for the same binding site. Therefore we omitted this 
compound from further discussion. 
Correlation between the peptide recruitment profiles and ligand interaction profiles
The hierarchical clustering of the peptide recruitment profiles revealed that ten different RXR 
ligands induce only three distinct peptide recruitment profiles. Each peptide recruitment 
profile is believed to represent a conformation of the receptor surface. We hypothesize that 
ligands that bind similarly in the LBP induce a similar conformation at the receptor surface 
that leads to a similar peptide recruitment profile. 
To investigate whether there are indeed differences between the binding modes of ligands, we 
first analyzed the binding mode of all compounds that have been co-crystallized with hRXRα 
LBD. These compounds are the natural ligand 9-cis RA [6, 33, 38-40], its isomer all-trans 
RA [44], the synthetic agonists BMS649 [45] and LG79 [46] and two fatty acids, DHA [45] 
and PDA [47]. The binding modes of these compounds are represented by so-called ligand-
receptor interaction profiles. Figure 7 shows the ligand-receptor interaction profiles of the 
six co-crystallized ligands with 9-cis RA highlighted as solid black line. The ligand-receptor 
interaction profile describes the number of contacts between each residue in the LBD and 
the ligand. Residues in the LBD have been assigned so-called 3D numbers to allow easy 
comparison of different structures [48]. Figure 7 shows that the six ligands have interactions 
with residues in H3, H5, the beta sheet, H7 and H10. The most important ligand binding 
positions are 335, 339, 556 and 1057, which is in agreement with other members of the NR 
family [49]. The ligand-receptor interaction profiles of the six compounds in Figure 7 show 
that the number of contacts between various residues and the ligand differ among the six 
ligands. This suggests that the ligands have distinct binding modes. We therefore performed 
a hierarchical clustering on the six ligand-receptor interaction profiles. The dendrogram of 
the hierarchical clustering of these ligand-receptor interaction profiles was used to determine 
a boundary to cluster compounds that are similarly bound in the LBP (data not shown). The 
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resulting four different clusters with the corresponding ligand-receptor interaction profiles of 
the individual compounds in these clusters are shown in Figure 8. 
9-cis RA, BMS649 and L79 form the largest cluster (Figure 8, cluster 4, 9-cis RA black 
line). 
The compounds in this cluster are described as agonists. BMS649 and L79 are synthetic 
agonists that better fill the LBP as compared to 9-cis RA. The natural ligand only occupies 
59% of the total LBP volume [50]. One part of the pocket that is not occupied by 9-cis RA 
is near residues at 3D positions 548 and 549 (W305 and N306 in hRXRα, respectively). The 
synthetic agonists are designed to better fill this side of the pocket, which is reflected in the 
ligand-receptor interaction profiles that show higher number of contacts between the ligand 
and positions 549 and 552 (Figure 8, cluster 4) than observed in the other clusters.
The three remaining clusters each contain one ligand (Figure 8, cluster 1-3). Cluster 1 contains 
all-trans retinoic acid (at-RA), which is the natural ligand of RAR. The X-ray structure of this 
compound with RXRα crystallized as a tetramer with H12 of each monomer in the coactivator 
groove of the adjacent monomer [44]. The formation of a tetramer also led to a displacement 
of the N-terminal part of H3 and the C-terminal part of H10. Therefore, the ligand-receptor 
Figure 7. Ligand-receptor interaction profiles of compounds in hRXRα crystal structures. A ligand-
receptor interaction profile describes for each position in the LBD the number of interactions with 
the ligand. The profile of 9-cis RA is highlighted as a solid black line. The profiles of the five other 
compounds that are co-crystallized with hRXRα (all-trans retinoic acid, DHA, PDA, BMS649 and L79) 
are shown in light gray. The secondary structures of the LBD that correspond with the 3D numbers are 
displayed below the graph.
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interaction profile of this compound is dissimilar to the other profiles.  Cluster 2 and 3 
both contain a fatty acid, PDA and DHA, respectively. The major difference in the ligand-
receptor interaction profile that separates these two clusters is the high number of contacts 
of DHA with position 1057 (Figure 8, cluster 3) that is not observed in the ligand-receptor 
interaction profiles of any other compound. Clustering of the ligand-interaction profiles of 
these six ligands suggest that there are four different binding modes of RXR compounds in 
Figure 8. Ligand-receptor interaction profiles of the compounds in hRXRα crystal structures grouped 
by hierarchical clustering (unweighted, correlation as similarity measurements). Cluster 1 contains at-
RA. Cluster 2 and 3 contain PDA and DHA, respectively. Cluster 4 contains 9-cis RA, BMS649 and 
L79. Each line represents the ligand-receptor interaction profile of a compound. 
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the available crystal structures, which can be detected by this method. 
Since the RXRα crystal structure data is limited to six compounds, of which only two are in 
the peptide recruitment data set, we manually modeled each of the 10 compounds that were 
profiled in the peptide recruitment assay and studied the interaction between the receptor 
and the ligand by MD. TTNPB was excluded from the initial set, because this compound 
does not bind to the RXRα LBD (see above). Figure 9 shows the ligand-receptor interaction 
profiles that were calculated from model structures of the ten compounds. To identify how 
unique or similar the different binding modes of the ligands in the LBP are, we performed the 
same clustering procedure on the ligand-receptor interaction profiles as was applied to the 
profiles of the compounds in the crystal structures. From the dendrogram (data not shown) 
two distinct ligand-receptor interaction profile clusters could be identified. The corresponding 
profiles of the individual compounds in both clusters are shown in Figure 10. 
The first cluster contains oleic acid, DHA, phytanic acid, PDA and LG100754. The second 
cluster contains all agonists: 9-cis RA (black line), targretin, LG100324, LG100268 and 
methoprene acid. A clear difference between the two clusters is the number of contacts of the 
compounds with residues in the C-terminal part of H10, in particular 3D positions 1057 and 
1061. In general, compounds from the agonist cluster have a lower number of contacts with 
these residues than the compounds in the other cluster. To reveal a structural explanation for 
the differences in binding mode of compounds from the agonist cluster and the other cluster 
we superposed hRXRα crystal structures, each with a compound from one of the clusters (9-
cis RA from the agonist cluster and DHA from the other cluster, Figure 11). Figure 11 clearly 
shows the differences of interaction between each of the two compounds and the H10 region. 
While the side chain of cysteine 1057 (corresponding to residue 432 in hRXRα) is in the 
Figure 9. Ligand-receptor interaction profiles of 10 RXR compounds that were modeled in the hRXRα 
LBD and were tested in the peptide recruitment profiling. TTNPB was excluded from this set since it 
was shown that it does not bind to the RXRα LBD. The secondary structures of the LBD that correspond 
with the 3D numbers are displayed below the graph. MD = molecular dynamics.
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same orientation in both structures, leucine 1061 (436 in hRXRα)  showed a movement of its 
side chain. In the crystal structure with DHA, the side chain of this leucine is shifted towards 
H12, while in the crystal structure with 9-cis RA this residue is pointing into the pocket of the 
LBP. The movement of this side chain towards H12 suggests a destabilization of this helix.
The clustering of the ligand-receptor interaction profiles does not distinguish between 
compounds that were dissociative (DHA, oleic acid and phytanic acid) or silent (LG100754 
and PDA) in their induced peptide recruitment profiles. We therefore compared the 
individual ligand-receptor interaction profile of LG100754 with the profiles of representative 
compounds from the two other clusters (9-cis RA for the associative, DHA for the dissociative 
peptide recruitment cluster, Figure 10). In addition, the binding mode of LG100754 was 
compared to that of 9-cis RA by superposition of the X-ray RXRα structure with 9-cis RA 
Figure 10. The ligand-receptor interaction profiles of 10 RXR compounds which were calculated from 
the structures that were generated by molecular modeling. The profiles were grouped after hierarchical 
clustering (unweighted, similarity by correlation). Cluster 1 contains oleic acid, DHA (black line), 
phytanic acid, PDA and LG100754 (black line).  Cluster 2 contains 9-cis RA (black line), targretin, 
LG100324, LG100268 and methoprene acid. Each line represents the ligand-receptor interaction profile 
of a compound. Profiles of DHA and LG100754 are indicated by arrows.
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Figure 11. Comparison of the binding modes of DHA (orange) and 9-cis RA (green). All chains from 
RXRα crystal structures with 9-cis RA [6, 33, 38-40] or DHA [45] were superposed and the side chains 
of the cysteines at 3D position 1057 and the leucines at 3D position 1061 are shown. The secondary 
structure representation is based on the backbone of 1FM6 [38] , H10 = helix 10, H12 = helix 12. Color 
version: see Appendix 2.
Figure 12. Comparison of the binding modes of LG100754 (cyan) and 9-cis RA (green). The coordinate 
set of RXRα with LG100754 of the frame with the lowest interaction energy was superposed on 
the RXRα crystal structure with 9-cis RA [38]. The three areas where differences in ligand binding 
are observed are indicated with one representative residue for each area. The secondary structure 
representation is based on the backbone of 1FM6 [38], H3 = helix 3, H5 = helix 5 and H7 = helix 7. 
Color version: see Appendix 2.
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(1FM6 [38]) and the coordinate set of RXRα with LG100754 of the frame with the lowest 
interaction energy (Figure 12). Interestingly, the binding mode of LG100754 in the LBP is 
different from 9-cis RA in three areas. The first area is near the tryptophan at position 548 
(3D number, 305 in hRXRα). The propoxy group of LG100754 points towards this residue 
whereas the other ligands do not occupy this space. This leads to a higher number of contacts 
in the ligand-receptor interaction profile of LG100754 at 3D residue positions 548, 549, 
552 and 553 (corresponding to residues 305, 306, 309 and 310 in hRXRα) compared to the 
profiles of the other two compounds. The second area is in the N-terminal part of H3. The 
tetra-hydronaphthalene moiety of the homodimer antagonist is shifted towards this part of 
the LBD, leading to a higher number of contacts with 3D residue positions 331 and 332 
(corresponding to residues 264 and 265 in hRXRα). The third area comprises residues in H7. 
The binding mode of LG100754 shows a lower number of contacts between LG100754 and 
3D residue positions 738 and 739 (corresponding to residues 345 and 346 in hRXRα) than 
9-cis RA and DHA.
Discussion
We hypothesized that the binding mode of a ligand in the LBP determines the conformation 
at the receptor surface through allosteric coupling. For this purpose, we determined whether 
compounds that bind differently in the LBP act differently in cofactor recruitment, by 
comparing the clustering based on ligand-receptor interaction profiles with the clustering 
of the compounds based on peptide recruitment profiles. We observed two distinct binding 
modes of ligands in the LBP by means of clustering of the ligand-receptor interaction profiles 
while we observed three distinct conformations of the RXRα LBD by means of clustering of 
the peptide recruitment profiles. These three distinct conformational changes of the RXRα 
LBD can be described as an associative, dissociative or silent peptide recruitment profile. We 
observed that the five compounds in the associative peptide recruitment profile cluster are the 
same five compounds in one of the two clusters of the ligand-receptor interaction profiles. 
This indicates that there is indeed a correlation between the binding mode of a ligand and 
the conformation at the surface. However, the ligand-receptor interaction profiles do not yet 
discriminate between compounds that induce no conformational change at all (silent peptide 
recruitment profile) and compounds that destabilize H12 (dissociative peptide recruitment 
profile). 
In this discussion we will focus on two issues. First, we discuss how well the data from a 
peptide recruitment assay reflects the effect of a compound in a cellular context. Secondly, 
we give a structural explanation for the three distinct conformational changes at the RXRα 
surface, i.e. the structural mechanism underlying the associative, dissociative and silent 
peptide recruitment profile.
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Peptide recruitment assay vs in vitro transactivation assay 
Current models of NR activation suggest that agonist compounds promote the association of 
a coactivator and the dissociation of a corepressor. Agonist compounds stabilize H12 in an 
active conformation thereby facilitating the binding of a coactivator protein and reducing the 
affinity of corepressors. On the other hand, antagonists displace H12 from the active position 
which results in enhancement of the binding of corepressors and reduction of the binding of 
coactivators. Finally, the so-called selective nuclear receptor modulators (SNRM) induce 
such a conformation of H12 that both coactivator and corepressor can bind [51, 52]. This 
may lead to an increase or decrease in gene transcription depending on the concentration of 
coactivators and corepressors in a cell. In this study however, the coactivators and corepressors 
are represented by short peptide fragments and the ligand induced recruitment or dissociation 
of these fragments was measured by peptide recruitment. This raises two questions:
(1) How well does a peptide recruitment profile reflect the effect of a compound in a cell?
We observed that compounds in the associative cluster recruited not only coactivator peptides, 
but also corepressor peptides. In the context of the above described models for NR activation, 
our data indicate that 9-cis RA and other RXR agonists are not classical agonists, but actually 
act as SNRMs. The observation that these SNRMs induce coactivator and corepressor binding 
suggests that these compounds only partially stabilize H12 in the agonist position. This offers 
H12 sufficient conformational freedom to take the antagonist position in the presence of a 
corepressor peptide, and the agonist position in the presence of a coactivator peptide. The 
final agonist or antagonist response of the compound in a particular cell type depends on the 
concentrations of cofactors in this cell type [51, 52]. Since several studies have shown that 
these compounds act as agonists in various cell-based assays [18, 41-43] this suggests that 
these cell types have a higher concentration of coactivators than corepressors.
Compounds in the dissociative cluster reduced the binding of coactivator peptides while 
they increase the binding of corepressor peptides, i.e. the profile of a typical antagonist. This 
suggests that these compounds behave as full antagonists in cell-based assays. However, 
several studies show that fatty acids rather activate than inhibit RXRα-mediated gene 
transcription [19, 21]. One possible explanation is that concentrations of corepressors in 
these cell-based assays may have been too low to compete with high levels of coactivators 
and that other cell-types with high corepressor concentrations are needed to demonstrate the 
antagonist activity of fatty acids.
Compounds in the silent cluster did not induce a change in binding affinity for either coactivator 
or corepressor peptides, suggesting that there will be no change in gene transcription. Most 
likely, these compounds will be silent antagonists due to competition with the natural ligand 
9-cis RA under physiological conditions.
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(2) How well does the peptide recruitment assay reflects the interaction between a full-length 
NR and a full-length cofactor in vitro?
In general, we observed that our peptide binding data agree well with the binding data of 
full-length cofactors that has been described in the literature. For example, the full-length 
cofactor recruitment of SRC3, FHL2, SRC1 and RIP140 [33, 34, 53, 54] is reflected by 
the recruitment of peptides derived from these coactivators. In addition, we noticed that the 
coactivator peptides can be classified as peptides that already strongly bind to the LBD in the 
absence of an agonist, peptides that only bind in the presence of a ligand and peptides that 
do not bind. Peptides with a hydrophobic residue at position -1 in the peptide sequence, did 
already strongly bind to the LBD in the absence of ligand, indicating that these coactivators 
force H12 in an agonist position, even in the absence of ligand. This suggests that these RXRα-
cofactor complexes are continuously active in gene transcription even without ligand. 
Peptides that lack a hydrophobic residue at position -1 did only bind to the RXRα LBD 
in the presence of 9-cis RA. This indicates that the cellular action of these coactivators is 
only activated when 9-cis RA is present. This suggests that these coactivators may be more 
important for ligand induced gene transcription processes as compared to coactivators that 
always bind to RXRα. However, binding experiments with full length cofactors and NRs are 
needed to study this in more detail. 
Peptide recruitment profiles and underlying structural mechanisms
1. Associative and dissociative peptide recruitment profiles
To determine the structural mechanism underlying the induced association/dissociation of 
peptides we focused on compounds that induce an associative peptide recruitment profile 
and on compounds that induce a dissociative peptide recruitment profile. Comparison of 
the ligand-receptor interaction profiles of both clusters revealed that the compounds that 
induce a dissociative peptide recruitment profile have a significant higher number of contacts 
with residues 1057 and 1061 (3D-number, C432 and L436 in hRXRα, respectively) in the 
C-terminal part of H10 [45]. This suggests that compounds that are in contact with the 
C-terminus of H10 destabilize H12 and can act as antagonists. A similar mechanism for 
antagonism has been described for ER [55].
2. Silent peptide recruitment profile
Clustering of the ligand-receptor interaction profiles could not distinguish between compounds 
that induced a dissociative or silent peptide recruitment profile. However, the proposed ligand 
binding mode of LG100754 (Figure 12) shows that there are three plausible explanations for 
the observation that this compound acts as a “silent” antagonist. 
(1) The shift of LG100754 towards H3 excludes a high number of contacts with the C-
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terminal part of H10, which is needed to destabilize H12 (see above).
(2) W548 in H5 is described in stabilizing H12 via a water molecule [6], and therefore the 
position of this residue is important. Ligands protruding the area near this residue could 
disrupt the stabilization of H12. This hypothesis is strengthened by the observation that 
ligands that are identical to LG100754, but have a methoxy or ethoxy group instead of a 
propoxy group, act as an agonist or partial agonist, respectively [56, 57].
(3) The N-terminal part of H3 is described in direct interactions with H12 and the C-terminal 
part of H11. In addition, an analysis of ligand-receptor contacts in all NR LBDs revealed that 
partial agonists interact more strongly with this part of H3 [49]. LG100754 has a significant 
higher number of contacts with H3 that could destabilize H12. This suggests that the 
homodimer antagonist has a unique binding mode, which leads to a minor effect on peptide 
binding in the peptide recruitment assay.
Final conclusion
In summary, this work shows for one class of compounds that there is a correlation between 
the binding mode of a ligand (represented by a ligand-receptor interaction profile) and 
the conformational change it induces at the surface of the RXRα LBD (represented by a 
peptide recruitment profile). We therefore conclude that clustering of ligand-receptor 
interaction profiles is a very useful tool to discriminate compounds that may induce different 
conformations. We also conclude that compounds can be easily and more accurately classified 
by their peptide recruitment profiles. These peptide recruitment profiles showed that five 
well-known RXRα “agonists” actually behave like SNRMs, while three fatty acids act as 
antagonists and two compounds act as silent antagonists.  
We therefore envision that the methods described in this paper can be of great value for drug 
design. With these methods new compounds can be profiled based on their ligand binding 
properties and their peptide recruitment properties. Moreover, the combination of both 
profiles will lead to useful insights in the working mechanism of a NR LBD, which in turn 
aid the design of compounds with a desired effect.
Materials and Methods
Plasmid construction and protein purification
cDNA coding for the ligand-binding domain of human RXRα (hRXRα, amino acids 221-
462) was cloned into the EcoRI and XHoI sites of pGEX-4T-1 (Amersham Biosciences). The 
protein was expressed as a fusion protein with glutathione S-transferase (GST) in Escherichia 
coli DH5α and purified by affinity chromatography.
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Ligands
Table 1 shows the structures of the ligands that were used in the peptide recruitment assay. 
Oleic acid, phytanic acid, DHA, pentadecanoic acid (PDA), methoprene acid, TTNPB, 9-cis 
RA (all purchased from Sigma-Aldrich), LG100324, LG100268, LG100754, targretin (all 
synthesized in house) were diluted in dimethyl sulfoxide (DMSO) to a final concentration of 
10 mM. 
Peptides
Table 2 (Appendix 1, Supplemental Data) shows the sequences of the 52 N-terminal 
biotinylated peptides (Neosystems) derived from 15 different cofactors, five NRs and 
various phage display peptide libraries [28, 58]. Most of the peptides (33) contain the 
Table 1. Chemical structures of RXR compounds used in this study.
OH O
O
OH
OH O
9-cis retinoic acid oleic acid cis-4,7, 10, 13, 16, 19-
docosahexaenoic acid
OH
O
O
OH
N
O
OH
phytanic acid Targretin LG100268
O
OH
N
OH
O
O
OH
O
O
OH
LG100324 LG100754 methoprene acid
OH
O
OH
O
TTNPB pentadecanoic acid
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LXXLL coactivator motif whereas three peptides possess a FXXLF motif and two peptides 
have a FXXLY motif. Twelve repressor peptides in the set are described by the consensus 
sequence (L/I/V)XXX(L/I/V)XXX(L/I/V), and two peptides (NCoR_4 and NCoR_4M) 
show a LXXXMXXXT sequence. Due to similarity between the consensus sequences of a 
coactivator and corepressor motif, it is possible that some peptides contain both coactivator 
and corepressor motifs.
Time-resolved fluorescence resonance energy transfer (TR-FRET) assay
A TR-FRET assay was performed with 52 peptides in the absence and presence of ligand. 
Each reaction mixture (pH 7.2) contains 50 mM Tris, 50 mM KCl, 1 mM EDTA, 1 mM 
DTT, 0.1mg/ml bovine serum albumin, 10 nM RXRα LBD, 0.1 μM biotinylated peptide, 10 
μM ligand, 8 nM allophycocyanin (APC)-labeled Streptavidin (PerkinElmer Life Sciences) 
and 1.25 nM LANCE Eu-W1024-labeled anti-GST antibody (PerkinElmer Life Sciences). 
Reactions were carried out in 384-well plates. Plates were centrifuged and incubated for 24 
h at 4 ºC. Fluorescence at 665 nm was measured on a Victor (Wallac).
To directly visualize the effect of a ligand on recruitment of the different peptides, the 
modulation index (MI) was calculated, i.e. the ratio between the fluorescence intensity in 
the presence of a ligand and the fluorescence intensity in the absence of ligand. A MI of 2.0 
indicates a two fold increase of the amount of peptide bound, while a MI of 0.5 indicates a 2 
fold decrease in the amount of peptide bound. This non-linear behavior was translated into 
a linear positive signal for an increase in peptide binding and a linear negative signal for a 
decrease in peptide binding by calculating the 10log(MI). Log(MI) values above zero indicate 
recruitment of peptides, and thus an associative effect of the ligand on peptide binding. On 
the contrary, negative values indicate dissociation of peptides and therefore a dissociative 
effect of the compound on peptide binding. A log(MI) value of around zero means that a 
peptide does not bind or that the binding is not changed by the ligand. 
To determine the apparent Kd values of specific peptides the binding curves were determined 
in a peptide concentration range between 0.1 nM – 1 μM. To determine EC
50
 values of 
ligands, we measured ligand dose-response curves with ligand concentrations ranging from 
31.6 pM - 1 μM.
Molecular dynamics simulations of manually docked compounds in the RXRα LBD
Molecular dynamics (MD) simulations were performed using QUANTA/CHARMm [59] 
following a protocol that was described previously by Kouwijzer et al. [60]. The hRXRα 
LBD of 1FM6 (chain A) was selected as template structure. The initial binding modes of 
six ligands were obtained from available X-ray structures of either hRXRα or hRXRβ by 
superposition of the structures onto the template structure. The superposed hRXRα structure 
with DHA (1MV9 [45]) was used to construct the initial binding mode of phytanic acid, 
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and the superposed hRXRβ structure with LG100268 [61] was used to model LG100754, 
LG100324 and targretin (Table 3, Appendix 1, Supplemental Data). The complexes were 
protonated, charges were assigned and ligand atom types and bond orders were corrected. 
The MD run started with a heating phase of 10 ps, followed by a 100 ps run at 400 K during 
which time the coordinate sets were saved every picosecond. These coordinate sets were 
energy minimized and for each of these hundred frames the average interaction energy 
between ligand and protein was calculated. The ten coordinate sets with the lowest average 
interaction energy were used to calculate an average ligand-receptor interaction profile.
Ligand-receptor interaction profiles
The number of contacts between ligands and residues in the RXRα LBD were calculated 
by the Automatic Residue Extraction System (ARES), as was previously described for the 
analysis of ligand binding in all NR LBDs [49].  For each unique receptor-ligand combination 
ARES automatically creates a so-called ligand-receptor interaction profile. A contact is 
included in the profile when the distance between the Van der Waals’ surfaces of the atoms of 
a ligand and a residue is less than 1 Å. A unique number is assigned to each residue position 
that is structurally conserved within the family of the NR LBDs [48]. This 3D number starts 
with one or two digits that indicate the helix number, similarly ‘B’ and ‘L’ reflect residues 
in the beta sheet and loops, respectively. Residues that are not structurally conserved and 
therefore do not have a 3D number all got the number zero. Contacts in multiple copies of 
the same LBD-ligand complex were normalized. If, for example, a LBD-ligand complex is 
observed two times in one PDB file and three times in another, all contacts in all five chains 
are summed up and divided by five.
 
Data analysis
The TR-FRET assay and the contact analysis by ARES yielded peptide recruitment profiles and 
ligand-receptor interaction profiles, respectively. Spotfire DecisionSite (Spotfire, Somerville, 
USA) was used to cluster both types of profiles by a hierarchical unweighted clustering 
routine with a similarity measure that was based on correlation. Resulting dendrograms were 
used to determine the boundary to separate clusters.   
C
hapter 4
113
References
1. Mangelsdorf, D.J., et al., The nuclear receptor superfamily: the second decade. 
Cell, 1995. 83(6): p. 835-9.
2. Giguere, V., Orphan nuclear receptors: from gene to function. Endocr Rev, 1999. 
20(5): p. 689-725.
3. Kliewer, S.A., J.M. Lehmann, and T.M. Willson, Orphan nuclear receptors: shifting 
endocrinology into reverse. Science, 1999. 284(5415): p. 757-60.
4. Renaud, J.P., et al., Crystal structure of the RAR-gamma ligand-binding domain 
bound to all-trans retinoic acid. Nature, 1995. 378(6558): p. 681-9.
5. Renaud, J.P. and D. Moras, Structural studies on nuclear receptors. Cell Mol Life 
Sci, 2000. 57(12): p. 1748-69.
6. Egea, P.F., et al., Crystal structure of the human RXRalpha ligand-binding domain 
bound to its natural ligand: 9-cis retinoic acid. Embo J, 2000. 19(11): p. 2592-
601.
7. Darimont, B.D., et al., Structure and specificity of nuclear receptor-coactivator 
interactions. Genes Dev, 1998. 12(21): p. 3343-56.
8. Nolte, R.T., et al., Ligand binding and co-activator assembly of the peroxisome 
proliferator-activated receptor-gamma. Nature, 1998. 395(6698): p. 137-43.
9. Ding, X.F., et al., Nuclear receptor-binding sites of coactivators glucocorticoid 
receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): 
multiple motifs with different binding specificities. Mol Endocrinol, 1998. 12(2): p. 
302-13.
10. Xu, H.E., et al., Structural basis for antagonist-mediated recruitment of nuclear co-
repressors by PPARalpha. Nature, 2002. 415(6873): p. 813-7.
11. Perissi, V., et al., Molecular determinants of nuclear receptor-corepressor 
interaction. Genes Dev, 1999. 13(24): p. 3198-208.
12. Hu, X. and M.A. Lazar, The CoRNR motif controls the recruitment of corepressors 
by nuclear hormone receptors. Nature, 1999. 402(6757): p. 93-6.
13. Iannone, M.A., et al., Correlation between in vitro peptide binding profiles and 
cellular activities for estrogen receptor-modulating compounds. Mol Endocrinol, 
2004. 18(5): p. 1064-81.
14. Downes, M., et al., A chemical, genetic, and structural analysis of the nuclear bile 
acid receptor FXR. Mol Cell, 2003. 11(4): p. 1079-92.
15. Lee, G., et al., T0070907, a selective ligand for peroxisome proliferator-activated 
receptor gamma, functions as an antagonist of biochemical and cellular activities. 
J Biol Chem, 2002. 277(22): p. 19649-57.
16. Chambon, P., A decade of molecular biology of retinoic acid receptors. Faseb J, 
1996. 10(9): p. 940-54.
17. Horton, C. and M. Maden, Endogenous distribution of retinoids during normal 
development and teratogenesis in the mouse embryo. Dev Dyn, 1995. 202(3): p. 
312-23.
18. Heyman, R.A., et al., 9-cis retinoic acid is a high affinity ligand for the retinoid X 
receptor. Cell, 1992. 68(2): p. 397-406.
19. Lengqvist, J., et al., Polyunsaturated fatty acids including docosahexaenoic and 
arachidonic acid bind to the retinoid X receptor alpha ligand-binding domain. Mol 
Cell Proteomics, 2004. 3(7): p. 692-703.
114
R
X
R
 p
ro
fi l
in
g
20. de Urquiza, A.M., et al., Docosahexaenoic acid, a ligand for the retinoid X receptor 
in mouse brain. Science, 2000. 290(5499): p. 2140-4.
21. Lemotte, P.K., S. Keidel, and C.M. Apfel, Phytanic acid is a retinoid X receptor 
ligand. Eur J Biochem, 1996. 236(1): p. 328-33.
22. Dawson, M.I., Synthetic retinoids and their nuclear receptors. Curr Med Chem 
Anti-Canc Agents, 2004. 4(3): p. 199-230.
23. Li, Y., et al., Structural and biochemical basis for selective repression of the orphan 
nuclear receptor liver receptor homolog 1 by small heterodimer partner. Proc Natl 
Acad Sci U S A, 2005. 102(27): p. 9505-10.
24. Sablin, E.P., et al., Structural basis for ligand-independent activation of the orphan 
nuclear receptor LRH-1. Mol Cell, 2003. 11(6): p. 1575-85.
25. Watkins, R.E., et al., The human nuclear xenobiotic receptor PXR: structural 
determinants of directed promiscuity. Science, 2001. 292(5525): p. 2329-33.
26. Uppenberg, J., et al., Crystal structure of the ligand binding domain of the human 
nuclear receptor PPARgamma. J Biol Chem, 1998. 273(47): p. 31108-12.
27. Xu, H.E., et al., Molecular recognition of fatty acids by peroxisome proliferator-
activated receptors. Mol Cell, 1999. 3(3): p. 397-403.
28. Hsu, C.L., et al., The use of phage display technique for the isolation of androgen 
receptor interacting peptides with (F/W)XXL(F/W) and FXXLY new signature 
motifs. J Biol Chem, 2003. 278(26): p. 23691-8.
29. Dubbink, H.J., et al., Distinct recognition modes of FXXLF and LXXLL motifs by the 
androgen receptor. Mol Endocrinol, 2004. 18(9): p. 2132-50.
30. He, B., et al., The FXXLF motif mediates androgen receptor-specific interactions 
with coregulators. J Biol Chem, 2002. 277(12): p. 10226-35.
31. Northrop, J.P., et al., Selection of estrogen receptor beta- and thyroid hormone 
receptor beta-specific coactivator-mimetic peptides using recombinant peptide 
libraries. Mol Endocrinol, 2000. 14(5): p. 605-22.
32. Heery, D.M., et al., Core LXXLL motif sequences in CREB-binding protein, SRC1, 
and RIP140 define affinity and selectivity for steroid and retinoid receptors. J Biol 
Chem, 2001. 276(9): p. 6695-702.
33. Pogenberg, V., et al., Characterization of the interaction between retinoic acid 
receptor/retinoid X receptor (RAR/RXR) heterodimers and transcriptional 
coactivators through structural and fluorescence anisotropy studies. J Biol Chem, 
2005. 280(2): p. 1625-33.
34. Farooqui, M., et al., Effects of retinoid ligands on RIP140: molecular interaction 
with retinoid receptors and biological activity. Biochemistry, 2003. 42(4): p. 971-
9.
35. Seol, W., M. Chung, and D.D. Moore, Novel receptor interaction and repression 
domains in the orphan receptor SHP. Mol Cell Biol, 1997. 17(12): p. 7126-31.
36. Ghosh, J.C., et al., Interactions that determine the assembly of a retinoid X receptor/
corepressor complex. Proc Natl Acad Sci U S A, 2002. 99(9): p. 5842-7.
37. Stanley, T.B., et al., Subtype specific effects of peroxisome proliferator-activated 
receptor ligands on corepressor affinity. Biochemistry, 2003. 42(31): p. 9278-87.
38. Gampe, R.T., Jr., et al., Asymmetry in the PPARgamma/RXRalpha crystal structure 
reveals the molecular basis of heterodimerization among nuclear receptors. Mol 
Cell, 2000. 5(3): p. 545-55.
39. Suino, K., et al., The nuclear xenobiotic receptor CAR: structural determinants of 
C
hapter 4
115
constitutive activation and heterodimerization. Mol Cell, 2004. 16(6): p. 893-905.
40. Xu, H.E., et al., Structural determinants of ligand binding selectivity between the 
peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A, 2001. 
98(24): p. 13919-24.
41. Levin, A.A., et al., 9-cis retinoic acid stereoisomer binds and activates the nuclear 
receptor RXR alpha. Nature, 1992. 355(6358): p. 359-61.
42. Boehm, M.F., et al., Design and synthesis of potent retinoid X receptor selective 
ligands that induce apoptosis in leukemia cells. J Med Chem, 1995. 38(16): p. 3146-
55.
43. Harmon, M.A., et al., Activation of mammalian retinoid X receptors by the insect 
growth regulator methoprene. Proc Natl Acad Sci U S A, 1995. 92(13): p. 6157-
60.
44. Gampe, R.T., Jr., et al., Structural basis for autorepression of retinoid X receptor by 
tetramer formation and the AF-2 helix. Genes Dev, 2000. 14(17): p. 2229-41.
45. Egea, P.F., A. Mitschler, and D. Moras, Molecular recognition of agonist ligands by 
RXRs. Mol Endocrinol, 2002. 16(5): p. 987-97.
46. Haffner, C.D., et al., Structure-based design of potent retinoid X receptor alpha 
agonists. J Med Chem, 2004. 47(8): p. 2010-29.
47. Xu, R.X., et al., A structural basis for constitutive activity in the human CAR/
RXRalpha heterodimer. Mol Cell, 2004. 16(6): p. 919-28.
48. Folkertsma, S., et al., A family-based approach reveals the function of residues in 
the nuclear receptor ligand-binding domain. J Mol Biol, 2004. 341(2): p. 321-35.
49. Folkertsma, S., et al., The nuclear receptor ligand-binding domain: a family-based 
structure analysis. Curr Med Chem, 2005. 12(9): p. 1001-16.
50. Otero, M.P., et al., Stereoselective synthesis of annular 9-cis-retinoids and binding 
characterization to the retinoid X receptor. J Org Chem, 2002. 67(17): p. 5876-82.
51. Smith, C.L. and B.W. O’Malley, Coregulator function: a key to understanding tissue 
specificity of selective receptor modulators. Endocr Rev, 2004. 25(1): p. 45-71.
52. Gronemeyer, H., J.A. Gustafsson, and V. Laudet, Principles for modulation of the 
nuclear receptor superfamily. Nat Rev Drug Discov, 2004. 3(11): p. 950-64.
53. Muller, J.M., et al., FHL2, a novel tissue-specific coactivator of the androgen 
receptor. Embo J, 2000. 19(3): p. 359-69.
54. Tzameli, I., et al., Complex effects of rexinoids on ligand dependent activation or 
inhibition of the xenobiotic receptor, CAR. Nucl Recept, 2003. 1(1): p. 2.
55. Shiau, A.K., et al., Structural characterization of a subtype-selective ligand reveals 
a novel mode of estrogen receptor antagonism. Nat Struct Biol, 2002. 9(5): p. 359-
64.
56. Lala, D.S., et al., Activation of specific RXR heterodimers by an antagonist of RXR 
homodimers. Nature, 1996. 383(6599): p. 450-3.
57. Canan Koch, S.S., et al., Identification of the first retinoid X, receptor homodimer 
antagonist. J Med Chem, 1996. 39(17): p. 3229-34.
58. Huang, H.J., J.D. Norris, and D.P. McDonnell, Identification of a negative regulatory 
surface within estrogen receptor alpha provides evidence in support of a role for 
corepressors in regulating cellular responses to agonists and antagonists. Mol 
Endocrinol, 2002. 16(8): p. 1778-92.
59. CHARMm version 31b, QUANTA 2005, Accelrys, San Diego, USA.
60. Kouwijzer, M.L. and J. Mestres, Molecular docking and dynamics simulations in 
116
R
X
R
 p
ro
fi l
in
g
the ligand binding domain of steroid hormone receptors. Trends in Drug Research 
III, 2002: p. 57-66.
61. Love, J.D., et al., The structural basis for the specificity of retinoid-X receptor-
selective agonists: new insights into the role of helix H12. J Biol Chem, 2002. 
277(13): p. 11385-91.
C
hapter 5
117
Chapter 5
NRMD: Nuclear Receptor Mutation Database
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Abstract
The NRMD is a database for nuclear receptor mutation information. It includes mutation 
information from Swiss-Prot/TrEMBL, several web-based mutation data resources, and 
data extracted from the literature in a fully automatic manner. Because it is also possible 
to add mutations manually, a hundred mutations were added for completeness. At present, 
the NRMD contains information about 893 mutations in 54 nuclear receptors. A common 
numbering scheme for all nuclear receptors eases the use of the information for many kinds 
of studies. The NRMD is freely available to academia and industry as a stand-alone version 
at: www.receptors.org/NR/.
C
hapter 5
119
Introduction
Nuclear receptors (NRs) play a crucial role in the regulation of gene expression, and are thus 
an important target for the pharmaceutical industry. NRs consist of multiple domains, among 
which are a DNA-binding domain and a ligand-binding domain (LBD). The NRMD deals 
mainly with mutations in the LBD. 
Binding of hormones such as testosterone, vitamin D3 or retinoic acid to LBDs leads to 
dimerization and binding of a co-activator or co-repressor, which in turn leads to transcription 
regulation. A good understanding of this process at the molecular level is important for the 
pharmaceutical industry. Mutation studies are an important source of data on the role of 
individual amino acids, and together with structural data about amino acid - ligand interactions, 
they play a central role in the rational drug design process. 
The function of residues in NRs is mainly determined by their location [1] (www.receptors.
org/NR/struct/alignmt.html). Therefore, a mutation of a residue at a certain position in one 
receptor is likely to have a similar effect as the mutation of a different residue at the equivalent 
position in another receptor. The structural equivalence of residue positions can thus be used 
to transfer information about mutations in one NR to all other NRs. To aid this transfer of 
information, we introduced a common structure-based numbering scheme for all NRs. 
The NRMD is part of a larger project aimed at the design of Molecular Class Specific 
Information Systems (MCSISs). Well-known examples of MCSISs are the GPCRDB (www.
gpcr.org) [2] and the NucleaRDB (www.receptors.org/NR/) [3]. The NRMD currently exists 
as a stand-alone mutation information resource, but full integration in the NucleaRDB is well 
underway.
Results
Several mutation information resources are available. Swiss-Prot/TrEMBL [4] contain 
sequences of about 1300 NRs, and from their annotation, information about 359 variants can 
easily be extracted. A fully automatic search of OMIM [5] for NR mutations is difficult, but 
a human-aided computer script could extract 156 mutants from this resource. The Vitamin D 
receptor (VDR) pages contain well-documented information about vitamin D receptors. The 
Photoreceptor cell-specific Nuclear Receptor pages (PNR) [6] specialize in the photoreceptor 
cell-specific nuclear receptor, and the Glucocorticoid Receptor Resource (GRR) [7] contains 
a lot of information about glucocorticoid receptors. The NucleaRDB provides point mutation 
data (www.receptors.org/NR/mutation/) automatically extracted from the literature [8]. Using 
pattern matching, the method “MuteXt” retrieves articles and extracts point mutations, which 
are then validated by plausibility filters. These filters use the sequence data and the in-text 
distances between receptor names, organism types and mutants. The preliminary evaluation 
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Table 1. Mutation information resources.
Nuclear receptor information resources. The seven tables hold the name of the resource, the number of 
NR mutations we found in the resource, its location in the WWW, and the reference. Due to redundancy, 
the total number of mutations given by the table is not 893. 
Name # mutants 
found
address Ref.
Swiss-Prot/TrEMBL 359 www.expasy.org [4]
OMIM 156 www.ncbi.nih.gov/Omim [5]
VDR 48 vdr.bu.edu
PNR 21 www.retina-international.com/sci-
news/nr2e3mut.htm
[6]
GRR 256 nrr.georgetown.edu/GRR/muta-
tion/mutation.html
[7]
MuteXt 378 www.receptors.org/NR/mutation [8]
Manual 136
Figure 1. Front page of the NRMD. Source: origin of the mutation information. Species and Receptor: 
obvious. Region: indicates secondary structure element in which the mutation should reside. From, To: 
allow for selection of original and introduced residue type. Position allows searching for residues at a 
given position using the structure-based common numbering scheme or the Swiss-Prot numbering, to 
choice. The top four tables are multiple selection fields. The bottom selection field allows for searching 
the mutational effect fields using keywords.
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of MuteXt yields a recall of 85%, a precision of 90% and a coverage of 70%. The recall is 
the percentage of point mutations that are correctly extracted (true positives/ (true positives 
+ false negatives)), the precision is the percentage of validated point mutations that are 
correct (true positives/ (true positives + false positives)) and the coverage is the percentage 
of relevant point mutations that the system extracted (true and false positives/point mutations 
present in the documents). Table 1 summarizes the resources at the basis for the NRMD, and 
Table 2 summarizes the information stored per mutation.
A WWW-based form gives access to a system that allows the user to query the information. 
Figure 1 shows the layout of this form.
Field Example Description
Mutation D351Y Mutation notation
Accession 463 Unique identifier
Pentapeptide LADRE Pentapeptide sequence with muta-
ted residue in third position
Link www.receptors.org/NR/mutation/
D351_ESR1_HUMAN.html
URL of the original mutation 
resource
Source NucleaRDB Name of the original resource
V/M Variant Indicates whether a mutation is 
a natural occurring variant or an 
experimental mutagen
Receptor description ER alpha Name of the nuclear receptor
Species Homo sapiens (Human) Species name
Id P03372 Swiss-Prot accession code
Gene name NR3A1 Nuclear receptor gene name
PubMed 10815929 Link to PubMed abstract
Position in alignment 340 Residue position according to the 
structural alignment
Effect Cadmium did not activate mutants 
E523Q, E523A, H524A, or 
D538N but activated E380Q…
Description of the observed effect 
of the mutant
Table 2. Information per mutant.
Three columns are given. Left: the name of the data field. Middle: example of actual data stored in 
NRMD. Right: description. Mutations can also be insertions, chimers, deletions, or combinations. 
Bibliographic information is the PubMed index. Effects include all described effects ranging from 
expression pattern to antagonism, but effects are only stored if available in the original resource from 
which the mutation was retrieved.
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In summary, the NRMD combines NR mutation information from all known sources. 
Most data collection is fully automatic for the web-based resources so that updates will 
automatically lead to an update of the NRMD. Moreover, mutation information from the 
literature continues to be added manually. To ensure high quality data, mutations are only 
accepted if they are made in a sequence available from Swiss-Prot or TrEMBL, and if the 
mutation is annotated correctly (i.e. residue number, residue type, sequence name, accession 
code, etc. all are the same in Swiss-Prot or TrEMBL and in the mutation information resource). 
Additional information about the NRMD is available at: www.receptors.org/NR/.
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FRET peptide recruitment assay. Peptides that were obtained from a phage display peptide library are 
indicated by F.D. pept. (phage display peptide). Consensus sequence of coactivator and corepressor 
motifs are indicated in bold. Peptides are labeled at the N-terminus with biotin.
Protein Peptide name Postion Sequence
NCOR1_HUMAN NCoR_1 1926-1948 N-Biotinyl-     TITAANFIDVIITRQIASDKDAR   -C
NCOR1_HUMAN NCoR_2 2047-2068 N-Biotinyl-        RLITLADHICQIITQDFARNQV -C
NCOR1_HUMAN NCoR_3 2259-2280 N-Biotinyl-        SNLGLEDIIRKALMGSFDDKVE -C
NCOR1_HUMAN NCoR_3L 2251-2275 N-Biotinyl-GHSFADPASNLGLEDIIRKALMGSF      -C
NCOR1_HUMAN NCoR_4 2380-2397 N-Biotinyl-    STQFPYNPLTMRMLSSTP         -C
NCOR1_MOUSE NCoR_4M 2393-2410 N-Biotinyl-    STQFPYNPLTIRMLSSTP         -C
NCOR2_HUMAN SMRT_ID1 2128-2152 N-Biotinyl-     GHQRVVTLAQHISEVITQDYTRHHP -C
NCOR2_HUMAN SMRT_ID2 2331-2352 N-Biotinyl- AVQEHASTNMGLEAIIRKALMG        -C
PRGR_HUMAN PR_H12 907-933 N-Biotinyl-  EMMSEVIAAQLPKILAGMVKPLLFHKK  -C
F.D. PEPT. BT1 - N-Biotinyl-     ELFDAFQLRQLILRGLQDDIPYH   -C
F.D. PEPT. BN2 - N-Biotinyl-     EYHEKRWLEGHIHHRIKSLLENS   -C
F.D. PEPT. BL29 - N-Biotinyl-     KWESLDALQGLISSHLSAMGPIP   -C
HAIR_HUMAN HR_1 793-815 N-Biotinyl-        ITNILDSIIANVVERKINEKALG-C
HAIR_HUMAN HR_2 1008-1026 N-Biotinyl-          VEVADLVSILVHADTPLPA  -C
Q8N3L6_HUMAN LCoR 39-63 N-Biotinyl-  VTTSPTAATTQNPVLSKLLMADQDS    -C
HAIR_HUMAN HRCoA_1 552-576 N-Biotinyl-  TGLAKHLLSGLGDRLCRLLRREREA    -C
HAIR_HUMAN HRCoA_2 744-768 N-Biotinyl-  AEDRAGRGPLPCPSLCELLASTAVK    -C
NCOA1_HUMAN SRC1_2 676-700 N-Biotinyl-  CPSSHSSLTERHKILHRLLQEGSPS    -C
NCOA1_HUMAN SRC1_3 735-759 N-Biotinyl-  LDASKKKESKDHQLLRYLLDKDEKD    -C
NCOA1_HUMAN SRC1a_4 1421-1441 N-Biotinyl-  TSGPQTPQAQQKSLLQQLLTE        -C
NCOA2_HUMAN SRC2_1 627-651 N-Biotinyl-  DGQSRLHDSKGQTKLLQLLTTKSDQ    -C
NCOA2_HUMAN SCR2_1S 636-650 N-Biotinyl-           KGQTKLLQLLTTKSD     -C
NCOA2_HUMAN SRC2_3 732-756 N-Biotinyl-   QEPVSPKKKENALLRYLLDKDDTKD   -C
NCOA3_HUMAN SRC3_2 671-695 N-Biotinyl-  SNMHGSLLQEKHRILHKLLQNGNSP    -C
NCOA3_HUMAN SRC3_3 724-748 N-Biotinyl-  QEQLSPKKKENNALLRYLLDRDDPS    -C
NCOA3_HUMAN SRC3_4 1043-1067 N-Biotinyl-  NLEGQSDERALLDQLHTLLSNTDAT    -C
CBP_HUMAN CBP_1 58-80 N-Biotinyl-    NLVPDAASKHKQLSELLRGGSGS    -C
NRIP1_HUMAN RIP140_1 119-143 N-Biotinyl-  MVDSVRKGKQDSTLLASLLQSFSSR    -C
NRIP1_HUMAN RIP140_3 172-196 N-Biotinyl-   EKDLRCYGVASSHLKTLLKKSKVKD   -C
NRIP1_HUMAN RIP140_5 366-390 N-Biotinyl-  LERNNIKQAANNSLLLHLLKSQTIP    -C
NRIP1_HUMAN RIP140_6 487-511 N-Biotinyl-  SKNSKLNSHQKVTLLQLLLGHKNEE    -C
NRIP1_HUMAN RIP140_7 699-723 N-Biotinyl-  SGSEIENLLERRTVLQLLLGNPTKG    -C
NRIP1_HUMAN RIP140_8 805-831 N-Biotinyl-  PVSPQDFSFSKNGLLSRLLRQNQDSYL  -C
NRIP1_HUMAN RIP140_9 922-946 N-Biotinyl-  EHRSWARESKSFNVLKQLLLSENCV    -C
PRGC1_HUMAN PGC_1 130-155 N-Biotinyl-  DGTPPPQEAEEPSLLKKLLLAPANTQ   -C
NCOA6_HUMAN ASC2_2 1481-1504 N-Biotinyl-      SPAMREAPTSLSQLLDNSGAPNVT -C
Table continues on page 125.
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Table 3. Template structures that were used to determine the initial binding modes of RXR ligands in 
the hRXRα LBD. These template structures were used as starting points to model the binding mode 
of the RXR compounds that were used in this study. The chain and template ligand that were used to 
model the binding mode is depicted for each of the 10 RXR compounds in this study.
Protein Peptide name Position Sequence
PPRB_HUMAN TRAP220_1 590-614 N-Biotinyl-  GHGEDFSKVSQNPILTSLLQITGNG    -C
PPRB_HUMAN TRAP220_2 631-655 N-Biotinyl-  PVSSMAGNTKNHPMLMNLLKDNPAQ    -C
NCOA4_HUMAN ARA70 321-339 N-Biotinyl-         SRETSEKFKLLFQSYNVND   -C
F.D. PEPT. D22 - N-Biotinyl-         LPYEGSLLLKLLRAPVEEV   -C
F.D. PEPT. C33 - N-Biotinyl-         HVEMHPLLMGLLMESQWGA   -C
F.D. PEPT. D47 - N-Biotinyl-         HVYQHPLLLSLLSSEHESG   -C
F.D. PEPT. Ppt4-1 - N-Biotinyl-            QPKHFTELYFKS       -C
F.D. PEPT. D30 - N-Biotinyl-         HPTHSSRLWELLMEATPTM   -C
SHP_HUMAN SHP_1 9-33 N-Biotinyl-    CPCQGAASRPAILYALLSSSLKAVP  -C
SHP_HUMAN SHP_2 106-130 N-Biotinyl-    TFEVAEAPVPSILKKILLEEPSSSG  -C
DAX1_HUMAN DAX_3 136-159 N-Biotinyl-      GEDHPRQGSILYSLLTSSKQTHVA -C
DAX1_HUMAN DAX_3_cys 134-159 N-Biotinyl-    FCGEDHPRQGSILYSLLTSSKQTHVA -C
ANDR_HUMAN ARAF1 17-32 N-Biotinyl-          KTYRGAFQNLFQSVRE     -C
ANDR_HUMAN ARAF1s 16-30 N-Biotinyl-         SKTYRGAFQNLFQSV       -C
NR1H3_HUMAN LXRa_H12 427-447 N-Biotinyl-        ALRLQDKKLPPLLSEIWDVHE  -C
SLIM3_HUMAN FHL2 208-225 N-Biotinyl-           YCLNCFCDLYAKKCAGC   -C
Compound Template structure (chain, receptor, ligand) Reference
9-cis-retinoic acid 1FM6 (A, hRXRα, 9-cis-retinoic acid) [3]
oleic acid 1DKF (A, hRXRα, oleic acid) [4]
cis-4,7,10,13,16,19–
docosahexaenoic acid
1MV9 (A, hRXRα, cis-4,7,10,13,16,19–doco-
sahexaenoic acid )
[5]
phytanic acid 1MV9 (A, hRXRα, cis-4,7,10,13,16,19–doco-
sahexaenoic acid)
[5]
targretin 1H9U (A, hRXRβ, LG100268) [6]
LG100268 1H9U (A, hRXRβ, LG100268) [6]
LG100324 1H9U (A, hRXRβ, LG100268) [6]
LG100754 1H9U (A, hRXRβ, LG100268) [6]
methoprene acid 1UHL (A, hRXRβ, methoprene acid) [7]
pentadecanoic acid 1XVP (A, hRXRα, pentadecanoic acid) [8]
Table 2 continued from page 124.
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[14]. The ligands are named according to the 3-letter code of the ligand in the PDB file. The AC is from 
the Swiss-Prot database [15].
PDB AC Receptor Ligand 
(PDB 
name)
Ligand Ligand structure
1DKF [2] P28700 mRXRα OLI oleic acid
O
OH
1FBY [7], 
1FM6 [1], 
1FM9 [1], 
1K74 [8],
1XLS [9]
P19793 hRXRα REA 9-cis retinoic acid
 OH O
1G5Y [10] P19793 hRXRα REA all-trans retinoic acid  
OH
O
1XDK [11] P28700 mRXRα REA 9-cis retinoic acid
 OH O
1MV9 [3] P19793 hRXRα HXA docosa hexaenoic acid
 OH O
1MVC [3], 
1MZN [3]
P19793 hRXRα BM6 BMS 649
 
O
O
OH
O
1RDT [12] P19793 hRXRα L79 (S)-(2e)-3[4-(5,5,8,8-tetra-
methyl-5,6,7,8-tetrahydro- 2-
naphthalenyl)tetrahydro-1-
benzofuran-2-yl]-2- propenoic 
acid  
O
O
OH
Table continues on page 127.
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PDB AC Receptor Ligand 
(PDB 
name)
Ligand Ligand structure
1XVP [6], 
1XV9 [6]
P19793 hRXRα F15 Pentadecanoic acid  
OH
O
1H9U [4] P28702 hRXRβ LG2 LG100268
 
N
O
OH
1UHL [5] P28702 hRXRβ MEI methoprene acid  
O
O
OH
1G1U [10] P19793 hRXRα - - -
1LBD [13] P19793 hRXRα - - -
Table 4 continued from page 126.
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Chapter 1 - Figure 2. Working mechanism of a drug. A drug (a) typically binds in the ligand binding 
pocket (b) of a target protein (c). The binding of the drug leads to a conformational change at the surface 
of the protein, which leads to a change in interactions with other proteins (d) and other factors in the 
cell (e). The final balance of all these interactions and their effect on gene transcription will define the 
pharmacological effect in humans (f). Diethylstilbestrol (DES (a),(b)), estrogen alpha receptor (ERα) 
((b), (c)) are from 3ERD [9]. Figure (e) http://en.wikipedia.org/wiki/Image:Epithelial-cells.jpg. 
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Chapter 1 - Figure 5. Profiling of NR ligands at the molecular level: peptide recruitment profiling 
and ligand-receptor interaction profiling. Peptide recruitment profiling describes the ligand-induced 
variation in affinity of peptides for the NR LBD. Ligand receptor interaction profiles are derived from 
structural analysis of crystal structures or models and describe the number of contacts between a ligand 
and the residues in a protein in a 2D fingerprint.
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Chapter 2 - Figure 2. (a) Apo form of a NR LBD (figure based on PDB entry 1LBD [14], human 
retinoid X receptor (hRXRα)). (b) Structure with a bound agonist (3ERD [15], hERα, human estrogen 
receptor alpha). Act = the nuclear receptor coactivator 2 (NCoA-2) box II. (c) Structure with a bound 
antagonist and corepressor (1KKQ [16], hPPARα). Rep = the nuclear receptor co-repressor 2 (N-CoR2). 
(d) Structure with a bound antagonist (3ERT [15], hERα). Figures were generated with YASARA 
(http://www.yasara.org). Helices 1-12 are shown as cylinders, the sheet as (red) arrows.
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Chapter 2 - Figure 3. (a) Structurally conserved regions of the NR LBD mapped on 3ERD [15]. Figure 
was generated with YASARA (http://www.yasara.org). (b) A C
α
 trace of the structurally averaged LBD 
residues is shown in red. The three-dimensional blue ellipsoids represent the spread of the positions of 
the superposed alpha carbons. Details of the ellipsoid calculations are given on the website http://www.
receptors.org/NR/articles/JMB04/structsup.html.
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Chapter 2 - Figure 4. Location of the 56 ligand binding positions in the NR LBD. (a) LIG1 (purple, six 
residues). (b) LIG2 (red, ten residues). (c) LIG3 (orange, 14 residues). (d) LIG4 (yellow, 26 residues). 
(e) Main hydrogen bond forming positions (light blue). Ligand (BMS184394) is shown in purple. The 
depicted structure is the LBD of the human retinoic acid receptor gamma (hRARγ), 1FCX [62].
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Chapter 2 - Figure 7. Structural location of the residues in the five boxes. (a) Box
11
 (purple). (b) Box
12
 
(orange). (c) Box
22
 (yellow). (d) Box
23
 (green). (e) Box
33
 (light blue). In (f) box
33
 residues (light blue) 
are shown again but this time accessible residues are indicated with small dots. For easy reference, the 
coactivator helix of the glucocorticoid receptor-interacting protein 1 (GRIP-1), as observed in a PDB 
file of hERα (3ERD [15]), and the agonist dihydrotestosteron as observed in the PDB file of the human 
androgen receptor (1I37 [66]) are shown in yellow and purple, respectively.
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Chapter 3 - Figure 1. Distribution of the function of the 87 NR ligands observed in the PDB files used 
in this study.
Chapter 3 - Figure 2. (a) Ligands, ions and heteroatoms of the 87 LBD ligand-bound structures 
superposed onto the C
α
 coordinates of 1FCY [45].
(b) The electron density is calculated for all ligands and all densities are added up. The yellow dashed 
contour lines surround space where at least 5 ligands have been superposed. The orange, solid contour 
lines surround space where at least 25 ligands have been superposed. The electron density was calculated 
using WHAT IF [41].
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Chapter 3 - Figure 4. The ligand-binding residue positions in the LBD are indicated by colored spheres 
at their C
α
 positions. (a) LIG1 (purple, 6 residues). (b) LIG2 (red, 6 residues). (c) LIG3 (orange, 17 
residues). (d) LIG4 (yellow, 27 residues). The C
α
 backbone structure is from 1FCX [45].
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Chapter 3 - Figure 5. Dendograms based on (a) LIG1 residues 335, 339, 552, 556, B154, 1057, (b) 
COF1/2 residues 347, 351, 448, 452, 456, 1247, 1250, (c) HOM1 residues 947, 1038, 1051 and HET1 
residues 944, 947, 1041, 1045, 1048, 1051 (7 residues in total due to HOM1 - HET1 overlap). Residues 
are colored according to their type. Most hydrophobic residues are green, cysteines are brown, glycines 
are purple, prolines are yellow, and the hydrophylic residues are red, gray, or blue. Residues are shaded 
using the same colors at similarity threshold levels of 40% for LIG1 residues and 30% for COF1/2 and 
HOM1/HET1 residues (BLOSUM62 similarity matrix). The beta-sheet and H12 residues are missing 
for NR0B1 DAX1 and NR0B2 SHP and for NR1D1 NRD1 and NR1D2 NRD2, respectively. Residues 
are sorted from left to right according to their 3D number. Dendograms were created with CLUSTALW 
[48] version 1.82 with default values. Figure continues on page 139 and 140.
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Figure 5 continued from page 138 and continues on page 140.
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Figure 5 continued from page 139.
A
ppendix 2
143
Chapter 3 - Figure 7. The cofactor-binding residue position in the LBD are indicated by colored 
spheres at their C
α
 positions. (a) COF1 (purple, 1 residue). (b) COF2 (red, 6 residues). (c) COF3 (orange, 
5 residues). (d) COF4 (yellow, 7 residues). (e) The corepressor-binding residues using the same criteria 
and colors for the COF1-4 as in Figure 6a and Figure 7a-d, respectively. 3ERD [55] was used for the 
coactivator pictures (a-d) and 1KKQ [22] was used for the corepressor picture (e).
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Chapter 3 - Figure 9. The homo- and heterodimerization residue positions in the LBD are indicated 
by colored spheres at their C
α
 positions. (a) HOM1 (purple, 3 residues). (b) HOM2 (red, 7 residues). 
(c) HOM3 (orange, 5 residues). The C
α
 backbone structure is from 3ERD [55]. (d) HET1 (purple, 6 
residues). (e) HET2 (red, 7 residues). (f) HET3 (orange, 4 residues). The C
α
 backbone structure is from 
1FM9 [27].
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Chapter 4 - Figure 4. Hierarchical clustering of the peptide recruitment profiles of 11 different RXR 
compounds using a hierarchical unweighted clustering routine with a similarity measure that was based 
on correlation. The peptide recruitment profile of each ligand was represented as a row with 52 cells in 
the distance matrix. Each cell is colored according to the log(MI) value of the peptide with  green being 
the highest log(MI) and red the lowest log(MI) value. The vertical red line indicates the boundary that 
was chosen to define the separate clusters.
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Chapter 4 - Figure 11. Comparison of the binding modes of DHA (orange) and 9-cis RA (green). All 
chains from RXRα crystal structures with 9-cis RA [6, 33, 38-40] or DHA [45] were superposed and 
the side chains of the cysteines at 3D position 1057 and the leucines at 3D position 1061 are shown. 
The secondary structure representation is based on the backbone of 1FM6 [38] , H10 = helix 10, H12 
= helix 12.
Chapter 4 - Figure 12. Comparison of the binding modes of LG100754 (cyan) and 9-cis RA (green). 
The coordinate set of RXRα with LG100754 of the frame with the lowest interaction energy was 
superposed on the RXRα crystal structure with 9-cis RA [38]. The three areas where differences in 
ligand binding are observed are indicated with one representative residue for each area. The secondary 
structure representation is based on the backbone of 1FM6 [38], H3 = helix 3, H5 = helix 5 and H7 = 
helix 7.
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Summary 
148
Despite new technical developments and increasing expenditure of pharmaceutical 
companies in their research and development, the expected increase in the number of newly 
approved drugs failed to appear. Actually, the opposite occurred. The development time for 
a typical drug increased and the costs to bring a drug to the market are higher than ever. 
Most compounds do not reach the market because they fail in early stages of development. 
Undoubtedly, it is very important for the pharmaceutical industry to accelerate the process of 
drug discovery at all its stages to ensure a constant flow of high quality drugs that ultimately 
reach the market. 
Chapter 1 deals with this challenge and describes how the content of this thesis may facilitate 
the drug discovery process, using the superfamily of the nuclear receptors (NRs) as an 
example.
In Chapter 2 we demonstrate that a family-based approach which combines theoretical 
and experimental data revealed the function of structurally conserved residues in the NR 
protein family. The combined analysis of sequence entropy and sequence variability divided 
the residues of the NR ligand binding domain (LBD) in five classes; (1) the main function 
or active site, (2) support for the main function, (3) signal transduction, (4) modulator or 
ligand binding and (5) the rest. The analysis revealed that the main function of an NR LBD 
is cofactor binding. In addition, the analysis predicted the existence of signal transduction 
residues between ligand-binding pocket, the cofactor-binding pocket and the dimer interface, 
suggesting communication between these regulatory binding sites. The predicted function 
for each residue was compared with mutation data from different sources, for which we 
created the nuclear receptor mutation database (NRMD). Chapter 5 describes this database 
that automatically extracts NR mutations from different sources and stores these in a 
relational database. The mutation and structural data available for the classified residues 
agreed well with the functional classification, which gives us faith in the predictive value 
of the classification scheme for those residues for which experimental data are not (yet) 
available. This study illustrates the power of family-based approaches towards the analysis 
of protein function, and it points out the problems and possibilities presented by the massive 
amounts of data that are becoming available in the “omics era”. The results shed light on the 
nuclear receptor family but also make it very clear that many more (automated) literature 
data-extraction, and sequence and structure analysis methods are required to classify residues 
better, and with more detail.
Chapter 3 describes the interactions of the LBD with ligand, cofactor, and dimer partner as 
observed in the available crystal structures. These interactions were studied qualitatively, 
by simply counting the average number of contacts of each residue with the three binding 
partners. Despite the qualitative nature of this work, the differences in the number of contacts 
were significant enough to reveal the residue positions in the LBD that are most frequently 
involved in the binding of a ligand. The identity of these residues facilitates the process 
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of drug design in various ways. First, these residues guide the docking of novel ligands, 
because all NR ligands interact with these residues and it is very likely that novel ligands will 
do so as well. The identity of subfamily specific residues facilitates the docking of ligands 
in a receptor of a particular subfamily. Second, the residue types of the residues that most 
frequently interact with a ligand determine the shape and the physico-chemical properties 
of the centre of the LBP. We observed a correlation between these properties and the main 
scaffold characteristics of the ligand. Knowing the properties of the LBP’s centre therefore 
helps to design a compound library for a specific NR. The third application of the acquired 
information on the residues that are always involved in ligand binding is based on the 
dendogram of these residues of the 48 human NRs. Obviously, a dendogram that is based on 
these residues better predicts cross-reactivity of ligands than a phylogenetic tree that is based 
on the full sequences. The hit-rate of screening for compounds that activate orphan NRs can 
be improved if one selects a library of compounds that activate the nearest non-orphan NR 
in the dendogram.
The contact analysis also revealed the identity of residues in the LBD that show a selective 
interaction with antagonists or partial agonists. This is crucial information in the design of 
ligands that need to have this particular function. Furthermore, we identified the most frequent 
coactivator-binding and dimerpartner-binding residues. Information on the identity of these 
residues helps to obtain insight in the mechanism of cofactor recruitment and dimerization 
throughout the NR superfamily. 
In Chapter 4 we investigated the ligand-induced conformational changes at the surface of 
the NR LBD by a time-resolved resonance energy transfer assay with 52 different cofactor 
peptides by measuring the ligand-induced peptide recruitment for eleven compounds. Each 
peptide recruitment profile is believed to represent a conformation of the receptor surface. 
Simultaneously, we analyzed the binding mode of these compounds using available crystal 
structures and molecular docking. So-called ligand-receptor interaction profiles were created 
by an automated method that converts the 3D data of ligand-protein interaction into 2D 
fingerprints which represents the binding mode of a ligand in the LBP. For a subset of 
compounds we found a correlation between the conformational changes at the surface and 
the calculated binding mode. Therefore we concluded that the clustering of ligand-receptor 
interaction profiles is a useful tool to discriminate compounds that may induce different 
conformations of the NR LBD surface.
We successfully combined ligand-receptor interaction profiles and peptide recruitment 
data to reveal the underlying structural elements that are involved in the ligand-induced 
conformations of the NR LBD surface. This knowledge can be applied to the design of 
novel drugs that need to induce a similar conformation of the NR-LBD surface. It is believed 
that the conformation of the NR LBD surface determines the interaction with cofactors in 
a specific cell-type. Clustering of conformations as measured by the peptide recruitment 
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profiles provided novel insight in the ultimate cellular effect of the compounds. Compounds 
that have been identified as agonists in cellular assays turned out to be so-called selective NR 
modulators in peptide recruitment assays. Performing these assays in an early stage of drug 
discovery thus helps to predict the cellular and pharmacological effect.
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Ondanks nieuwe technologische ontwikkelingen en de toename van investeringen van de 
farmaceutische industrie in hun research en development, bleef een verwachte stijging van 
het aantal nieuwe medicijnen uit. In feite gebeurde het omgekeerde. De tijd die het kost 
om een nieuw medicijn te ontwikkelen steeg en de kosten om een medicijn op de markt te 
brengen zijn nu hoger dan ooit. De meeste stoffen bereiken de markt niet omdat ze falen 
in de vroege fases van development. Het is daarom een uitdaging voor de farmaceutische 
industrie om het proces van medicijn ontwikkeling in ieder stadium te versnellen, zodat een 
constante aanvoer van kwaliteits stoffen die uiteindelijk op de markt kunnen belanden, is 
gegarandeerd. Hoofdstuk 1 behandelt deze uitdaging en beschrijft hoe de inhoud van dit 
proefschrift bijdraagt aan het versnellen van het proces van medicijn ontwikkeling, waarbij 
de eiwitfamilie van de nucleaire receptoren (NRs) centraal staat. 
In Hoofdstuk 2 tonen we aan dat een eiwitfamilie-gebaseerde benadering, waarin theoretische 
en experimentele data worden gecombineerd, de functies van structureel geconserveerde 
aminozuur residuen binnen één eiwit familie identificeert. De gecombineerde analyse van 
sequentie entropie en sequentie variabiliteit verdeelde de residuen van het NR ligand bindend 
domein (LBD) in vijf klassen; residuen die betrokken zijn bij (1) de hoofd functie of ‘active 
site’ van het eiwit, (2) ondersteuning van deze functie, (3) signaal overdracht (zogenaamde 
communicatie residuen), (4) modulator of ligand binding en (5) andere processen. De analyse 
wees uit dat de hoofdfunctie van een NR LBD cofactor binding is. Ook voorspelde de analyse 
het bestaan van residuen die betrokken zijn bij signaal overdracht tussen de ligand bindende 
pocket (LBP), de cofactor bindende groeve en het dimerizatie-oppervlak, wat suggereert dat 
er communicatie tussen deze drie regulatie sites optreedt. 
De voorspelde functie voor elk structureel geconserveerd residu werd vergeleken met 
beschikbare mutatie data uit diverse bronnen. Hiervoor werd de Nuclear Receptor Mutation 
Database (NRMD) ontwikkeld. In Hoofdstuk 5 beschrijven we deze database, die automatisch 
NR mutaties uit diverse bronnen verzamelt en deze opslaat in een relationele database. De 
beschikbare mutatie en structurele data kwamen goed overeen met de voorspelde functie, wat 
ons vertrouwen geeft in de voorspellende waarde van deze methode voor residuen waarvoor 
(nog) geen experimentele data beschikbaar zijn.
De studie illustreert de kracht van een eiwitfamilie-gebaseerde benadering om de functie 
van een eiwit te analyseren, maar geeft ook de problemen aan die verbonden zijn met 
de enorme hoeveelheid data die beschikbaar zijn gekomen in het ‘omics’ tijdperk. Meer 
(geautomatiseerde) literatuur data-extractie en sequentie- en structuur analyse methodes zijn 
nodig om residuen beter en met meer precisie te classificeren.
Hoofdstuk 3 beschrijft de interacties tussen het NR LBD en het ligand, de cofactor of de 
dimerizatie partner door analyse van alle beschikbare NR kristal structuren. Deze interacties 
werden kwalitatief bestudeerd, door analyse van het gemiddelde aantal contacten van elk 
residu met elk van de drie bindingspartners. Ondanks het kwalitatieve karakter van dit werk, 
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waren de verschillen in aantal contacten significant genoeg om residu-posities in het LBD 
te identificeren die altijd betrokken zijn bij ligand binding. De identiteit van deze residuen 
draagt op verschillende manieren bij aan het proces van medicijnontwikkeling. Ten eerste 
ondersteunt kennis van deze posities de docking van nieuwe liganden, omdat alle NR 
liganden een interactie hebben met deze residu-posities, en het dus zeer waarschijnlijk is 
dat nieuwe liganden dit ook zullen doen. Op eenzelfde manier, helpt de identiteit van residu-
posities die alleen binnen een bepaalde subfamilie contact maken met een ligand bij het 
docken van liganden in een receptor afkomstig uit die specifieke subfamilie. Ten tweede, 
bepalen de residuen op de posities die altijd betrokken zijn bij ligand binding de vorm en 
de fysisch-chemische eigenschappen van het centrum van de LBP. We namen een correlatie 
waar tussen deze eigenschappen en het karakter van de main scaffold van het ligand. Op basis 
van de vorm en eigenschappen van het centrum van een LBP kan op die manier een stoffen 
bibliotheek ontworpen worden voor een screenings assay om actieve stoffen te identificeren 
voor een bepaalde NR. Ten derde kan men een dendrogram maken van de residuen die altijd 
betrokken zijn bij ligand binding voor de 48 humane NRs. Een dendrogram gebaseerd op de 
belangrijkste ligand bindende posities voorspelt crossreactiviteit beter dan een dendrogram 
gebaseerd op de volledige sequenties van de NRs. Het aantal hits dat gevonden wordt in 
een screening voor een orphan NR kan worden verbeterd als men stoffen selecteert die de 
dichtstbijzijnde niet-orphan NR activeren.
Verder identificeerde de contact analyse de residu-posities in het LBD die specifiek 
antagonisten of partiele agonisten binden. Dit is cruciale informatie wanneer men liganden 
wil ontwikkelen met deze specifieke kenmerken. Tenslotte analyseerden we de coactivator 
en dimeerpartner bindende residu-posities. Kennis van residu types op de posities die altijd 
binden met een cofactor of dimeer partner, helpt om inzicht te krijgen in het onderliggende 
mechanisme van respectievelijk cofactor binding en dimerizatie.
In Hoofdstuk 4 onderzochten we de ligand geïnduceerde conformationele veranderingen 
aan het oppervlak van het NR LBD door de interacties van 52 verschillende cofactor 
peptiden met de NR LBD te meten in een time-resolved resonance energy transfer (TR-
FRET) assay onder invloed van verschillende liganden. Elk peptide recruitment profiel 
wordt verondersteld een conformatie van het oppervlak van de receptor te representeren. 
Van deze liganden analyseerden we de wijze van binding in de pocket van het NR LBD 
met behulp van beschikbare kristal structuren en moleculaire docking. Een geautomatiseerde 
methode die de complexe 3D data van ligand-eiwit interacties omzet in 2D fingerprints 
creëerde zogenaamde ligand-receptor interactie profielen, die de binding van een ligand aan 
de receptor representeren. Voor een subset van stoffen stelden we een correlatie vast tussen 
de conformationele veranderingen aan het oppervlak en de berekende bindingswijze van de 
stof in de pocket. Op basis van deze bevindingen concludeerden we dat clustering van ligand-
receptor interactie profielen een nuttige methode is stoffen te onderscheiden die verschillende 
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conformaties van het NR LBD oppervlak induceren. 
Bovendien leidde een combinatie van ligand-receptor interactie profielen en peptide 
recruitment data tot een opheldering van de onderliggende structurele elementen die ten 
grondslag liggen aan de ligand geïnduceerde conformaties van het NR LBD oppervlak. Deze 
kennis kan worden toegepast in het ontwerpen van nieuwe medicijnen die vergelijkbare 
conformaties van het NR LBD oppervlak moeten induceren. We veronderstellen hierbij dat 
de conformatie van het NR LBD oppervlak bepaalt met welke cofactoren een interactie wordt 
aangegaan en dat deze interactie de uiteindelijke cellulair response bepaalt. Clustering van 
deze conformaties, in de vorm van peptide recruitment profielen, verschafte daarom nieuw 
inzicht in het uiteindelijke effect van de stoffen. Stoffen die eerder geïdentificeerd waren als 
agonisten in cellulaire assays bleken zogenaamde selective NR modulators te zijn op basis van 
de resultaten uit de peptide recruitment assay. Uitvoering van deze assay in een vroegtijdig 
stadium in de medicijn ontwikkeling draagt daarom bij om cellulaire en pharmacologische 
effecten van potentieel nieuwe medicijnen te kunnen voorspellen.
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Dankwoord
Promoveren is een eenzame weg naar de top. Het is een mooie, maar zware reis.
Eenmaal boven, aan het einde van de rit, ben je zoveel energie verloren en dan moet ook het 
dankwoord er nog even uitgeperst worden. Daar gaan we:
Allereerst, mijn promotor, Jacob de Vlieg. Jacob, ik wil jou bedanken omdat je mij een kans 
gaf promotieonderzoek te doen aan het CMBI in Nijmegen, maar tegelijkertijd ook in een 
industriële omgeving bij Organon. Bedankt voor je enthousiasme, inbreng, het vertrouwen 
dat je me hebt gegeven en je kijk vanuit een drug design perspectief (“Wat kun je ermee?” 
was een vaak gestelde, maar erg relevante vraag). 
Paula, hoe kan ik jou bedanken? Ik heb vaak ‘in je wiel gezeten’. Als copromotor heb jij 
altijd voor me klaar gestaan. Ook toen ik in Zweden op een congres zat en vergeten was 
mijn poster mee te nemen. Zonder jou was dit proefschrift er (nog) niet geweest. Naast al je 
werkzaamheden bij Organon heb je altijd tijd voor me. Ik bewonder jouw doorzettingsver-
mogen en waardeer het feit dat je veel over hebt voor de mensen om je heen. Ik heb veel van 
je geleerd, zowel op het gebied van de wetenschap als op het persoonlijk vlak. Daar ben ik 
je zeer dankbaar voor.
Gert, bedankt voor jouw wetenschappelijke bijdrage aan mijn proefschrift (die natuurlijk niet 
beperkt bleef tot het eerste hoofdstuk), maar daarnaast ook voor de vele ‘social events’ waar 
jij zo goed in bent. Het kamperen in Schotland tijdens een conferentie, met op de heenreis 
een lekke band in hartje Glasgow, en de vele barbecues bij jou thuis waren onvergetelijke 
momenten. Om maar niet te spreken van mijn eerste overzeese congres bezoek in Boston, 
waar we samen in een hittegolf belandden.
Eind 2000 begon het avontuur in Nijmegen, bij het CMBI. Contractueel liep het op zijn 
zachtst gezegd niet geheel vlekkeloos. Barbara, jij hield je hoofd koel, ik bleef, en sindsdien 
heb je me altijd geholpen met mijn administratie. Bovendien toonde je altijd interesse in hoe 
het met het proefschrift (en mij) ging, iets wat ik erg gewaardeerd heb. 
In die beginperiode kreeg ik ook twee studenten: Henk-Jan en Joost. Met deze situatie wist ik 
geen raad, want ik was nog maar net 3 maanden bezig, nota bene met een niet of nauwelijks 
gedefinieerd onderwerp. Jullie zijn de reden geweest dat ik doorgegaan ben. We vormden een 
enthousiaste groep en kregen het project draaiende en veel belangrijker, er is een vriendschap 
ontstaan die nooit is verdwenen. 
In die tijd werden we begeleid door een postdoc genaamd ‘Crazy Pig Frenchy’, die het merk-
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waardige talent bezat varkens te kunnen imiteren. Merci Manu! Studenten uit die tijd: Wilco 
(33 km/u gemiddeld de Tivoli op) Fleuren, Jeroen Eitjes, Richard Hamer en Richard N. (Pin-
dasnor), allen bedankt. Verder wil ik alle mensen op het CMBI bedanken, in het bijzonder 
Esther (secretariaat), Wim & Wilmar (hard- en software) en (commando-) Gijs. 
In deze periode werd de basis gelegd voor het eerste artikel. Hiervoor ben ik veel dank ver-
schuldigd aan Laerte Oliveira, de man achter de entropie-variabiliteit theorie, en Florence 
Horn die zorgde voor een nauwkeurig bijgehouden NucleaRDB. 
In het kader van mijn promotieonderzoek ging ik in juni 2003 bij Organon experimenten 
doen. Er moesten zowel in vitro (in het laboratorium) als in silico (met de computer) proeven 
gedaan worden. 
De experimenten in het lab werden uitgevoerd in de groep van Arie Visser, binnen de MPO 
(Molecular Pharmacology Oss) sectie. Arie, bedankt voor je hulp bij het tot stand komen van 
het laatste hoofdstuk van dit boekje. Jouw kennis van ‘de peptiden’ bleek hier onmisbaar. Bo-
vendien was de sfeer binnen jouw groep erg goed. Dit werd hoofdzakelijk veroorzaakt door 
Frankrijk liefhebber/paraglider Peter Carati en DJ Willy Joosten (naast professioneel DJ, 
ook huis-, tuin- en keukenpsycholoog en enneagram specialist). Ik wil jullie bedanken voor 
de ontzettend leuke tijd. En last, but (zeker) not least: Arnold. Tja, als muren oren hadden... 
Wat heb ik verschrikkelijk veel gelachen met jou. Nu jij je draai dan eindelijk gevonden hebt, 
vrees ik dat onze droom om op klompjes in de vrachtwagen door (Noord) Europa te gaan 
toeren dan toch niet verwezenlijkt gaat worden. Jammer. Dat je mijn paranimf bent, spreekt 
voor zich. Er zijn maar weinig mensen met wie ik het zo goed kan vinden en die een goede 
balans tussen werk en minder serieuze dingen hebben weten te vinden.
Tenslotte wil ik iedereen binnen de MPO sectie bedanken voor de mogelijkheid en onder-
steuning die ik heb gekregen om de experimenten uit te voeren, in het bijzonder wil ik Rein 
Dijkema noemen, die me ervan overtuigde een lezing te houden op een groot congres, wat 
me zeker een stuk verder heeft gebracht.
Wanneer het experimentele werk erop zat, ging ik naar de MDI (Molecular Design & Infor-
matics) om computer werk te verrichten. Daar wachtten mijn room mates Scott  en Ralph me 
op. Scott, bedankt voor je inbreng van jouw kennis over NRs, het corrigeren van mijn engels, 
and remember RKC-AZ. Ralph, bedankt voor alle Queen oneliners (vooral ’s ochtends ‘It’s a 
beautiful day, the sun is shining, I feel good’ is een ware klassieker/knaller), dat vind je mooi 
hè? Jouw bijdrage in het project in de vorm van het computerprogramma ARES is heel be-
langrijk voor mijn promotie geweest. Joost (van Kempen), voor velen beter bekend als chef 
Verhuizing, je was pas laat mijn kamergenoot, maar mede door jou ziet het boekje er nu zo 
mooi uit. Je hebt me overtuigd om mijn proefschrift van een goede lay-out te voorzien, en op 
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elke vraag die ik daarover had, wist jij antwoord. 
Alle andere MDIers die op een of andere manier hebben bijgedragen aan het proefschrift en 
de prettige werksfeer, bedankt!
Henkie (Henk-Jan), we zijn nu praktisch buren in de mooiste wijk van Nijmegen. Jij weet 
als geen ander dat er naast wetenschap veel meer is en daarom hebben we, nadat je student 
bij mij bent geweest, altijd contact gehouden. Laten we nog eens naar Kopenhagen gaan en 
dan eens kijken of er naast het hotel bij het vliegveld nog meer te doen is, misschien is het 
centrum ook wel wat. Daarnaast mag je zeker nog eens die salto herhalen met landing plat 
op je buik... daarbij toegekeken door een strand vol mensen. Kortom, ik ben blij dat je mijn 
paranimf wilt zijn.
Chris Kapski, samba voetballer, met altijd wel een pijntje in de kleine teen of linker oorlel, 
om zo de echte confrontatie uit de weg te gaan. Onze twee weken op Gran Canaria, waarbij 
we het samba voetbal in Playa del Ingles hebben geïntroduceerd, waren top! Ik, als voetbal-
vader voor jou, en Fons waren trots op je. Maak je dromen waar in Litouwen. 
TTT (Tim), ik ben blij dat we een beetje steun bij elkaar konden vinden. Onze inspirerende 
gesprekken (voornamelijk op de tribune in de Goffert) over de grote voordelen van het pro-
moveren hebben ons kracht gegeven om dit fascinerende traject te doorlopen. Het is even 
doorzetten maar dan heb je ook wat. Bedankt voor je hulp. Ik weet dat je er niet te koop mee 
loopt, maar van al mijn collega’s heb jij de meest gebruikte database! 
Ver in het zuiden gaat er nog steeds niks boppe it Hearrenfean. Ik wil de complete selecties 
van S.C. Heerenveen bedanken voor de mooie voetbaljaren. 
Jarenlang vormde het aan de Daalseweg gelegen studentenhuis ‘de Dahlia’ mijn thuisbasis. 
Ondanks diverse huissamenstellingen (met o.a. hockey international kleine Kaatje, en Lot-
ski) toch altijd weer de basis voor een goed ‘thuis’. In het bijzonder wil ik Jean Paul (Jeepeet-
ski) bedanken, als ik het even had gehad kon jij me weer opbeuren. Een blikje cola en een 
magnetron maaltijd, ‘I like it’, het was een onvergetelijke tijd. 
Uit de biologie tijd oet Grun: Chris, Ferenc en Gitte. Nog altijd contact en over een jaar zijn 
we alle vier gepromoveerd! Ook Dennis bedankt, als ik ooit nog doorloopproblemen krijg in 
gootsteen/sifon systemen dan weet ik wie ik kan bellen, juist, Klaasje! Uit Fryslân: Harry, die 
ik sinds de luiers ken. We hebben samen nog op de plastic tractor door Langezwaag gereden, 
dat waren pas mooie tijden. In de begintijd van mijn promotie zijn we vaak samen op vakan-
tie geweest, wat erg ontspannen was. 
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Uit ‘Wolluk’: Rob en Michael (drikske doen) als alles goed gaat mogen jullie me eindelijk 
doctor Simon gaan noemen. Ook Hein, Tina, Sander (de tip om naar Costa M. te gaan bleek 
een gouden) bedankt voor de nodige ontspanning tijdens het allerlaatste gedeelte van mijn 
promotie.
En dan de familie. 
Zusje Wiepie en Jorrit bedankt voor de vele momenten van afleiding de afgelopen jaren, en 
... ‘als ik er de kracht nog voor heb’ gaan we in 2007 weer naar de Toppers.
Heit en Mem, van jullie leerde ik de kleine dingen te waarderen. Jullie hebben me altijd ge-
stimuleerd en mijn gang laten gaan. Uiteindelijk is dit er dan uitgekomen. Bedankt voor jullie 
steun en liefde. Het is altijd fijn om thuis te zijn.
Lieve Els, jouw aandeel in de promotie is zo belangrijk geweest. Jouw nuchtere benadering 
heeft me veel rust gebracht en me er uiteindelijk door heen gesleept. Ondanks het grote ver-
schil hebben we zoveel gemeen. Samen met Tum (warme zomeravond gesprekken) en Kiew 
(voor de speelmomenten) bist do de sinne yn mien libben,
Simon.
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Curriculum vitae
Simon Folkertsma werd op 6 april 1976 geboren als zoon van Lolke en Dirkje Folkertsma in 
het Friese Langezwaag. Hij volgde zijn VWO opleiding aan het Nassau College te Heerenveen, 
waar hij in 1994 zijn eindexamen behaalde. Vervolgens ging hij Biologie studeren aan de 
Rijksuniversiteit Groningen en behaalde daarnaast in 1996 de propedeuse van de opleiding 
Fysiotherapie aan de Hanzehogeschool in Groningen. In het tweede jaar van zijn studie 
Biologie koos hij de specialisatie Moleculaire Biologie. Zijn eerste afstudeerstage (1999) 
doorliep hij aan de vakgroep Ontwikkelingsgenetica onder leiding van Dr. Bart Eggen. De 
tweede afstudeerstage werd in 2000 uitgevoerd onder leiding van Dr. Sietse Mosselman en 
Dr. Rein Dijkema binnen de Target Discovery (TDO) groep van Organon in Oss. In de zomer 
van 2000 studeerde Simon af als moleculair bioloog. Aan het einde van dat jaar maakte 
hij de overstap naar de bioinformatica en werd AIO in Nijmegen aan het CMBI (Centrum 
voor Moleculaire en Biomoleculaire Informatica) binnen de Computational Drug Design 
(CDD) groep van Prof. Dr. Jacob de Vlieg. Een groot deel van het werk beschreven in dit 
proefschrift werd uitgevoerd bij Organon onder begeleiding van Dr. Paula van Noort en Drs. 
Arie Visser.
Sinds april 2006 werkt Simon als post-doctoraal onderzoeker in de CDD groep binnen de
afdeling Molecular Design and Informatics (MDI) van Organon.
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